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Single ventricle heart defects are among the most severe types of congenital heart problems 
and require surgical intervention for survival. The common procedure is to use a set of three, staged 
palliative surgeries to re-route blood around the non-functioning ventricle resuling in a “Fontan” 
physiology, which connects the vena cave directly to the pulmonary arteries in what is referred to 
as a total cavopulmonary connection (TCPC).  Short term outcomes of this approach are 
promising, but almost all patients suffer from long term morbities including a variety of issues 
with the lungs, liver, lymphatics and gastrointestinal system.  
This thesis focuses on evaluating currently proposed solutions for two of the most common 
problems faced by Fontan patients: pulmonary arteriovenous malformation (PAVMs) and Fontan 
associated liver disease (FALD).   The use of (1) surgical planning and (2) Y-grafts are 
hypothesized to offer more balanced hepatic flow distrubtion (HFD), a key factor in PAVM 
formation.  These methods are currently being implemented in a small portion of Fontan patients. 
In terms of FALD, both (1) improved TCPC efficiency and (2) mechanical circulatory support 
(MCS) are hypothesized to reduce hepatic congestion and stop or delay the progression of liver 
disease in these patients.   
These four proposed solutions were investigated using patient specific computational 
modeling, medical image analysis, and in vitro testing. A total of ~220 patient data sets were 
analyzed in this thesis. Four MCS devices were tested.   Surgical planning was found to offer 
accurate HFD predictions for specific graft types and was used to correct PAVMs in several Fontan 
revision cases. Y-grafts offered similar HFD to traditional connection types at the immediate post-
operative state but showed significantly more balanced HFD at ~3 year follow up.  TCPC 
efficiency and LPA stenosis approximately 7 years prior to biopsy were predictive of future liver 
xxviii 
 
disease.  MCS devices varied in their ability to reduce hepatic congestion, with the more powerful 
devices being the most successful.  Overall, the proposed solutions for both PAVMs and FALD 




Congenital heart defects are the most common types of birth defects and are responsible for 
the largest proportion of infant mortality attributable to birth defects.1 Over 1.3 million babies are 
born with a congenital heart defect each year.2  The most severe of these congenital heart defects 
can result in a “single ventricle” physiology where both the pulmonary and systemic circulations 
are pumped in parallel by a single functioning ventricle.  This physiology can damage the heart 
and lungs, and results in the mixing of oxygenated and deoxygenated blood. If left untreated, the 
newborn will not survive. 
Over the last 40 years surgeons have pioneered a set of 3 staged surgeries to palliate single 
ventricle heart defects.  These surgeries are known as the Norwood, Glenn and Fontan procedures, 
and take place when the patient is around 3 days, 3 months, and 3 years of age, respectively.  The 
final result of these operations is a total cavopulmonary connection (TCPC), which is a complete 
anastomosis of the inferior and superior vena cava to the pulmonary arteries. In this new 
configuration, blood bypasses the right side of the heart and passively flows to the lungs for 
oxygenation. The single ventricle is left to pump oxygenated blood throughout the body. These 
patients are often referred to as “Fontan” patients. 
Short term outcomes of the Fontan palliation are very promising, with a 1-year survival rate 
around 95%. However, as these patients age, long term complications are inevitable. Pulmonary 
arteriovenous malformations (PAVMs) and liver disease are two of the most prevalent morbitities, 
and are thought to be directly related to poor Fontan hemodynamics. Currently, the first and second 
“generation” of Fontan patients are beginning to experience these complications and clinicians are 
actively looking for solutions to these problems. 
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The central purpose of this thesis is to investigate the effectiveness of current, clinically 
implemented “solutions” for two of the most common modes of Fontan failure including PAVMs 
and liver disease. The work in this thesis will utilize both computational and experimental 
modeling and will involve around 150 patient data sets.  This work is possible through 
collaborations with both Children’s Healthcare of Atlanta and Children’s Hospital of Philadelphia, 
as well as ventricular assist device companies including Medtronic (Heartware), Design Mentor 
and Abbott (Thoratec).  
This thesis will consist of two specific aims, with Specific Aim 1 focused on PAVMs and 
Specific Aim 2 focused on liver disease. Specific Aim 1 will test if surgical planning can be used 
to accurately predict post-operative hepatic flow distribution (a factor in PAVM formation), and 
if Y-grafts can provide more balanced hepatic flow distribution than traditional Fontan 
connections. Specific Aim 2 will test if the extent of liver fibrosis in Fontan patients is associated 
with poor Fontan hemodynamics, and if ventricular assist devices can decrease Fontan hepatic 
congestion by augmenting flow and decreasing inferior vena cava pressure. 
3 
 
2. HYPOTHESES AND SPECIFIC AIMS 
 
Specific Aim 1a: Evaluate the accuracy of Surgical Planning to predict post-operative 
hepatic flow distribution and resolve pulmonary arteriovenous malformations. 
Hypothesis: Surgical planning can accurately predict post-operative hepatic flow distribution. 
While surgical planning has been used in a plethora of previous studies, no conclusive evidence or 
long-term follow up data exists showing whether surgical planning was accurate or beneficial. 
Specific Aim 1a will use patient-specific, computational fluid dynamic (CFD) modeling to analyze 
the accuracy of surgical planning predictions of hepatic flow distribution (HFD), a known factor 
in pulmonary arteriovenous malformation (PAVM) formation.  This aim will include all patients 
in the Georgia Tech Fontan database who were part of a surgical planning protocol and underwent 
a “Fontan revision” due to the formation of PAVMs (5-10 patients).  Pre- and post-operative MRI 
and clinical data exist for each patient. Predicted results will be compared with long-term follow 
up data to determine if surgical planning was effective in predicting HFD. The relationship 
between HFD and PAVM resolution will also be explored. 
 
Specific Aim 1b: Evaluate the ability of Y-grafts to provide balanced hepatic flow 
distribution and therefore prevent pulmonary arteriovenous malformations. 
Hypothesis: Y-grafts will provide more balanced hepatic flow distribution than traditional Fontan 
connections. 
Y-grafts are a relatively new option for Fontan completion, and are hypothesized to provide 
balanced HFD to the left and right pulmonary arteries via the Y-graft’s two outlets (thus preventing 
the formation of PAVMs). Specific Aim 1b will use patient-specific CFD modeling to analyze the 
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ability of a Y-graft to offer balanced HFD, preventing the formation of PAVMs.  We will perform 
a direct comparison between 30 consecutive Y-graft patients and 30 age and BSA matched 
traditional Fontan patients.  In this comparison we will determine if a Y-graft provides more 
balanced HFD than a traditional Fontan connection.  In addition, we will also study how HFD 
changes over time in Y-graft patients.  To do this, we have acquired long-term follow up MRI and 
clinical data, in addition to immediate post-operative data, for 10 Y-graft patients. 
 
Specific Aim 2a: Investigate the relationship between total cavopulmonary connection 
hemodynamics and Fontan associated liver failure. 
Hypothesis: The extent of liver fibrosis in Fontan patients is associated with poor Fontan 
hemodynamics. 
Specific Aim 2a will use CFD modeling to investigate potential relationships between Fontan 
hemodynamics and liver failure. This aim will assess if (a) liver failure is correlated with 
concurrent TCPC hemodynamics (at the same time point), and if (b) prior TCPC hemodynamics 
are predictive of future liver failure. Through our collaboration with the Children’s Hospital of 
Philadelphia and their Single Ventricle Survivorship program, we have acquired concurrent MRI, 
catheterization and liver biopsy data for 35 Fontan patients.  In addition, we have serial data (at a 
time point prior to the liver biopsy) for 25 of these patients.  For each dataset, we will perform 
patient-specific simulations using MRI derived anatomy and blood flow waveforms. 
Hemodynamic metrics including pressure drop, TCPC resistance, energy loss, vessel size and 
percent stenosis will be calculated.  Percent collagen deposition, as a measure of liver fibrosis, will 




Specific Aim 2b: Evaluate the use of ventricular assist devices to support the Fontan 
circulation and prolong liver health as a bridge to heart transplantation.  
Hypothesis: Ventricular assist devices can decrease Fontan hepatic congestion by augmenting 
flow and decreasing inferior vena cava pressure. 
Heart transplantation is currently the only option to fundamentally correct a failing Fontan heart. 
However, Fontan associated liver disease can be a contraindication to heart transplant, and 
combined heart and liver transplantation is extremely rare.  Therefore, the purpose of Specific Aim 
2b is to determine if VADs can be used to promote liver health in a failing Fontan patient until 
heart transplantation. In this aim we will use both experimental and computational modeling to 
determine if VADs are a viable option for right-sided Fontan support, and if VADs can decrease 
hepatic congestion in order to delay liver failure.  To accomplish this, we will test 4 currently 
available pumps (Circulite, VentriFlo, PediMag and CentriMag) in a previously designed and 
validated Fontan mock circulatory loop. The experimental loop will be tuned to match “failing” 
Fontan pressures and flows acquired from clinical data. During these experiments we will evaluate 
each pump’s ability to decrease hepatic pressure while increasing cardiac output. Additionally, the 
experimental data will be used to validate mechanically assisted Fontan computational fluid 
dynamic model.  The computational model will then be used to determine if a VAD will work for 
multiple patient anatomies and multiple cannula varitions.      
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3. BACKGROUND AND SIGNIFICANCE 
3.1 Cardiac Physiology 
The heart is a muscular organ that powers the cardiovascular system.  Each day, the heart 
beats around 100,000 times and pumps approximately 1,800 gallons of blood. A normally 
functioning heart is separated into two sides and four chambers (Figure 3-1).  The right side of the 
heart consists of the right atrium and right ventricle.  The right atrium is basically a reservoir which 
collects deoxygenated blood returning from the upper and lower body via the superior and inferior 
vena cava (IVC and SVC). The right atrium pumps blood through the tricuspid valve into the right 
ventricle.  Once filled, the right ventricle begins to contract.  The increased pressure causes the 
tricuspid valve to close and the blood moves through the pulmonary valve to the left and right 
lungs via the left and right pulmonary arteries (LPA and RPA).  
 
Figure 3-1 Cardiac Physiology. A four-chambered, cross-sectional view of the healthy heart. 
 
The left side of the heart receives oxygenated blood from the pulmonary veins into the left 
atrium. When the pressure in the left atrium exceeds left ventricular pressure, blood moves into 
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the left ventricle through the mitral valve.  The left ventricle is the stronger of the two ventricles 
and is responsible for delivering oxygenated blood throughout the body.  As the left ventricle 
begins to contract, the mitral valve closes and blood travels through the aortic valve into the aorta.  
The aorta branches into several vessels taking blood to the upper and lower body. 
 
3.2 Single Ventricle Congenital Heart Defects 
A normally functioning heart prevents the mixing of oxygenated and deoxygenated blood, 
allowing for well oxygenated blood to promote proper organ function and sustain life. Arterial 
blood oxygen saturation is typically around 95-100% in a healthy individual, falling to near 70% 
on the venous side before entering the pulmonary circulation. An arterial oxygen saturation below 
90% is considered low.   
However, there are a number of congenital heart defects that can result in a single ventricle 
physiology, where oxygenated and deoxygenated blood can freely mix within the heart.  These 
defects impose immediate danger to the child and require immediate surgical action to avoid death. 
Two of the most common single ventricle congenital heart defects include tricuspid atresia and 
hypoplastic left heart syndrome, which will be discussed in the following sections. 
 
3.2.1 Tricuspid atresia 
Tricuspid atresia is severe congenital heart defect where the tricuspid valve does not exist, 
or is completely closed. This is obviously a major problem since blood can no longer travel through 
the four chambers of the heart as designed. In addition, it is very common for a number of other 
defects to accompany tricuspid atresia, including an underdeveloped right ventricle, and both atrial 
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and ventricular septal defects (Figure 3-2). Tricuspid atresia is often associated with pulmonary 
stenosis and transposition of the great arteries.  
 
Figure 3-2 Tricuspid atresia. Aorta (AO), left and right atrium (LA, RA), left and right ventricle 
(LV, RV), pulmonary artery (PA). 
 
The consequence of this defect is a single ventricle physiology. Blood is free to mix 
between the atria and ventricles, which causes semi-oxygenated blood to be sent to both the 
pulmonary and systemic circulations. The only pathway for blood to enter the pulmonary 
circulation is through the left ventricle to the right ventricle and then the pulmonary arteries.   
 
 
3.2.2 Hypoplastic left heart syndrome 
Hypoplastic left heart syndrome is a congenital heart defect where the left side of the heart 
is severely underdeveloped. As shown in Figure 3-3, the left ventricle is much smaller than the 
right ventricle.  Other abnormalities associated with hypoplastic left heart syndrome can include a 
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very small or closed mitral or aortic valve, or septal defects between the atria or ventricles. In this 
situation, the abnormally small left ventricle cannot adequately pump blood through the systemic 




Figure 3-3 Hypoplastic left heart syndrome. Left and right atrium (LA, RA), left and right 
ventricle (LV, RV), pulmonary artery (PA). 
 
Consequently, the right ventricle becomes the only functioning pump in the cardiovascular 
system and must drive blood through both the systemic and pulmonary circulations.  The right 
ventricle is not made for this workload, as it is designed to operate at a much lower pressure.  This 
can be detrimental to the patient if corrective actions are not taken. Additionally, the blood that is 
moving throughout the body is not completely oxygenated due to the mixing of oxygenated and 
deoxygenated blood in the heart, and therefore cannot supply the body with sufficient oxygen. 




3.3 Fontan Palliation 
The Fontan procedure is the current strategy of choice to palliate single ventricle congenital 
heart defects.  This surgical procedure must be accomplished through several stages since a 
complete right heart bypass is impossible at birth (vessels are too small and pulmonary vascular 
resistance is too high). The end result of this procedure is referred to as a total cavopulmonary 
connection (TCPC), where deoxygenated blood returning from the body bypasses the heart and 
moves passively to the lungs. This configuration successfully separates oxygenated and 
deoxygenated blood, but creates a one “pump” circulatory system (Figure 3-4). The individual 
stages of this procedure are detailed in the following sections.  
 
 
Figure 3-4 Schematics of healthy circulation (left), single ventricle congenital heart defect 
circulation (middle) and Fontan circulation (right). 
 
3.3.1 Stage 1: Norwood Procedure 
The Norwood procedure was introduced by Dr. William Norwood and is performed within 
the first days to weeks of life.3 There are several versions of the Norwood procedure (Figure 3-5), 
but the general purpose of the procedure is to implement a shunt that allows for increased blood 
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flow to the lungs, with the goal of increasing blood oxygenation. The operation is usually 
accompanied by reconstruction of the hypoplastic aorta.  
 
Figure 3-5 Norwood procedure variations. 
 
The various versions of this procedure all shunt blood from the systemic to pulmonary 
circulation, but have different insertion sites for the inlet and outlet of the shunt.  The modified 
Blalock-Taussig shunt takes blood from the right subclavian artery and empties into the right 
pulmonary artery, while the Sano procedure shunts directly from the right ventricle to the 
pulmonary arteries.3,4  This stage allows for sufficient oxygenation for several months until the 
next stage of the operation.  
 
3.3.2 Stage 2: Glenn Procedure 
  
The second stage of Fontan palliation is known as the Glenn procedure.  The goal of this 
stage is to increase lung perfusion and begin separating oxygenated and deoxygenated blood. This 
stage occurs between 3-6 months of age, once the relatively high pulmonary vascular resistance 
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associated with the neonatal circulation has decreased. The first step in this procedure is to remove 
the shunt from stage 1.  The SVC is then disconnected from the right atrium and directly connected 
to the pulmonary arteries (Figure 3-6).  
 
Figure 3-6 Glenn procedure. 
 
Deoxygenated blood from the upper body now bypasses the heart and flows passively 
through the pulmonary circulation. At this stage of life, upper body flow accounts for 
approximately 60% of cardiac output, so more than half of deoxygenated blood is now separated 
from oxygenated blood. This configuration remains for several years until the final stage of 
palliation. 
 
3.3.3 Stage 3: Fontan procedure 
The final stage is known as the Fontan procedure. In this stage, the complete separation of 
deoxygenated and oxygenated blood is completed by re-routing blood from the IVC to the 
pulmonary arteries, bypassing the right atrium. In this configuration, only oxygenated blood enters 
the heart, and the two ventricles effectively function as a single pump pushing blood throughout 
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the systemic circulation. Without further complications, patient oxygen saturation can stabilize in 
the 90’s, promoting growth and proper organ function.  
The Fontan procedure was first reported in 1971 by Fontan and Baudet.5  Since their first 
procedure, the Fontan procedure has progressed through several iterations including the atrio-
pulmonary connection, lateral tunnel connection and the extracardiac conduit (Figure 3-7).6,7  Each 
design change was motivated by health problems including arrhythmias and thrombus 
formation.8,9  More recent configurations continue to surface including the Y-graft, hepatic to 
azygous shunt and hepatic to innominate vein connection.10,11 
 
Figure 3-7 Progression of Fontan connection options. 
 
 
3.4 Patient Outcomes 
Fontan patient outcomes have improved substantially since the surgery was first performed.  
However, there remains much room for improvement. A study by Pundi et al. provides an overall 
assessment of Fontan outcomes up to 40 years after surgery and includes approximately 1000 
patients.12  Overall survival at 10, 20, and 30 years after surgery were 74, 61 and 43 percent 
respectively (Figure 3-8A). When divided into surgical era, obvious improvements in 10-year 
survival rates can be seen in the more recent decades (Figure 3-8B), with approximately 70% and 





Figure 3-8  Fontan survival in terms of (A) overall patient cohort and (B) surgical era. Taken 
from Pundi et al., “40 year Follow up…”, JACC 2015. 
 
Significant differences were also seen in 10-year survival rates based on type of Fontan, 
with the extracardiac conduit outperforming all other connection types (Figure 3-9). Lateral tunnel, 
atriopulmonary and all other non-extracardiac conduit options performed similarly in terms of 10-
year survival rate.  Of the 1052 patients in this study, 177 (17%) had at least 1 early reoperation 
due to various complications including bleeding and need for a pacemaker. The major cause of 
death among these patients was primarily a cardiac cause, however the cause of death in many 
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patients was multifactorial and included respiratory failure, renal insufficiency, hepatic 
insufficiency, bleeding etc.  
 
 





A number of complications have been associated with the Fontan circulation.  Relatively 
short-term issues including pulmonary arteriovenous malformations (PAVMs), Fontan associated 
liver disease (FALD), protein losing enteropathy, arrhythmias and plastic bronchitis are often seen 
in this population.12–18 Additionally, long-term complications including heart failure, respiratory 
failure, renal insufficiency, poor quality of life and death are unfortunately inevitable as these 
patients age.12,19–21 These numerous issues have led experts to say that “…freedom from morbidity 
is likely close to zero” and conclude that Fontan patients are “doomed to a circulatory failure.”12,22  
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 While each of these morbidities deserves in depth study, this thesis focusses on two of the 
most common issues including PAVMs and liver disease.  These two complications are 
hypothesized to be hemodynamic driven, which we are well equipped to study in our lab. 
Additionally, there are currently proposed “solutions” to each of these problems that need to be 
explored and potentially validated. Finally, through existing collaborations we have obtained very 
rare data sets that will allow me to investigate the efficacy of these proposed solutions. A more 
detailed description of PAVMs and Fontan associated liver disease, as well as a description of the 
proposed solutions, is given in the following sections. 
 
3.5.1 Pulmonary Arteriovenous Malformations 
Pulmonary arteriovenous malformations are a common morbidity in Fontan patients in 
which abnormally dilated vessels create a right-to-left shunt between the pulmonary arteries and 
pulmonary veins.13,18,23,24 When this occurs, the dilated vessels offer the path of least resistance 
and receive a large proportion of pulmonary blood flow.25 Gas transport cannot occur adequately 
in blood moving quickly through these large vessels and the patient suffers from low oxygen 
saturation (Figure 3-10). PAVMs are very rare in the average population, with an incidence of only 
2-3 per 100,000.25 This condition is often asymptomatic, but can lead to dyspnea, embolic events 









Despite the rarity of this disease in the average population, PAVMs are commonly seen in 
Fontan patients.13,18,23 Previous work has investigated the exact cause of this discrepancy, and 
though not fully understood, the lack of a “hepatic factor” (lack of IVC flow) to a specific lung 
has been shown to cause PAVMs.14,26,27 Hepatic factor is delivered from the liver, through the right 
heart or TCPC (for 2-ventricle or Fontan circulation respectively), and finally through the LPA 
and RPA to the left and right lungs. A balanced hepatic flow distribution (HFD) to the left and 
right lungs is needed to prevent PAVMs.14  Poor HFD (leading to PAVMs) is often the cause for 
a Fontan revision surgery, where the surgeon will perform an additional open heart surgery in order 
to improve the surgical design of the TCPC.28,29 
Achieving a balanced HFD is inherently different for a 2-ventricle or Fontan circulation 
(Figure 3-11), which explains the discrepancy in PAVM prevalence between the healthy and 
Fontan populations.  In a normal 2-ventricle circulation, hepatic blood joins blood returning from 
the lower body in the IVC, and then mixes with blood from the upper body in the right atrium and 
right ventricle before moving through the pulmonary arteries towards the lungs. This opportunity 
for hepatic blood to thoroughly mix in the right heart with all lower and upper body blood flow 
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allows for the concentration of this “hepatic factor” to be relatively consistent throughout the entire 
volume of blood entering the left and right pulmonary arteries. This allows an ample amount of 
hepatic factor to reach both the left and right lungs and prevent the formation of PAVMs. 
 
Figure 3-11 Schematic of hepatic flow and positioning of liver for 2-ventricle (left) and Fontan 
(right) circulation. 
 
In contrast, the Fontan circulation (lacking a right atrium and ventricle) allows very little 
opportunity for hepatic flow to mix with blood returning from the upper body. After hepatic blood 
enters the IVC and mixes with blood returning from the lower body, the only time it comes into 
contact with upper body blood flow is while moving through the TCPC. The amount of mixing 
that will occur in the TCPC is highly dependent on TCPC design and individual vessel flow rates.  
Therefore, in the setting of a TCPC, hepatic flow distribution (HFD) becomes a fluid mechanics 
problem. Unfortunately, due to surgical freedom, patient circumstances and sometimes a lack of 
planning, many TCPCs are not ideal connections (Figure 3-12).  Potential solutions to this problem 





Figure 3-12 Representative examples of total cavopulmonary connections. Streamlines colored 
by inlet: IVC (blue), SVC (green), LSVC (red). 
 
3.5.2 Fontan Associated Liver Disease 
Fontan associated liver disease (FALD) is a well-documented complication which may 
have its roots in genetic, biochemical and hemodynamic origins (Figure 3-13).  Additionally, liver 
insult may occur at birth (hypoxia and hypoperfusion), during the various perioperative states 
(Norwood,  bidirectional Glenn and Fontan surgeries), and throughout the chronic condition of 
elevated CVP and relatively diminished CO.15  Regardless of cause, FALD is now recognized as 




Figure 3-13 Potential mechanisms that initiate and cause progression of Fontan associated liver 
disease. 
 
Liver disease results from chronic damage to the liver and is accompanied by the 
accumulation of extracellular matrix (ECM) proteins. These ECM proteins distort the architecture 
of the liver and form fibrous scars, leading to the development of arterialized nodules and eventual 
cirrhosis (Figure 3-14).31 Typically caused by alcohol abuse and the hepatitis C virus, Fontan 
patients free from either of these risk factors begin developing liver disease as early as the teenage 
years.30  
 





It is hypothesized that the elevated CVP and low CO inherent to the Fontan physiology 
lead to this early progression of liver disease.15,32,33 The reason for elevated CVP and low CO in 
Fontan patients is illustrated in Figure 3-15. In a 2-ventricle circulation, the right ventricle provides 
the energy needed to move blood through the pulmonary circulation. This allows blood returning 
from the body to be at very low pressure (low central venous pressure). However, in the Fontan 
circulation with no right-sided pump, blood must move passively from the vena cava through the 
pulmonary circulation. This requires blood pressure upstream of the pulmonary arteries to be 
higher than the pulmonary arteries (high central venous pressure).  
 
 
Figure 3-15 Relative pressure changes in 2-ventricle circulation (left) and Fontan circulation 
(right). LV: left ventricle, Ao: aorta, S: systemic circulation, RV: right ventricle, RA: right 
atrium, PA: pulmonary arteries, P: pulmonary circulation, LA: left atrium, LV: left ventricle. 
 
A general consensus among experts is that “hepatic congestion” (high hepatic pressure and 
low flow through the liver) is the hemodynamic mechanism that leads to liver disease in Fontan 
patients.22,34,35 Hepatic congestion can be a result of low cardiac output and elevated central venous 
pressure as previously mentioned, but may also be affected by the overburdened single ventricle, 
the TCPC, and high pulmonary vascular resistance. Potential solutions to this problem focus on 





3.6 Proposed Solutions  
To address these two common modes of Fontan failure, clinicians are actively seeking and 
“trying out” potential solutions. Surgical planning and Y-graft use are hypothesized to improve 
hepatic flow distribution and therefore prevent/resolve PAVMs, and TCPC design optimization 
and mechanical circulatory support are hypothesized to delay/prevent the progression of Fontan 
associated liver disease. Though several of these “solutions” are currently being implemented 
clinically, their efficacy remains to be assessed. A description of the aforementioned proposed 
solutions for PAVMs and FALD is given below. 
 
3.6.1 Surgical Planning (PAVMs) 
Fontan surgical planning is an image-based, collaborative effort which is hypothesized to 
result in improved patient outcomes. The current surgical planning paradigm is a multi-step 
process that involves collaboration between clinicians and engineers.  The major steps include 
preoperative image acquisition, image processing, creation of virtual surgical options, and 
numerical simulations of those proposed options (Figure 3-16).11,36–38 Communication between 
clinicians and engineers is essential to verify segmented images, discuss the viability of surgical 
options and review simulation results. Overall, surgical planning is meant to analyze the 





Figure 3-16 Surgical planning paradigm. 
 
 
The data flow, order of events, and forms of data transfer between the clinical and 
engineering setting are shown in Figure 3-17. The only physical transfer of data from the clinical 
setting to engineering setting is the imaging data which begins the surgical planning process. 
Analyses including 3D reconstructions of the preoperative anatomy and proposed surgical options, 
as well as a final surgical planning report, are ultimately sent back to the clinic at the respective 
steps in the surgical planning process.  Frequent communication between the two settings is 
important during the entire process, including segmentation, creation of realistic surgical options 





Figure 3-17 Interaction and types of data transfer between clinical and academic settings. 
Events are positioned chronologically from top to bottom. 
 
A common motivation for Fontan surgical planning is the progression (or concern for 
progression) of pulmonary arteriovenous malformations (PAVMs).  PAVMs are extremely rare in 
the average population (2/100,000), but are much more common in Fontan patients where a poorly 
designed total cavopulmonary connection (TCPC) may lead to unbalanced hepatic flow 
distribution (HFD), a known factor in PAVM formation/progression.13,14,18,23,25–27 This type of 
surgical planning can involve both Fontan revision cases (a previous Fontan surgery resulted in 
PAVMs and therefore must be revised) as well as stage 2-3 cases (often performed on patients 
with more complex anatomies and hence the need for added insight to determine the best surgical 
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strategy). The goal to optimize patient outcomes has led to a variety of Fontan connections (Figure 
3-18).  
 
Figure 3-18 Representative post-operative anatomies including (a) standard extracardiac 
conduit, (b) Y-graft, (c) hepatic to azygous, and (d) hepatic to innominate vein Fontan 
connections. The graft is highlighted red. 
 
Though limited to case studies and relatively short-term follow up data, several previous 
studies have provided a preliminary understanding of surgical planning prediction accuracy.38   
Sundareswaran et al published the first use of surgical planning to correct PAVMs (determined by 
an increase in oxygen saturation) in 2009.28  Unfortunately, this single patient case report included 
no post-operative imaging data to compare the predicted and post-operative HFD.   Haggerty et al 
provided the most thorough study to date which included only four patients with short follow up 
times (2 patients less than one month).39  This study compared HFD and graft resistance and found 
“sufficient agreement” between the predicted and post-operative states. However, the use of steady 
flow conditions and fixed outlet flow splits, as well as the small sample size, limit the 
generalizability of these findings. 
 
3.6.2 Y-grafts (PAVMs) 
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The use of Y-grafts for Fontan completion is a recent modification (2012) that is proposed 
to offer more balanced hepatic flow distribution, therefore preventing the formation of PAVMs 
(Figure 3-19). This option was motivated by intuition that directing hepatic flow through two Y-
graft arms would encourage a more balanced HFD. Y-grafts are not specifically made for Fontan 
use, so these procedures use commercially available aorta-illiac grafts “off-label”, and upside-
down compared to their designed use. The diameter of the “trunk” of these grafts is divided in half 
for the two arms. For example, a 20mm Y-graft has a 20mm (diameter) trunk and two 10mm arms. 
A simple calculation reveals that these grafts have a 50% decrease in total cross-sectional area as 
blood moves from the trunk into the two Y-graft arms. Y-grafts are made of 
polytetrafluoroethylene (PTFE). One of the initial concerns about this option was the additional 
surgery time and sutures needed for 3 anastomosis locations rather than two.  
 
Figure 3-19 Y-graft for Fontan completion. Hepatic blood flow is directed towards the left and 
right pulmonary arteries via two Y-graft arms. 
 
Y-graft use has been limited to several institutions including Children’s Healthcare of 
Atlanta (CHOA), Children’s Hospital of Philadelphia, Hospital for SickKids and University of 
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California San Francisco among others. There have been roughly 70 Y-graft Fontan cases to date, 
with ~50 of them performed by Dr. Kirk Kanter at CHOA.  Our clinical collaboration with CHOA 
and Dr. Kanter have given us access this data. 
Relatively few studies exist examining these patients as this is a new patient cohort with 
small numbers.  A feasibility study was first published by Dr. Kanter addressing the intra-operative 
details as well as hospitalization times and general hemodynamics for six consecutive patients.10 
Several engineering studies then assessed energy losses and hepatic flow distribution in these 
patients.40–42 Substantial effort was then directed towards optimizing Y-graft design to achieve 
better outcomes.43,44   Each of these studies used a very small patients cohort (n<6) which limited 
the generalizability and statistical power of their analyses and results. Additionally, most studies 
were based on immediate post-operative imaging data which may not be representative of the 
patient’s adapted state.  Overall, due to the rarity of these patients, no studies exist with any 
substantial sized patient cohort or longer-term follow up data.  
 
 
3.6.3 Improved Fontan Energetics (FALD) 
 
In addition to the overburdened single ventricle in a Fontan patient, the total 
cavopulmonary connection constitutes a major bottleneck in the Fontan circulation.22  It is 
hypothesized that the efficiency of the TCPC plays a major role in patient outcomes and that the 
TCPC is the limiting resistance in the Fontan circulatory system (Figure 3-20).   Though 
pulmonary vascular resistance may be a major player is some cases, the interest in improving 
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Fontan energetics stems from the fact that TCPC design is something that can be controlled (to a 
point).  
 
Figure 3-20 Simplistic representation of flow through several constrictions. Only the most severe 
constriction (c) will determine flow rate. 
 
Importantly, the location of the liver with respect to the TCPC has generated much concern 
for the potential pressure build up and eventual hepatic congestion that could be caused by an 
inefficient TCPC.  The liver is located immediately upstream of the TCPC, and therefore any 
increase in resistance of the TCPC would lead to an increased pressure in the liver. Therefore, the 
idea is that by decreasing TCPC resistance, the liver will experience a lower pressure and less 
hepatic congestion, hopefully leading to decreased liver disease.  Figure 3-21 shows a simple 





Figure 3-21 Simplistic comparison of the effect of TCPC resistance. 
 
 
Fontan energetics have been the focus of numerous previous studies which sought solely 
to characterize the TCPC and determine important factors that influence energy efficiency.45,46  
Studies have also correlated TCPC energy loss with exercise performance in terms of minute 
oxygen consumption and work at anaerobic threshold.47–50 Several current (unpublished) studies 
have investigated relationships between energy loss and patient outcomes including transplant, 
protein losing enteropathy, quality of life and death as endpoints.  
An area left mostly untouched by these previous studies is the use of detailed cardiac 
magnetic resonance (CMR) derived flow dynamics and computational fluid dynamics (CFD) to 
assess and correlate local Fontan flows and energetics with liver fibrosis. Individual vessel flow 
rates could provide new information regarding factors not seen in previous studies using more 
global flow metrics. Additionally, investigating the energetics of the Fontan pathway and the 
TCPC may offer insights into surgical optimization and novel design as a method to potentially 





3.6.4 Mechanical Circulatory Support (FALD) 
The current methodology of Fontan palliation results in a one “pump” circulatory system 
with passive, non-pulsatile flow to the lungs. Inherent hemodynamic differences exist between a 
biventricular circulatory system and this modified physiology, including elevated central venous 
pressures (CVP) and insufficient cardiac output (CO), as well as a myriad of ventricular function, 
impedance and congestion issues.12,16,22,32,51 As these patients survive into early adulthood, 
numerous long-term complications are common, with liver disease, protein losing enteropathy and 
plastic bronchitis among the most prevalent.15,16,52–54    
In order to moderate these long-term problems, a circulatory correction rather than 
palliation is needed; and with a limited number of immediate heart transplants available, 
mechanical circulatory support (MCS) has become a potential option as a bridge to transplant 
therapy (Figure 3-22). However, the use of MCS in Fontan patients poses unique challenges 
including low preload and afterload, an absent upstream capacitance chamber, and potentially 
difficult anatomic implementation.55  
 
Figure 3-22 Relative pressure changes in 2-ventricle circulation (left), Fontan circulation 
(center, and Fontan with VAD (right). The VAD is positioned to replace to function of the right 
ventricle.  LV: left ventricle, Ao: aorta, S: systemic circulation, RV: right ventricle, RA: right 






The two approaches for Fontan MCS include (1) designing a new pump specifically for 
Fontan use, or (2) using an existing pump off-label with the hope that it can provide adequate 
support in an environment other than its intended use. Option 1 requires significant lead time for 
design iterations, testing, and regulatory approval with the hope that such development will 
provide an ideal Fontan MCS solution. On the other hand, option 2 trades the benefits of using a 
device specifically tailored for Fontan MCS for the immediate availability of existing pumps. 
Proponents of option 2 argue that Fontan patients are failing now, and the clinic cannot wait for 
the ideal solution to arrive.   
A very limited number of studies exist that explore MCS use in the Fontan physiology, and 
even fewer studies exist that investigate either right-sided Fontan support or failing Fontan support. 
Weinstein et al. reported lower bridge-to-transplant/recovery success rates in single vs 
biventricular patients using the Berlin Heart EXCOR device.56  In this study, only 3 of 5 patients 
with a total cavopulmonary connection (TCPC) were successfully supported.  Niebler et al. 
presented a single case report showing successful ventricular support (148 days) using a 
HeartWare HVAD.57  In terms of right-sided support (the focus of the present study), Rodefeld et 
al. reported a 6 hour MCS support in a Fontan animal model, Prêtre et al. demonstrated successful 
support (11 months) in a single patient using a Berlin Heart, and Tree et al. studied the Circulite 
device using a benchtop model.58–60 These few studies constitute the majority of literature 
investigating right-sided support in a failing Fontan physiology. Clearly, further effort is needed 
to evaluate MCS devices in this scenario and potentially offer improved support for failing Fontan 





3.7 Previous Fontan Hemodynamic Studies 
In additional to those mentioned in the previous sections, numerous other studies have 
investigated Fontan hemodynamics from both a clinical and engineering standpoint. Three of the 
main areas of interest for these studies include TCPC characterization, exercise capacity and liver 
disease. The following sections will summarize some of the major findings in each of these areas. 
 
3.7.1 TCPC characterization 
A substantial amount of effort has been focused on characterizing the total cavopulmonary 
connection. This characterization includes the geometry, flow rates, and local hemodynamics, as 
well as the relationship between the three and how they change over time.  Tang et al. performed 
a study including 108 Fontan patients with the goal of identifying important geometric 
characteristics that influence Fontan hemodynamics (indexed power loss and HFD in this study).61 
They investigated vessel diameter, connection angle, and distances between vessels among other 
parameters. Computational fluid dynamics were used to assess hemodynamics on each patient. 
They found that indexed power loss was inversely correlated with minimum Fontan pathway 
diameter, and left and right pulmonary artery diameters. Hepatic flow distribution was correlated 
with caval offset, pulmonary flow distribution and the angle between the Fontan pathway and 
superior vena cava. Though none of these correlations were very strong, they conclude that these 
findings have important implications on future connection design as well as a better understanding 
of what may cause unbalanced HFD and therefore PAVM formation.  
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Haggerty et al. similarly characterized TCPC hemodynamics in a large cohort (n=100) to 
provide reference values for future studies and quantify the variability between patients.45 This 
study found that power loss varied by two orders of magnitude, and Fontan resistance was around 
15-20% of published values of pulmonary vascular resistance in these patients.  No differences 
were seen (in terms of power loss) between intra-atrial and extracardiac connections. Additionally, 
severe stenosis was seen to be the major determinant for the least efficient Fontan connections.  
Other studies have used serial imaging data to quantify geometric and hemodynamic 
changes over time in Fontan patients. Restrepo et al. examined Fontan pathway growth in lateral 
tunnel and extracardiac connections.62 Lateral tunnel connections were seen to increase in size 
over time (the heart wall is growing) while extracardiac connections did not (GoreTex cannot 
grow). In general, vessel sizes and growth over time were highly varied among patients. All flow 
rate (except SVC) increased proportionally to body surface area. In another study by the same 
group, although flow rates increased proportionally to body surface area, vessel diameters did not 
match somatic growth.63 As a result, energy losses increased significantly with time. 
In general, these studies effectively characterize the geometry, flow rates, growth and 
hemodynamics of the TCPC.  The main limitation in these studies, from a translational standpoint, 
is the lack of association with patient outcomes. Due to data availability this may have not been 
possible. These studies were an important first step in understanding the makeup of the Fontan 
population and describing the fluid dynamics within the TCPC.  
 
3.7.2 Exercise capacity 
Exercise capacity has been an area of interest in the Fontan population for a number of 
years. This has been used as a measure of a patient’s ability to sustain a normal activity level as 
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well as participate in more vigorous activities. A plethora of studies have been devoted to this 
topic.  
 Cheng et al. quantified vessel flow rates in Fontan patients both at rest and at exercise, 
finding that all flow rates increased (as expected).64 Additionally, the LPA/RPA flow ratio was 
consistent between rest and exercise, suggesting that blood flow distribution is dominated by distal 
pulmonary resistance. In this cohort of patients, IVC/SVC flow split was 50/50% at rest. During 
exercise, the IVC flow rate increased by approximately 3x while the SVC flow rate remained 
constant. Several studies have also found that heart rate, cardiac output and stroke volume are sub-
normal during exercise after the Fontan procedure.65,66 However, exercise tolerance was found to 
be approved post-Fontan compared with pre-Fontan, with arterial oxygen saturation, respiratory 
rate, minute ventilation etc. all improving.  
 Using serial data, Giardini et al. found that exercise capacity progressively declines in 
Fontan patients.67 Ventricular morphology and type of Fontan operation were the only significant 
predictors of the rate of deterioration. Gewillig et al. found no limitations in heart rate, afterload 
or contractility in Fontan patients, and reason that poor ventricular filling is the cause of diminished 
exercise performance.51 Others have further studied the effects of vena cava flow and ventricular 
function on exercise tolerance, as well as prognostic implications, and comparisons with the resting 
state and normal population.68–70   
 In terms of engineering analysis, Khiabani et al. found that exercise capacity in single 
ventricle patient after Fontan correlates with energy loss in the TCPC.50 A significant, negative 
correlation was seen between indexed power loss at exercise and minute oxygen consumption and 
work at anaerobic threshold. Indexed power loss was seen to increase at an exponential rate during 
exercise. Similarly, Whitehead et al. showed that power loss increases in a non-linear manner as 
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activity level increases.49 Some opponents to these engineering studies claim that local energy 
losses in the TCPC are much less important than more global metrics and heart function 
parameters, but the relative importance of these factors remains to be seen.  
  
 
3.7.3 Fontan associated liver disease 
As Fontan associated liver disease has become a well-recognized problem in this 
population, a number of clinical studies have investigated its causes. Asrani et al.  summarize the 
relationship between congenital heart disease and the liver and suggest that chronic, passive 
venous congestion and decreased cardiac output may promote hepatic complications.53 They also 
suggest that hepatic complications are in part related to time since the Fontan procedure and that 
the need for early cardiac transplantation and optimized management of the disease are imperative.  
A number of studies have stressed that liver disease is universal in the Fontan population.30,34 
These studies found varying levels in hepatic abnormalities in all  Fontan patients, regardless of 
time since Fontan procedure.  
Others have described the “precarious” state of the liver after the Fontan operation.15,17,22 
These studies again refer to diminished cardiac output and chronically elevated central venous 
pressure as potential culprits, and suggest that liver insult may occur at each level of the staged 
palliative operations. Importantly, groups are working towards improved, non-invasive methods 
to quantify liver fibrosis using elastography, imaging and biomarkers.71,72 Liver biopsies are 
currently the gold standard, but suffer from sampling error and invasiveness.  Other methods may 
offer an improved “global” view of the state of the liver and encourage increased monitoring. 
Currently, no engineering studies exist investigating the relationship between detailed fluid 
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mechanics of the TCPC and the extent of liver disease. Whether TCPC design/efficiency is a major 
factor in the progression of liver disease is currently unknown.    
 
 
3.8 Study Significance  
 
Within the last several years, experts have stated that “…it is reasonable to conclude that 
freedom from morbidity [for Fontan patients] is likely close to zero” and that Fontan patients are 
“doomed to a circulatory failure.”17,59  PAVMs are often the cause for Fontan revision surgeries 
and FALD has been termed a “universal” disease in Fontan patients.28,30  Clinicians are actively 
looking for solutions to these problems.  
As many as 25% of Fontan patients will develop clinically significant PAVMs with 
increasing cyanosis.23  The prevention of PAVMs can substantially improve the quality of life for 
Fontan patients. Additionally, for patients who currently have PAVMs, the use of surgical planning 
to revise the Fontan connection and resolve the PAVMs may substantially reverse this 
morbidity.28,29 
In relation to FALD, it is highly unlikely that a Fontan patient with liver disease will ever 
receive a heart transplant.73 Therefore, knowing when and how to intervene is a significant and 
challenging question. The proposed work is aimed at building healthier lives for Fontan patients 
by preventing the progression of cardiovascular related liver disease. This not only addresses 
Fontan associated liver disease, but would also increase the likelihood of Fontan heart 
transplantation. Lifelong health for these patients is dependent upon preventing long term 
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complications. The purpose of testing currently available VADs is to potentially offer immediate 




4.1 Medical Image Processing 
4.1.1 Image Acquisition 
All CMRs were performed at either the Children’s Hospital of Philadelphia or Children’s 
Healthcare of Atlanta with Siemens 1.5 T magnetic resonance imaging systems (Siemens Medical 
Solutions, Malvern PA). Patients were scanned supine, head first in the scanner with ECG leads 
placed under a breath-held protocol. After localizers were obtained, a stack of contiguous, static, 
diastolic steady state free precession (SSFP) images were obtained from the diaphragm to thoracic 
inlet to assess anatomy and provide inputs for CFD modeling. Slice thickness was generally 1-5 
mm and in plane resolution was 1.2x1.2 mm.  
 Through plane, retrospectively gated, phase contrast magnetic resonance (PC-MRI) was 
used to assess flows in the cavae, branch pulmonary arteries, pulmonary veins and across the aortic 
valve. IVC flow was measured supra-hepatic. The location of these planes in relation to the TCPC 
for one representative patient is shown in Figure 4-1. Velocity encoding (VENC) was generally 
150 cm/sec for the aorta and 60 cm/sec for the other vessels. Slice thickness was generally 4-5 mm 
with in plane resolution of 1.25x1.25 mm. The number of phases was a function of the heart rate 





Figure 4-1 Location of PC-MRI planes for blood flow velocity measurement for a representative 
patient. 
 
 Global ventricular function was calculated from cine images of the ventricular short axis. 
Endocardial and epicardial borders were semi-automatically traced and ventricular volumes were 
determined by multiplying the slice thickness with the segmented area. Slice volume was 
integrated along the ventricular longitudinal axis using Simpson’s rule to extract the total volume 
of the ventricle in a cardiac phase. This method was applied at end diastole and end systole to 
calculate end-diastolic volume (EDV) and end-systolic volume (ESV) respectively. Stroke 
Volume (SV) and ejection fraction (EF) were calculated as the EDV-ESV and SV/EDV 
respectively. 
4.1.2 Anatomy Segmentation 
Patient specific anatomies were reconstructed from CMR images. For convenience, images 
were often re-oriented to give axial images for segmentation. Images were then loaded into an 
open-source segmentation software, InVesalius or ITK-Snap, both of which have been validated 
for medical image reconstruction.74–77 In either software, various levels of automation can be used 
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to assist with segmenting the TCPC. Due to the high degree of variability among Fontan anatomies, 
fully automatic segmentation (and even semi-automatic in some cases) has been unfruitful, 
requiring manual segmentation. In either case, the TCPC is segmented from the IVC at the level 
of the diaphragm up to the innominate vein on the SVC. Pulmonary arteries are segmented until a 
branching point. The segmented anatomy was outputted as a .stl file for further processing in 
Geomagic.    
 
4.1.3 Blood waveform segmentation  
Blood flow waveforms for all vessels of interest were reconstructed from PC-MRI images 
to provide boundary conditions for modeling purposes. These vessels include the IVC, SVC, LPA, 
RPA, LSVC and AZ as appropriate. An open-source software (Segment, 
http://segment.heiberg.se) was used to segment the blood flow waveforms for all patients. Segment 
provides a straightforward and user friendly workflow for segmentation, and offers a wide variety 
of functionality including automatic region of interest refining and propagation, vessel tracking 
throughout the cardiac cycle, automatic parameter calculation and 3D velocity profile 
segmentation among others.77,78 To segment a blood flow waveform, a contour was drawn around 
the vessel of interest and propagated throughout all phases in the cardiac cycle (typically 20-30). 
Segment then calculated the flow rate at each phase by spatially registering the magnitude and 
directionality information of each pixel and computing the total flow rate within the specified 





4.2 Computational Fluid Dynamics 
A general methodology overview of patient specific CFD simulations can be seen below in Figure 
4-2  .11 
 
Figure 4-2 General process for patient-specific CFD simulations. 
 
4.2.1 Mesh Generation 
The step by step process for mesh generation can be found in Appendix 0.  In general, a 
polyhedral mesh of approximately DIVC/20 mm elements was used in order to achieve mesh 
independent results, where DIVC is the diameter of the IVC.79  Mesh sizing was varied across the 
model and flow extensions in order to create a high-quality mesh with as few elements as possible. 
An inflation layer was used to capture near wall velocity and pressure gradients.  ANSYS 
Workbench was used to add flow extensions, control meshing parameters and check mesh quality 
as detailed in Section 0  
. 
4.2.2 Blood waveform processing 
The blood flow waveforms segmented from the phase contrast CMR data must be 
processed before implementing as boundary conditions in a CFD simulation.  This is the case 
because of errors associated with medical imaging. For example, in the case of the TCPC, the flow 
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rate of the inlets (IVC and SVC) must be equal to the flow rates of the outlets (LPA and RPA) 
over a cardiac cycle (conservation of mass).  However, this is never the case. It is common for 
inlets and outlets to be around 20% different in magnitude. To account for this, it is common 
practice to scale the outlet waveforms (while maintaining the LPA/RPA flow ratio at each time 
point) in order the match the inlet flow magnitude and achieve conservation of mass.  The outlets 
are scaled (rather than the inlets) because clinical experience has shown that measuring flow rates 
from the larger vessels (IVC and SVC) are more accurate. Clinicians ensure that trusting the 
LPA/RPA ratio is accurate because similar errors may occur in each vessel. After scaling the outlet 
waveforms appropriately, a fast Fourier transform is then used to create a repeatable waveform 
that can be used in simulations.  The top 30 frequency components were used for waveform 
modeling to allow for a well-fitted curve (r2=0.999). A custom MATLAB script for scaling and 
creating the FFT waveform can be found in Appendix 0. 
 
 
4.2.3 Simulation Parameters  
A step by step guide to simulation set-up, including the various fluid and solver parameters 
(fluid properties, convergence criteria, number of time steps etc.) can be found in Appendix 0. All 
simulations were performed using ANSYS Fluent (Release 17.0) which is a finite volume 
pressure-based Navier-Stokes solver. Blood was modeled as a single-phase Newtonian fluid 
(µ=0.04 g/(cm·s), ρ=1.06 g/cm3). Patient specific blood flow waveforms extracted from PC-MRI 
were used as boundary conditions for each TCPC inlet and outlet. Twenty cardiac cycles were 
simulated to overcome transition effects and achieve period stability, using the final cycle for data 
43 
 
analysis. All simulations assumed rigid walls and employed flow extensions to develop velocity 
profiles.  
 
4.2.4 Flow field visualization 
Tecplot 360 (2013, Release 1) was used for flow visualization using the output of CFD 
simulations. Fluent outputs including a case and data file (.dat files) were opened in Tecplot. Slices 
were taken at desired locations from which streamlines were created. The velocity information at 
each data point was used to produce flow field animations, streamtraces and streamlines as needed.   
Various built in Tecplot functions were used to visualize velocity and pressure contours. 
Streamlines were exported for analysis in MATLAB. A custom MATLAB script and Tecplot 
macro were used to color streamlines by outlet. This procedure and associated codes can be found 
in Appendix 0. 
 
4.3 In vitro modeling 
4.3.1 Experimental loop design 
An overall schematic of the in vitro Fontan circulatory loop is shown in Figure 4-3. A 
programmable piston pump (Vivitro SuperPump, Model SPL 39891; Vivitro Systems Inc, 
Victoria, British Columbia) powered the loop, representing the single systemic ventricle (70 bpm), 
with a bileaflet mechanical heart valve (BMHV) on either side representing the atrioventricular 
and aortic valves.  Compliance chambers and ball valves were used to model aortic and systemic 
compliance and resistance respectively. All pathways were designed as 3-element Windkessel 
models, employing a resistance-compliance-resistance circuit (only one resistance shown in Figure 




Figure 4-3 Fontan in vitro loop design.  Schematic of in vitro Fontan circulatory loop with 
labeled components: (1) programmable piston pump (single ventricle), (2) bileaflet mechanical 
heart valves, (3) aortic and system compliance chambers, (4) systemic resistance, (5) patient-
specific total cavopulmonary connection, (6) pulmonary resistance, (7) pulmonary compliance 
chambers, (8) single atrium compliance chamber. 
 
Blood was modeled with a 36%/74% glycerin-saline solution (by volume) with 3.47 cSt 
kinematic viscosity. The in vitro loop employed a patient-specific, flexible total cavopulmonary 
connection (TCPC) anatomy reconstructed from magnetic resonance imaging with institutional 
review board (IRB) approval (H09279). The TCPC model was constructed of transparent silicone 
with a patient-specific matched bulk compliance (1.36 mL/mmHg).80 The model walls were 
1.4±0.1 mm thick and constructed of a shore 30A hardness flexibile silicone material that was dip 
molded to the segmented patient specific geometry.  
A National Instruments data acquisition (DAQ) system and custom LabVIEW virtual 
instrument were used to control the piston pump and record pressure and flow measurements (see 
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section 0). Data were collected for 4 flow rates (IVC, SVC, LPA, RPA) and 6 pressures (IVC, 
SVC, LPA, RPA, single atrium, single ventricle). The custom LabVIEW virtual instrument 
controlled the system and allowed the investigator to acquire, calibrate, and display all 16 analog 
input voltage signals. Acquisition sampling frequency was adjustable, and the incoming signals 
were used in the real-time calculation of several important verification parameters: signal mean, 
signal maximum, and signal minimum. The time period over which each of these parameters was 
calculated was set independent of the sampling frequency. This allowed for cyclic averages during 
pulsatile experimental conditions. These parameters could be calculated on multiple signals 
simultaneously, which allowed for additional flow pulsatility and resistance verification.   
 
4.3.2 Data collection 
Flow probes and pressure transducers were positioned at every TCPC inlet and outlet as 
shown in Figure 4-3. Pressure relative to atmospheric pressure was measured via fluid-filled strain 
gauge pressure transducers (Model 6199; Utah Medical Products Inc., Midvale, UT). The pressure 
transducers had a measurement range of -50 to 300 mmHg and a sensitivity of 5 µV/V/mmHg, or 
± 2 %. The pressure transducer excitation voltage and signal amplification was provided by a 
custom-built signal conditioning box constructed by the Georgia Tech Mechanical Engineering 
Electronics Lab. Signal output from the conditioning box was read by LabVIEW. 
Flow rates were measured with 3 in-line and 1 clamp-on ultrasonic flow probes (Transonic 
Systems, Ithaca, NY). The 3 in-line flow measurements were performed with model 10PXN 
probes. The clamp-on measurement was with a model 8PXL probe. The flow probes utilized the 
Doppler effect to measure the flow at a frequency of 1.2 MHz. The flow signal from each probe 
was sent to a TS410 tubing flow module housed within a T402 multi-channel research console. 
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The research console applied a low pass filter at 100 Hz to each signal before the signal was read 
by LabVIEW. All flow probes had a resolution of 0.01 L/min. 
 
4.3.3 Experimental parameters 
Baseline failing Fontan conditions will first be established in each experiment. Baseline 
failing Fontan conditions were defined as a cardiac output (CO) of 3.5 L/min with Fontan pressures 
near 15-20 mmHg. The inferior and superior vena cava (IVC and SVC) and left and right 
pulmonary artery (LPA and RPA) flow splits were set to 60/40 and 50/50 respectively. Identical 
baseline conditions were used for all tested devices. Device parameters including flow rate, 
frequency, and filling/ejection times were investigated.   
 
4.3.3.1 Cannula and baffle restriction strategies 
Multiple cannula and baffle restriction strategies were tested including placing the VAD 
(1) in parallel with the Fontan baffle (inflow placed in the IVC near the diaphragm and egress 
located at the LPA/RPA confluence, Figure 4-4a), (2) in series with the Fontan baffle (same 
cannulation as (1) with baffle completely restricted, Figure 4-4c), and (3) performing a Fontan 
“takedown” and using the VAD as a true (albeit extracorporeal) right ventricle. 
Additionally, in an attempt to reduce potential recirculation, a Y-graft outflow cannula 
(inserting downstream in each pulmonary artery, Figure 4-4b) was tested in series and in parallel. 
The main difference between scenario 2 and 3 is that SVC flow can move directly into the 
LPA/RPA in scenario 2, therefore it is not a complete Fontan “takedown.” In scenario 3, all 
IVC/SVC flow must pass through the assist device before entering the pulmonary circulation. To 
experimentally achieve scenario 3, the pulmonary arteries were separated from the IVC/SVC using 
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two clamps (Figure 4-4d).  In addition to these 3 scenarios, various levels of baffle restriction (0-
100%) were explored in the “in parallel” configuration.  A schematic of the TCPC and VAD with 
vessels and cannula labeled is shown in Figure 4-4e. Outflow cannula will vary based on 
cannulation strategy. 
 
Figure 4-4 Cannulation strategies. (a) Fontan assist device (VAD) in parallel with single outflow 
cannula. (b) VAD in parallel with Y-graft outflow cannula. (c) VAD in series (complete Fontan 
baffle restriction). (d) Fontan takedown configuration (vena cava separated from pulmonary 
arteries). (e) Schematic of total cavopulmonary connection and VAD with vessels and cannula 






4.3.3.2 Banding designs 
A further investigation was performed looking into the effect of Fontan baffle banding 
design on hemodynamics. This was undertaken after realizing that complete baffle restriction was 
needed for certain devices.  Five banding designs were 3D printed for testing. Each band was 




Figure 4-5 Effect of banding design on hemodynamics. (a) Effect of banding on pressure; (b) Theoretical 
relationship between banding length (L) and area to maintain resistance (r=radius); (c) Top and side views 
of the five custom banding designs; (d) Effect of banding design on SVC pressure (VAD rpms labeled above 
each bar). Banding is calculated as percent constriction by area. All points on the curve in (b) theoretically 
offer the same resistance.  The asterisk in (d) indicates that SVC pressure increase was measured at the 








4.3.4 Mechanical circulatory support 
Four mechanical circulatory support devices will be assessed in this thesis.  Each device 
will be tested as a Fontan assist device (VAD), where the inflow cannula will be attached to the 
IVC and the outflow cannula will insert into the center of the TCPC junction. Various 
configurations will be tested and described in further detail in Chapter 8. For use as a Fontan assist 
device, each of these devices must be used “off-label.” A description of each device is given in the 
following sections.  
The two approaches for Fontan MCS include (1) designing a new pump specifically for 
Fontan use, or (2) using an existing pump off-label with the hope that it can provide adequate 
support in an environment other than its intended use. Option 1 requires significant lead time for 
design iterations, testing, and regulatory approval with the hope that such development will 
provide an ideal Fontan MCS solution. On the other hand, option 2 trades the benefits of using a 
device specifically tailored for Fontan MCS for the immediate availability of existing pumps. In 
this thesis, we are using the second approach and testing devices “off-label” with the goal of 
determining which devices may be able to provide immediate support to these patients. 
  
4.3.4.1 CircuLite 
The Circulite (Medtronic, Minneapolis, MN) device is a small, implantable ventricular 
support system (Figure 4-6). The device prides itself on requiring only a minimally invasive 
procedure for implantation. Circulite is designed for patients with chronic heart failure. The pump 
can provide up to 4.24 L/min of blood flow under the pressure conditions of the left ventricle in 
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heart failure. The device is meant to supplement the heart’s cardiac output and not completely 
replace the function of the left ventricle. Circulite is controlled and powered by a wearable external 
controller and battery pack connected via a percutaneous lead.  
 
Figure 4-6 Circulite ventricular assist device. 
4.3.4.2 VENTRIFLO™ True Pulse Pump 
The VENTRIFLO™ (Design Mentor, Pelham, NH) True Pulse Pump system is an 
extracorporeal blood pump that produces pulsatile blood flow using a flexible membrane as its key 
enabling technology (Figure 4-7). This device is designed for cardiopulmonary bypass, but it very 
tunable which may lend itself to “off-label” uses.  The pump driver incorporates an 
electromagnetic linear motor with a suspended magnet between the motor coils, providing unique 
pressure sensitivity with automatic stroke volume adjustment for a given motor current and 
vasculature pressure.81  Cadence, stroke strength and cycle timing of the pump are defined by the 
user.  VENTRIFLO™ employs one-way ball valves on either side of the pump to ensure 






Figure 4-7  VENTRIFLO™ True Pulse Pump. 
 
4.3.4.3 PediMag 
The Pedimag (Abbott (Thoratec), Pleasanton, CA) device is an extracorporeal circulatory 
support device used to stabilize patients in need of cardiopulmonary assistance (Figure 4-8).  
Pedimag is currently approved for clinical use up to six hours, as a short-term solution while 
surgical/long-term circulatory support decisions can be made. This device uses a magnetically 
levitated pump impeller which is hypothesized to reduce hemolysis issues.82 Under left ventricle 
pressures, Pedimag is rated to output up to 1.5 L/min. The entire pump system is made to be 
transportable. 
 





The Centrimag (Abbott (Thoratec), Pleasanton, CA) device is a “scaled-up” version of the 
Pedimag device (Figure 4-9). Centrimag uses the magnetically driven pump impellar technology 
as the Pedimag device. CentriMag is currently approved for use as a right ventricle assist device 
for up to 30 days in patients in cardiogenic shock due to acute right ventricular failure. The 
Centrimag and Pedimag pumps use identical hardware. CentrMag is more powerful than the 
smaller PediMag device, and can deliver 9.9 L/min under left cardiac failure conditions.83  
 
 




4.4 Data Analysis 
4.4.1 Anatomy characterization 
Vascular modeling toolkit (VMTK) was used to characterize patient specific anatomies. A 
detailed protocol can be found in Appendix 0. Parameters including average, minimum and 
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maximum vessel diameters, centerlines, and stenosis were calculated. Overall PA stenosis was 
defined using the following equation: 
𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑃𝐴 𝑆𝑡𝑒𝑛𝑜𝑠𝑖𝑠 % = 100
𝐴 , + 𝐴 ,
𝐴 , + 𝐴 ,
 
where 𝐴 ,  and 𝐴 ,  are the minimum cross-sectional areas of the LPA and RPA, and 
𝐴 ,  and 𝐴 ,  are the average cross-sectional areas of the LPA and RPA. A combined 
outlet stenosis value was used in place of unilateral PA stenosis measurements to give a more 
accurate representation of the total outlet obstruction to flow and allow a better comparison 
between patients. Additionally, IVCs and SVCs showed negligible percent stenosis and therefore 
were not included in this calculation.   
 
4.4.2 Hepatic flow distribution  
Hepatic flow distribution was quantified by seeding massless particles at the IVC and 
calculating the total flux of particles leaving the left and right pulmonary arteries. Hepatic flow 
distribution is defined as 𝐻𝐹𝐷 =  where 𝜃 is the total flux of particles throughout a 
cardiac cycle. The error in HFD prediction is defined as: 
𝐻𝐹𝐷   =  𝐻𝐹𝐷 − 𝐻𝐹𝐷  
HFD will also be discussed in terms of “HFD deviation from 50%”, and an even (50/50) split of 
hepatic flow to the LPA and RPA is assumed as ideal. This convention gives a “0” HFD deviation 
for balanced HFD cases, and an HFD deviation of 50 for extreme cases (all hepatic flow to either 
the LPA and RPA. HFD deviation is calculated as: 




4.4.3 Energy loss 
Calculations were performed to compute several TCPC efficiency related metrics including 
power loss (PL), indexed power loss (iPL) and TCPC resistance. The TCPC is thought to be a 
major “bottleneck” of the single ventricle circulatory system, and these metrics quantify how 
inefficient this connection is. Power loss was calculated from a simplified control volume approach 
as follows: 
𝑃𝐿 = 𝑝 +
1
2
𝜌𝑣 𝑣 · 𝑑𝐴 − 𝑝 +
1
2
𝜌𝑣 𝑣 · 𝑑𝐴 
where p is the static pressure, ρ is the blood density, A is the area of the inlet/outlet and v the 
velocity at the respective inlets or outlets. Power loss was calculated at every millisecond 
throughout the cardiac cycle and then averaged to obtain an overall PL value. Power loss was 
indexed (iPL) as (
/
) and a TCPC resistance was calculated 
∆
 where Qs is the 
systemic venous flow (L·min-1), BSA is body surface area (m2), ∆𝑃  is the pressure drop across 
the TCPC and ρ is blood density (kg·m-3).84 A custom post-processing MATLAB code was used 
to calculate these variables and check their convergence over multiple cardiac cycles. Results 
changing less than 5% between cardiac cycles were defined as converged.  This code with details 
is included in Appendix 0. 
 
4.4.4 Additional metrics 
Several additional metrics were calculated including pulmonary flow distribution (PFD), 
aortic to pulmonary collateral flow, particle residence time (PRT) and pulsatility index (PI). PFD 
was calculated as 𝑃𝐹𝐷 =  where Q is flow rate. Collateral flow was calculated as the 
difference between aortic and vena cava flow: 𝐶𝑜𝑙𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑓𝑙𝑜𝑤 = 𝑄 − 𝑄 − 𝑄  . This is 
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an important clinical metric which describes how much of the cardiac output is bypassing the 
TCPC. Particle residence time was calculated from CFD results by recording the amount of time 
required for 95% of all seeded particles to exit the TCPC domain.  Pulsatility index was defined 
as follows: 




where Qmax, Qmin, and Qavg are the maximum, minimum and average flow rates during the cardiac 
cycle, respectively, as determined from the phase contrast CMR data. In general, the Fontan 
circulatory system is much less pulsatile than a normal, biventricular system. Pulsatility is thought 
to affect mechanotransduction and therefore may affect a number of biological processes 
potentially leading to diseased conditions in the single ventricle patient.  
 
4.5 Statistical Analysis 
 
SPSS (IBM Corp., Version 24, Armonk, NY) was used for statistical analyses. The Shapiro-
Wilk test was used to determine normality for each parameter. Pearson’s and Spearman’s 
correlations were used to investigate bivariate correlations for parametric and nonparametric data 
respectively. For SA 2A, data was also binned into tertiles or quartiles based on liver score for 
further analysis. Depending on normality, either a Wilcoxon rank sum test or an independent 
sample t-test was used to test for equal medians between groups. 
For data with serial timepoints, a paired-sample t-test or Wilcoxon signed-rank test was used 
to investigate differences between timepoints. A multiple regression analysis, using the forward 
stepping method, was used to investigate if a combination of several parameters were predictive 
of another parameter. The DFBETA test and Grubb’s test were used to determine and remove 
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overly influential data points and outliers respectively. To account for multiple comparisons in the 
liver studies, a more stringent significance level of  α=0.01 was chosen to account for multiple 
testing. Standard descriptive statistics were calculated for all metrics. In most cases, statistical 
significance was determined using p<0.05 (except when correcting for multiple comparisons).  
Values are shown as average ± standard deviation [range]. Power analyses (G*Power, version 
3.1.9.2) were used to determine the required effect size needed for statistical significance at a given 
sample size. 
4.6 Institutional Review Board  
All patient data incorporated in this thesis were collected, shared and used under appropriate 
approval of each center’s institutional review boards ensuring the ethical treatment of human 
subject data. The respective IRB approval identification numbers are given below: 
 
Table 4-1 List of IRB approvlas for the patient data used in this thesis.  
Data (SA #) IRB approval # 
Surgical planning (SA 1A) H09279, H17434 
Y-grafts (SA 1B) H14005 
Comparison patients (SA 1B) H05236 
Liver study (SA 2A) H17229 





5. SPECIFIC AIM 1A 
 
Purpose: To evaluate the accuracy of surgical planning to predict post-
operative hepatic flow distribution and resolve pulmonary arteriovenous 
malformations. 
 
Hypothesis: Surgical planning can accurately predict post-operative hepatic flow 
distribution. 
 
5.1 Overview  
While surgical planning has been used in a number of previous studies, no conclusive 
evidence or long-term follow up data exists showing whether surgical planning was accurate or 
beneficial.  Specific Aim 1A will use patient-specific, computational fluid dynamic (CFD) 
modeling to analyze the accuracy of surgical planning predictions of hepatic flow distribution 
(HFD), a known factor in pulmonary arteriovenous malformation (PAVM) progression.  This aim 
will include all patients in the Georgia Tech Fontan database who were enrolled in a prospective 
surgical planning protocol before surgery. This included both Fontan revisions (n=5) as well as 
Stage 2-3 surgeries (n=7).  Pre- and post-operative MRI and clinical data exist for each patient. 
Predicted results will be compared with long-term follow up data to determine if surgical planning 




This Specific Aim utilizes medical image processing, computational fluid dynamics, anatomy 
characterization and statistical analysis. Please refer to Chapter 4 for a detailed description of the 
methodology for each. 
 
5.2.1 Study Design 
Surgical planning accuracy was investigated for both Fontan revisions and Fontan 
completions. To do this, each patient was prospectively enrolled in a surgical planning protocol 
prior to the respective surgery. A flow chart is used to explain the clinical history and points of 
evaluation for both the Fontan revision (Figure 5-1) and Fontan completion cases (Figure 5-2).  
All Fontan revision patients had previously developed PAVMs and were undergoing a revision 
surgery to correct the PAVMs. All fontan completion cases were enrolled in surgical planning due 
to their complex anatomies and concern for future development of PAVMs. 
 
Figure 5-1 Series of events required for all Fontan revision patients included in this study. In each 
case, the formation of PAVMs was the main cause for the re-operation. Hepatic flow distribution 






Figure 5-2 Series of events required for all Fontan completion patients included in this study. 
Hepatic flow distribution will be assessed at each of the timepoints indicated.  
 
5.2.2 Patient Selection  
A total of 12 single ventricle patients were included in this study. All patient data was 
received from the Children’s Hospital of Philadelphia and Children’s Healthcare of Atlanta under 
IRB approval (17-014377 and H09279 respectively) with a waiver of consent. Inclusion criteria 
were that the patient: (i) was enrolled in the surgical planning process prior to surgery, (ii) patient 
had pre- and post-operative cardiac magnetic resonance (CMR) and phase contrast CMR imaging, 
and (iii) imaging quality was sufficient for accurate anatomical segmentation as well as flow 
segmentation at every TCPC inlet/outlet.  This resulted in both Fontan revision cases (n=5) and 
stage 2-3 cases (n=7). Clinical data including age, gender, body surface area (BSA), imaging and 
surgery dates, and diagnosis was obtained for each patient.  
 
5.2.3 Surgical Planning 
5.2.3.1 General Process 
The current surgical planning paradigm is a multi-step process that involves collaboration between 
clinicians and engineers.  The major steps include preoperative image acquisition, image 
processing, creation of virtual surgical options, and numerical simulations of those proposed 
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options (Figure 5-3).36–38 Communication between clinicians and engineers is essential to verify 
segmented images, discuss the viability of surgical options and review simulation results. Overall, 
surgical planning is meant to analyze the performance of potential surgical options and therefore 
help inform the decision of graft type and positioning.   
Potential surgical options are evaluated and ranked according to various clinically 
important metrics. To date, the major goals of Fontan surgical planning have included minimizing 
energy loss in the total cavopulmonary connection (TCPC), providing a balanced hepatic flow 
distribution (HFD) to the left and right lungs, and avoiding extreme wall shear stress. Energy loss 
has been related to exercise intolerance and is hypothesized to affect overall patient outcomes and 
HFD is a known factor in PAVM progression.28,41,50,85,86 In situations where one specific surgical 
option is not optimal for all metrics, clinicians must evaluate which complication is of most 
concern for a given patient. For example, the progression of PAVMs is a very common motivation 
for surgical planning and therefore would focus on achieving balanced HFD. 
 




The data flow, order of events, and forms of data transfer between the clinical and 
engineering setting are shown in Figure 5-4. The only physical transfer of data from the clinical 
setting to engineering setting is the imaging data which begins the surgical planning process. 
Analyses including 3D reconstructions of the preoperative anatomy and proposed surgical options, 
as well as a final surgical planning report, are ultimately sent back to the clinic at the respective 
steps in the surgical planning process.  Frequent communication between the two settings is 
important during the entire process, including segmentation, creation of realistic surgical options 
(requires the most clinical input), and review of comprehensive results. 
 
Figure 5-4 Interaction and types of data transfer between clinical and academic settings. Events 




5.2.3.2 Anatomy prediction 
The preoperative anatomical segmentation is the basis for generating potential surgical 
options, which is performed following detailed discussion with the clinicians. The Glenn anatomy 
(for pre-Fontan planning) or original Fontan anatomy (for Fontan revisions), as well as structures 
that could create anatomical constraints for the proposed options (heart, aorta etc.) are included in 
the modeling.  While standard CAD software can be used to generate surgical options, the use of 
modeling software specifically designed for Fontan surgical planning drastically reduces the time 
and effort required, and reduces the need for any prior modeling expertise. For example, SURGEM 
III is a software which has been developed over the last decade specifically for Fontan surgical 
planning.37,87,88  SURGEM III is an interactive solid modeling tool whose name stems from 
“surgery modeler.”  It is designed to simplify and accelerate the surgical planning process, 
specifically the steps involved in creating and evaluating potential surgical options.  With this 
software, a user can easily choose a graft type (traditional conduit or Y-graft) and graft size (in 2 
mm increments) and position the insertion locations as desired (Figure 5-5). The user can modify 
graft centerline placement, insertion angle and offset options as needed (Figure 5-5c).  SURGEM 
III can also automatically generate a large number of combinations of graft size and insertion 
angles/offsets in order to evaluate the robustness of given surgical option.89  Finally, this software 
can preview and export a surface mesh of the proposed surgical option for the next step in the 




Figure 5-5 Creation of surgical options. (a) Fontan extracardiac baffle option. (b) Fontan 
bifurcated Y-graft option. (c) Automatic creation of baffle insertion angle/offset variations. (d) 
Preview of unioned (pre-op anatomy with proposed graft placement) mesh. 
 
5.2.3.3 Blood flow waveform prediction 
In this study, the pre-operative flow waveforms reconstructed from PC-MRI were directly used as 
the “predicted” flow waveforms. This prediction was used because it is the fastest prediction 
method and can fit within the relatively short clinical timeline.  
5.2.3.4 Additional metrics  
HFD prediction error is defined as: 
𝐻𝐹𝐷   =  𝐻𝐹𝐷 − 𝐻𝐹𝐷 . 
An absolute value is used to focus on total error rather than the direction of the discrepancy. 
Changes in flows pre- to post-operative are calculated as: 
𝐹𝑙𝑜𝑤 𝐶ℎ𝑎𝑛𝑔𝑒 = 𝑄 − 𝑄  
where Q represents flow rate.  
 
5.2.3.5 Pre-operative vs post-operative anatomy comparison 
To compare the predicted and post-operative anatomies, the TCPCs were first registered 
(Geomagic, 3D Systems, Rock Hill, SC) to account for differences in imaging coordinate systems. 
A mesh comparison software (CloudCompare, version 2.10, open source) was then used to 
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quantify average and maximum deviations between the surfaces of the two TCPCs. A detailed 
description of this process can be found in Appendix 13.6: Anatomy Comparison.  This was done 
for both the full TCPC and the graft alone.  Graft insertion offset was calculated by measuring the 
distance between the predicted and post-operative anastomosis locations. For Y-grafts, the largest 
insertion offset of the two branches was used.  
 
5.3 Results 
5.3.1 Clinical Data 
Clinical and surgical data is given in Table 5-1. The cohort consisted of 5 Fontan revisions 
and 7 Stage 2-3 cases. Implemented surgical options included 4 hepatic to azygous shunts, 4 Y-
grafts, 3 traditional extracardiac conduits and 1 hepatic to innominate vein connection. Average 
follow up time was 22±32 [0.2-98] months. All raw data for both pre and post time points as well 














































Patient 1 F H, PA Revision Left Hep to 
AZ 
4.7 12.8 97.8 60 56 4 
Patient 2 F H Revision Left Y-graft 19.0 19.0 0.3 38 45 7 
Patient 3 M H, D Revision Right Hep to 
AZ 
11.6 15.0 40.4 100 100 0 
Patient 4 F U Revision Right Y-graft 12.7 12.8 1.6 53 32 21 
Patient 5 M H, PA Revision Left ECC 17.5 18.3 9.0 26 71 45 
Patient 6 M HLHS Stage 2-3 - ECC 1.3 4.3 35.9 17 51 34 
Patient 7 M H, 
HLHS, 
Stage 2-3 - Y-graft 2.6 2.6 0.2 27 48 21 
Patient 8 F PA, TH Stage 2-3 - Y-graft 3.0 8.3 63.7 60 77 17 
Patient 9 M PA, 
DILV 
Stage 2-3 - ECC 2.2 2.2 0.3 73 80 7 
Patient 
10 
F H Stage 2-3 - Hep to 
AZ 





Stage 2-3 - Hep to 
AZ 





Stage 2-3 - Hep to 
Inn 
1.4 1.5 2.1 48 25 23 
*The pulmonary arteriovenous malformations (PAVMs) column indicates which lung contained 
the malformations. Diagnoses are abbreviated as heterotaxy (H), pulmonary atresia (PA), 
dextrocardia (D), hypoplastic left heart syndrome (HLHS), tricuspid hypoplasia (TH), double inlet 
left ventricle (DILV), unbalanced canal (U) and double outlet right ventricle (DORV). Surgical 
options are abbreviated as hepatic to azygous shunt (Hep to AZ), extracardiac conduit (ECC) and 




5.3.2 Revisions vs Stage 2-3 
Age at surgery and age at follow up were significantly different between the revision 
(13.1±5.7 and 15.6±2.9 years) and Stage 2-3 (2.1±0.9 and 3.5±2.5 years) cases respectively 
(p<0.001 for both, Table 5-2). Follow up time was not significantly different between the revision 
and Stage 2-3 cases (30±41 and 16±25 months respectively, p=0.49, Table 5-2).  No significant 
differences in pre- to post-operative changes in flow rates were seen between the revision and 
Stage 2-3 cases (Table 5-2). Additionally, no flow rates (grouped by surgery type or vessel) 
showed consistent directionality in flow rate changes. Significant differences in geometric 
variations (between the predicted and actual post-operative anatomy) were seen between the 
















Table 5-2 Fontan revision and Stage 2-3 comparison. 
  Revision Stage 2-3 p-value 
Age at surgery (yrs) 13.1±5.7 2.1±0.9 <0.001 
Age at follow up (yrs) 15.6±2.9 3.5±2.5 <0.001 
Follow up time (months) 30±41 16±25 0.492 
HFD prediction error 15±18 18±10 0.795 
IVC flow change (L/min) 0.22±0.16 0.25±0.19 0.782 
SVC flow change (L/min) 0.35±0.13 0.44±0.32 0.573 
AZ flow change (L/min) 0.61±0.45 0.20±0.17 0.104 
LPA flow change (L/min) 0.57±0.19 0.48±0.37 0.638 
RPA flow change (L/min) 0.80±0.60 0.25±0.22 0.052 
IVC flow change (%) 42±42 41±26 0.955 
SVC flow change (%) 36±21 48±29 0.462 
AZ flow change (%) 49±30 40±28 0.656 
LPA flow change (%) 38±21 59±35 0.274 
RPA flow change (%) 62±40 41±53 0.471 
PFD change (%) 9±9 14±6 0.261 
TCPC deviation (mm) 3.3±0.8 1.6±0.5 0.001 
TCPC max deviation (mm) 17.6±2.0 9.2±3.7 0.004 
Graft deviation (mm) 5.6±2.8 2.8±1.9 0.062 
Graft max deviation (mm) 15.3±4.4 9.3±4.5 0.046 
Graft insertion offset (mm) 13.5±8.3 5.8±4.5 0.063 
Change represents absolute difference between pre-operative and post-operative flows. Hepatic 
flow distribution (HFD); inferior and superior vena cava (IVC and SVC); left and right pulmonary 
artery (LPA and RPA); azygous vein (AZ); pulmonary flow distribution (PFD); total 
cavopulmonary connection (TCPC). 
 
5.3.3 HFD Prediction Error  
The predicted and post-operative HFD can be found in Table 5-1. Overall, HFDprediction error 
was 17±13%, and was not significantly different between revisions (15±18%) and Stage 2-3 
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(18±10%) cases (p=0.73, Table 5-2).  Stage 2-3 predictions underestimated HFD in 6/7 cases, 
while revisions were evenly split between overestimations and underestimations. CFD results 
comparing the predicted and post-operative streamlines for all Fontan revisions and Stage 2-3 
cases are shown in Figure 5-6 and Figure 5-7 respectively.  In addition, Figure 5-6 shows the pre-
operative HFD for all Fontan revisions, confirming a lack of hepatic flow to the lung with PAVMs.  
Overall, no significant correlations were found between HFD prediction error and age at surgery, 
age at follow up, or follow up time. Moderate correlations were seen between the percent change 
in IVC flow rate (r=0.60, p=0.04) and the change in PFD (r=0.60, p=0.04) from pre- to post-op 




Figure 5-6 Streamline comparison for the pre-operative, predicted, and post-operative states for 
all Fontan revision cases. Patients 1, 2 and 5 were diagnosed with left-sided pulmonary 




Figure 5-7 Streamline comparison between the predicted and post-operative states for all Stage 
2-3 patients. Hepatic flow distribution is noted as the percent of HFD to the left pulmonary 





5.3.4 Connection Types 
HFDprediction error was found to be associated with surgical connection type. A comparison 
of HFDprediction error between graft types can be seen in Figure 5-8. Hepatic to azygous shunts had 
significantly lower prediction errors than other connection types (6±7% vs 22±13% respectively, 
p=0.05, Figure 5-8b). In addition, a strong, positive correlation was seen between HFD prediction 
error and graft insertion offset within the Y-graft and ECC group (r=0.99, p<0.001, Figure 5-9d). 
Example cases of low, moderate and high graft insertion offsets are shown in Figure 5-9a-c.  
 
 
Figure 5-8 Effect of connection type on HFD prediction error. (a) Comparison between graft 






Figure 5-9 Relationship between HFD prediction error and graft insertion offset for 
extracardiac conduit and Y-graft Fontan connections. Representative cases are shown for (a) 
low, (b) moderate, and (c) high graft insertion offsets. A strong correlation (d) was se seen 
between prediction error and offset for these connection types. The overlay figures compare the 
predicted (blue) and post-operative (red) TCPCs on the left, and show a colormap of the offset 
between the predicted and post-operative grafts on the right for each representative case.  All 
cases use the same color scale. 
 
5.3.5 Potential Methodological Improvements 
The HFD prediction error associated with the “improved” post-operative anatomy and flow 
predictions and the current methodology is shown in Table 5-3. While a reduced or identical 
prediction error was seen for the majority of patients using either methodological improvement, 
(8/12 and 7/12 for the improved anatomy and improved flow scenarios respectively), a more 
substantial reduction in error was seen when using the improved anatomy prediction.  The current 
HFD prediction error (17±13%) was significantly reduced by improving anatomy prediction 
(9±6%, p=0.03, paired-sample t-test), but remained nearly the same when using only an improved 
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flow prediction (18±17%, p=0.73, paired-sample t-test). When comparing the two potential 
methodological improvements, improved post-operative anatomy prediction resulted in equivalent 
or more accurate HFD predictions for 9/12 patients when compared with improved flow 
prediction.  
Table 5-3 Comparison of HFD prediction errors between the current surgical planning process 
and potential methodological improvements. 
      HFD Prediction Error 








Patient 1 Revision Hep to AZ 4 6 11 
Patient 2 Revision Y-graft 7 13 1 
Patient 3 Revision Hep to AZ 0 0 0 
Patient 4 Revision Y-graft 21 10 29 
Patient 5 Revision ECC 45 16 58 
Patient 6 Stage 2-3 ECC 34 18 18  
Patient 7 Stage 2-3 Y-graft 21 7 38 
Patient 8 Stage 2-3 Y-graft 17 6 14 
Patient 9 Stage 2-3 ECC 7 13 5 
Patient 10 Stage 2-3 Hep to AZ 5 2 3 
Patient 11 Stage 2-3 Hep to AZ 16 3 23  
Patient 12 Stage 2-3 Hep to Inn 23 18 13 
Average - - 17±13 9±6* 18±17 
Hepatic flow distribution (HFD); hepatic to azygous shunt (Hep to AZ); extracardiac conduit 
(ECC); hepatic to innominate connection (Hep to Inn). Asterisk indicates statistically significant 






Previously limited by a lack of post-operative data, the current study offers the first 
assessment of prospective Fontan surgical planning accuracy for both Fontan revisions and Stage 
2-3 conversions using medium-term post-operative data. This study incorporates a unique data set 
resulting from more than a decade of surgical planning experience, and provides a methodological 
assessment necessary for the improvement of surgical planning accuracy.   
Though an exact “cut-off” for HFD to prevent PAVMs is currently unknown, and may vary 
between patients, the Fontan revision results (Table 5-1, Figure 5-6) confirm a lack of hepatic flow 
to the lung with PAVMs in each case. Furthermore, PAVMs regressed in each case where the 
revision resulted in increased hepatic flow to the affected lung. In combination with previous 
studies, these results emphasize the importance of achieving a balanced hepatic flow distribution 
through appropriate TCPC design.  
In this study, HFD prediction error averaged 17±13% across all patients.  Prediction error 
was similar between revision and Stage 2-3 cases, but differed across connection types. Intuitively, 
hepatic to azygous connections are more robust to variations in surgical implementation since all 
hepatic flow will join the azygous flow and then travel through the entire azygous vein before 
interacting with other flows regardless of exact placement of the shunt. No colliding flows from 
multiple vessels are present locally in hepatic to azygous connections, in contrast with Y-graft and 
ECC connections where slight offsets may substantially change the interactions between various 
inlets and therefore stray from predicted results (Figure 5-10).89 Therefore, hepatic to azygous 
predictions were found to be quite accurate, while predictions for other connection types were 





Figure 5-10 Schematic representation showing differences between (a) hepatic to azygous and 
(b) extracardiac conduits (ECC). Black arrows indicate inlet flows and red arrows indicate 
potential variations in graft placement. Differences in graft placement can affect flow collisions 
much more in ECC connections.  
  
Capitalizing on the available post-operative data, various simulations were run using the 
post-operative anatomy or flows as a surrogate for an “improved” prediction.  While it is unlikely 
that anatomy or flow prediction techniques will ever produce exact matches to post-operative 
outcomes, this analysis is instructive by showing the full potential of surgical planning accuracy if 
methodological improvements in either of these areas offered extremely accurate predictions. To 
reiterate, improvements in anatomy prediction led to a significant (p=0.03) reduction in HFD 
prediction error. Interestingly, improvements in flow prediction did not result in similar error 
reduction (Table 5-3).  These findings stress two critical points: (i) post-operative anatomy 
prediction is a primary factor in HFD prediction, and (ii) anatomy prediction methods must 
improve in order for Fontan surgical planning to offer more accurate HFD predictions.  
Again, improved flow prediction alone did not result in more accurate HFD predictions 
(p=0.73, Table 5-3).  In general, HFD is primarily driven by graft placement.61 In a complex 
connection such as the TCPC, relatively small offsets in graft placement and angulation can largely 
alter the collisions and interactions among flows from various vessels.61 These variations can affect 
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the preferential streaming of inlet flows including hepatic flow, which in turn will determine 
hepatic flow distribution.   Naturally, severe changes in individual flow rates can affect HFD 
prediction, however this was not observed in this cohort.  
Though it is common to use indexed flow rates (normalized by BSA) in pediatric studies 
involving changes over time, raw flow rates are shown in this study (Table 5-2) to emphasize the 
changes in actual inputs to the surgical planning process. While an indexed flow rate may remain 
constant over a several year follow up, the actual flow rate (and therefore the flow rate that needs 
to be predicted) does not. This raw data better represents how boundary conditions for the surgical 
planning process change over time.  
Multiple methods exist to predict post-operative Fontan anatomies and flows, ranging from 
simple (basic CAD software and using pre-operative flows as the “predicted” post-op flows) to 
more sophisticated (designated surgical planning software and lumped parameter modeling) 
methods.88,90 As the methods have progressed in complexity, anatomy prediction methods have 
become faster (software is designed specifically for Fontan surgical planning) and flow prediction 
methods have become slower (more complex calculations and “full body” modeling).  Meeting 
the clinical timeline for most surgical planning cases requires accelerated analysis.11  
Conveniently, the present results indicate that anatomy prediction is a primary shortcoming, which 
can hopefully be improved without lengthening the surgical planning process.   
Accurate anatomy prediction involves both predicting a viable surgical option and accurately 
implementing that option. Modeling a viable surgical option is heavily dependent on high quality 
imaging data, clinician involvement and inclusion of relevant anatomical landmarks. Current 
methods include the heart, aorta and pulmonary circulation, but future efforts could potentially add 
additional organs and the process of chest closure. Once a surgeon has selected the surgical option 
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to implement, closely replicating that option in vivo may be challenging. Little intra-operative 
guidance is currently offered as part of the surgical planning process. Some efforts have explored 
3D printing and augmented/virtual reality as planning/guidance tools, but further refinements are 
needed.91–94 In addition, growth is another difficult factor to model, but may be necessary to 
improve surgical planning results.62,63  It is possible that “variations” between a predicted and post-
operative anatomy are due to growth rather than imperfect surgical implementation.  
If Fontan surgical planning is to be used in clinical practice, the importance and necessity of 
follow up data and validation studies such as this cannot be overstated. Understanding the current 
accuracy and methodological shortcomings is imperative in order to correctly use the results and 
progress the field.  Future efforts and refinements to the surgical planning process will greatly 





6. SPECIFIC AIM 1B 
 
Purpose: To evaluate the ability of Y-grafts to provide balanced hepatic flow 
distribution and therefore prevent pulmonary arteriovenous malformations. 
 
Hypothesis: Y-grafts provide more balanced hepatic flow distribution than 
traditional Fontan connections. 
 
6.1 Overview 
Y-grafts are a relatively new option for Fontan completion, and are hypothesized to provide 
balanced HFD to the left and right pulmonary arteries via the Y-graft’s two branches (thus 
preventing the progression of PAVMs)10,40. Specific Aim 1B used patient-specific CFD modeling 
to analyze the ability of a Y-graft to offer balanced HFD, preventing the progression of PAVMs.  
We will perform a direct comparison between 30 consecutive Y-graft patients and 30 age and BSA 
matched traditional Fontan patients.  In this comparison we will determine if Y-grafts provide 
more balanced HFD than a traditional Fontan connection.  In addition, we will also study how 
HFD changes over time in Y-graft patients.  To do this, we have acquired medium-term follow up 





This Specific Aim utilizes medical image processing, computational fluid dynamics, anatomy 
characterization and statistical analysis. Please refer to Chapter 4 for a detailed description of the 
methodology for each. 
6.2.1 Study Design 
This study is composed of two parts: (1) a direct comparison between Y-grafts and 
traditional grafts, and (2) a serial study assessing the hemodynamic changes in Y-grafts over time. 
This design is illustrated in Figure 6-1 
 
 
Figure 6-1 Study design for Specific Aim 2B. Patient number in part 2 is limited by available data. 
 
6.2.2 Patient Selection  
For the first part of this study, a total of 60 patients were used. All LT/ECC patient data 
(n=30) were received from Children’s Healthcare of Philadelphia and all Y-Graft patient data 
(n=30) were received from Children’s Healthcare of Atlanta. Thirty consecutive Y-grafts 
performed by Dr. Kirk Kanter were used; LT/ECC patients were chosen to match age and BSA 
between groups. All Y-graft Fontan connections used commercially available Y-grafts. Clinical 
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data including age, gender, and BSA were obtained for each patient. All patient data for this part 
of the study can be found in Appendix D – Specific Aim 1B Cross-Sectional patient data. 
For the serial investigation, 10 Fontan patients with Y-graft connections were included. 
Inclusion criteria included (i) single ventricle patient with Y-graft Fontan connection, (ii) serial, 
post-operative CMR and phase-contrast CMR data, and (iii) sufficient image quality to accurately 
segment the TCPC and blood flow waveforms at each TCPC inlet/outlet. All Y-graft patient data 
was received from Children’s Healthcare of Atlanta (IRB: H09279). All Y-graft connections used 
commercially available aorto-iliac Y-grafts.   
A LT/ECC comparison group with identical follow up times was not available. Therefore, 
several, unique LT/ECC groups were chosen (each n=10) with follow up times both before and 
after the Y-graft cohort. All LT/ECC patient data was received from Children’s Hospital of 
Philadelphia (IRB: H05236). Clinical data including age, body surface area (BSA), gender, 
ventricle morphology, presence of fenestration and dates of surgery and CMR studies were 
obtained for each patient. All patient data for the longitudinal part of this study as well as the 
comparison groups can be found in Appendix E – Specific Aim 1B Longitudinal patient data. 
 
6.2.3 Statistical analysis  
The cross-sectional portion of this specific aim follows the statistical methods stated in 
Chapter 4.5. The longitudinal follows the same statistical methods, but a description is given here 
to clarify the statistical methods used. In the serial study of 10 Y-grafts, a paired sample t-test is 
used to determine if there is a significant directional change in HFD over time. This test will give 
a significant result if patients are moving in the same direction. For example, if all patients 
improved in HFD by 1% then a paired sample t-test will give a significant result. An independent 
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samples t-test was also used to show if the Y-graft group at timepoint 2 was more balanced in 
terms of HFD than at timepint 1. For example, if all patients improve in HFD by 1 %, the group 
will not have a significantly better HFD at timepoint 2, even though all patients changed in the 
same direction. A paired sample t-test will tell if the Y-grafts are improving, an independent 
sample t-test will show if that amount of improvement makes a significant difference between the 
two timepoints.  
  For the comparison between the Y-graft and ECC control groups in the longitudinal study, 
comparisons were made between the Y-grafts at timepoint 2 with the various control groups. As 
we did not care how the control groups compared with one another, we did not use an ANOVA 
for a multiple group comparison. We compared the Y-graft at timepoint 2 with the control groups 





6.3.1 Cross-sectional study 
6.3.1.1 Y-graft Hemodynamic Performance 
Figure 6-2 shows several clinically important hemodynamic metrics for the Y-graft cohort. 
The average PFD and HFD deviations from an ideal 50/50 split were 13.4±10.6 and 25.9±15.1, 
respectively (Figure 6-2a).  Figure 6-2b illustrates the effect of LPA stenosis on indexed power 
loss. A moderate positive correlation (r=0.67, p<0.01) was found between LPA stenosis and 
indexed power loss. The distributions of TCPC resistance and HFD deviation are shown in Figure 
6-2c Figure 6-2d. The distribution of TCPC resistance is skewed to the right with approximately 
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53% and 70% of Y-graft patients having resistances less than 1 and 2 Wood Units respectively. 
HFD deviation was relatively evenly distributed (Figure 6-2d). Only 13% of Y-graft patients have 
HFD deviations less than 10 (ideal) and 24% of Y-graft patients have deviations greater than 40 
(poor). 
 
Figure 6-2 Y-Graft hemodynamic performance. (a) Pulmonary and hepatic flow distribution 
(PFD and HFD) deviations. (b) Effect of LPA stenosis on index power loss (iPL). (c) 
Distribution of TCPC resistance. (d) Distribution of HFD deviation. 
6.3.1.2 Representative Y-graft Cases 
Figure 6-3 shows streamlines for six representative cases from the 30 patient Y-graft 
cohort. Patients Y1, Y2, andY3 show balanced HFD (low HFD deviation) while the final three 
(Y4, Y5, andY6) are unbalanced. Y1 represents an “ideal” case with balanced PFD, normal SVC 
positioning and no mid-PA stenosis. Y2 represents uneven PFD with mid-PA stenosis on the low 
PFD side. Y3 has bilateral SVCs, balanced PFD and mid-PA stenosis. Y4 has balanced PFD with 
the SVC positioned superior to a y-branch anastomosis. Y5 has unbalanced PFD with mid-PA 
stenosis on the high PFD side and Y6 represents balanced PFD with y-branch stenosis. HFD to the 
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LPA is noted for each model in Figure 6-3. (The posterior views for a variety of these patients can 
be found in Appendix D – Specific Aim 1B Cross-Sectional patient data Animations for several 
important comparative cases are provided in Appendix H. 
 
Figure 6-3 Representative Y-Graft cases with HFD noted. Streamlines colored by origin: 
IVC(blue), SVC(green) and LSVC(red). Percentages shown are percent of hepatic flow to the left 
pulmonary artery. 
 
6.3.1.3 Y-graft vs LT/ECC 
To further evaluate the commercially available Y-graft, a direct hemodynamic comparison 
was performed between the Y-graft and LT/ECC cohorts. Clinical data are shown in Table 6-1 for 
each graft type. Patients were selected to best match age and BSA between groups.  Y-graft 
resistance was significantly higher (p=0.03) than LT/ECC resistance, with averages of 1.51±1.52 
and 0.56±0.54 WU, respectively (Figure 6-4a). Overall, HFD deviation was not significantly 
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different between the groups with an average of 21±13 for the LT/ECC and 26±15 for Y-grafts 
(Figure 6-4b). Figure 6-4c shows no significant differences in particle residence time.     
Figure 6-4d and Figure 6-4e compare the distribution of TCPC resistance and HFD 
deviation between graft types, respectively.  Almost 77% of LT/ECC patients have a resistance 
less than 1 WU, compared to 53% of the Y-grafts. Additionally, 30% of commercially available 
Y-graft patients exhibit a resistance greater than 2 WU, while only 3% of the LT/ECC cohort have 
values this high (Figure 6-4d). Focusing on the two extremes of HFD deviation, 30% of LT/ECC 
patients had ideal HFD deviations (<10) compared to only 10% of Y-graft patients. At the other 
extreme, more than twice as many Y-graft patients (23%) have HFD deviations greater than 40 
(poor) than LT/ECC patients (10%).   
Figure 6-4f compares the sensitivity of iPL to LPA stenosis for both graft types. 
Commercially available Y-grafts were found to be more sensitive to LPA stenosis in terms of iPL 



















BSA (m2) 0.67 ± 0.12 0.66 ± 0.20 0.19 
Age (years) 3.65 ± 1.14 3.68 ± 2.49 0.17 
Gender (male) 70% 53% 0.19 
PA Stenosis (%)* 33.99 ± 12.60 26.82 ± 10.69 0.02 
Systemic Venous Flow (L/min)* 2.07 ± 0.61 1.57 ± 0.59 <0.01 
Pulmonary Flow Distribution (% LPA) 46.01 ± 15.00 46.00 ± 16.78 0.99 
PFD Deviation from 50%  
(percentage points) 
13.13 ± 7.91 13.40 ± 10.60 0.78 
Pulsatility Index (IVC) 0.66 ± 0.65 0.93 ± 0.72 0.14 






Figure 6-4 Hemodynamic Comparison of the Y-graft and LT/ECC. (a) Indexed power loss. (b) 
HFD deviation from 50%. (c) Particle residence time. (d) Distribution of iPL. (e) Distribution of 
HFD deviation. (f) Effect of LPA stenosis on iPL. 
 
6.3.2 Serial Y-graft study  
6.3.2.1 Clinical Data 
Clinical and hemodynamic data for all Y-grafts at both timepoints are shown in Table 6-2. 
Age increased from 3 [2.75-4.0] to 6 [5-6.25] years across the two timepoints, with a median follow 
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up time of 14 [7-25] days and 3.02 [2.13-3.31] years respectively. The cohort included 4/6 
male/female and 3/7 HLHS/non-HLHS.  
Indexed IVC flow increased from 0.57 [0.45-0.89] to 0.9 [0.66-1.1] L/min/m2 (p=0.005). 
Similarly, Qs increased from 1.83 [1.62-1.91] to 2.28 [1.93-2.83] L/min/m2 (p=0.020).  SVC, 
LPA, RPA, collateral flow and cardiac index showed no significant changes between timepoints. 
PFD became more balanced (PFD deviation from 50% decreased from 9 [5-26] to 6 [4-11]) though 
not statistically significant (p=0.173).  Finally, pulmonary artery stenosis did not significantly 
change over time.   
Table 6-2 Clinical and hemodynamic data for the Y-graft cohort. 
 Y-graft (n=10) Paired sample t-test 
 Timepoint 1 Timepoint 2 p-value 
Age (years) 3 [2.75-4.0] 6 [5-6.25] <1e-3* 
BSA (m2) 0.62 [0.60-0.76] 0.87 [0.76-0.99] <1e-3* 
Follow up time (years) 0.04 [0.02-0.07] 3.02 [2.13-3.31]   <1e-3* 
Gender 4/10 male - 
Morphology 3/10 HLHS - 
Fenestrated 9/10  - 
Cardiac Index (L/min/m2) 3.09 [2.8-3.8] 3.11 [2.89-3.69] 0.982 
IVC flow (L/min/m2) 0.57 [0.45-0.89] 0.9 [0.66-1.1] 0.005* 
SVC flow (L/min/m2) 1.16 [0.99-1.41] 1.1 [0.87-1.6] 0.224 
LPA flow (L/min/m2) 0.82 [0.58-1.23] 0.9 [0.65-1.07] 0.374 
RPA flow (L/min/m2) 0.905 [0.56-1.23] 0.82 [0.59-1.2] 0.200 
Qs (L/min/m2) 1.83 [1.62-1.91] 2.28 [1.93-2.83] 0.020* 
Collateral flow (L/min/m2) 1.14 [0.94-2.08] 0.59 [0.16-1.39] 0.264 
PFD deviation (percentage points) 9 [5-26] 6 [4-11] 0.173 
LPA stenosis (%) 14 [11-27] 13 [8-30] 0.987 
RPA stenosis (%) 13 [4-29] 13 [5-32] 0.760 
Overall PA stenosis (%) 15 [11-26] 14 [7-31] 0.847 
TCPC resistance (WU) 0.26 [0.12-0.42] 0.15 [0.12-0.20] 0.117 
HFD deviation (percentage points) 16 [6-30] 5 [2-16] 0.015* 
BSA: body surface area; IVC/SVC: inferior and superior vena cava; LPA/RPA: left and right 
pulmonary artery; Qs: systemic return; PFD: pulmonary flow distribution; HFD: hepatic flow 




6.3.2.2 HFD and TCPC Resistance 
Hepatic flow distribution significantly improved over time (paired sample t-test, p=0.015, 
Table 6-2). HFD deviation decreased from 16 [6-30] to 5 [2-16]. Nine out of ten patients had more 
balanced HFD at timepoint 2 than timepoint 1 (Figure 6-5).  On average, there was a 13 [3-18] 
point improvement in HFD deviation. In general, a HFD deviation <10 is clinically acceptable, 
though no exact cut-offs have been determined. Individual HFD values and follow up times can 
be found in Figure 6-5a.  Streamlines for all Y-grafts at both timepoints are shown in Figure 6-6.  
Overall, HFD was relatively balanced at timepoint 2 with an HFD deviation of only 5 [2-16].  
 
 
Figure 6-5 Serial comparison of Y-graft hepatic flow distribution (HFD). (a) Individual patient 
HFD values at timepoint 1 and 2 (T1 and T2). (b) Change in HFD over time. Each line 
represents a single patient. P-value indicates significance of paired sample t-test. (c) Overall 
comparison of HFD deviation for entire cohort. P-value indicates significance of independent 
sample t-test. Follow up time is indicated as number of months (##m).   Dashed black line 




Figure 6-6 Streamlines for all Y-graft patients. The overlay image compares anatomies at time 1 
(red) and time 2 (blue). Time interval shows time between time 1 and time 2. Hepatic flow 





TCPC resistance decreased from 0.26 [0.12-0.42] to 0.15 [0.12-0.20] WU, but was not 
statistically significant (paired sample t-test, p=0.117, Table 6-2). TCPC resistance decreased for 
eight out of ten patients (Figure 6-7). On average, TCPC resistance decreased by 0.10 [-0.25, 0.01] 
WU. Individual resistance values can be found in Figure 6-7a.     
 
 
Figure 6-7 Serial comparison of Y-graft TCPC resistance (RTCPC). (a) Individual patient RTCPC 
values at timepoint 1 and 2 (T1 and T2). (b) Change in RTCPC over time. Each line represents a 
single patient. P-value indicates significance of paired sample t-test. (c) Overall comparison of 
RTCPC for entire cohort. P-value indicates significance of independent sample t-test. Follow up 
time is indicated as number of months (##m).  TCPC: total cavopulmonary connection, WU: 
Wood units. 
 
6.3.2.3 Comparison with LT/ECC 
Three LT/ECC comparison groups were chosen using consecutive patients with (i) <3 year 
follow up, (ii) 3-6 year follow up, and (iii) >10 year follow up (n=10 for each group). These three 
groups were chosen in order to straddle the Y-graft follow up times since a comparison group with 
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identical, serial follow up times was not available. These 10 Y-graft patients are a subset of the 30 
Y-graft patients included in the cross-sectional study. The clinical and hemodynamic data for all 
three LT/ECC comparison groups are shown in Table 6-3. Follow up times were significantly 
different for the three comparison groups: 0.57 [0.45-0.68], 5.25 [4.4-5.4], and 12.87 [12-15.7] 
years respectively (p<0.001 for each).  
Table 6-3 Clinical and hemodynamic data for the LT/ECC comparison groups. 
 LT/ECC Group 1 
(FU <3 year) 
n=10 
LT/ECC Group 2 
(FU=3-6 year) 
n=10 
LT/ECC Group 3 
(FU >10 year) 
n=10 
Age (years) 3 [2.75-4] 7 [6-7.25] 15 [14-17.75] 
BSA (m2) 0.63 [0.58-0.67] 0.83 [0.725-1] 1.55 [1.24-1.64] 
Follow up time (years) 0.57 [0.45-0.68] 5.25 [4.4-5.4] 12.87 [12-15.7] 
Gender 4/10 male 6/8 male 3/10 male 
Morphology  5/10 HLHS 6/10 HLHS 5/10 HLHS 
Fenestrated 7/10 7/10 6/10 
Cardiac Index (L/min/m2) 4.49 [3.48-4.78] 3.67 [2.82-4.09] 3.39 [3.02-3.64] 
IVC flow (L/min/m2) 1.05 [0.83-1.35] 1.55 [1.14-2.73] 1.60 [1.29-2.09] 
SVC flow (L/min/m2) 1.56 [1.19-2.47] 1.26 [0.94-1.84] 0.78 [0.57-0.98] 
LPA flow (L/min/m2) 1.13 [0.85-1.47] 1.01 [0.74-1.29] 10.6 [0.85-1.27] 
RPA flow (L/min/m2) 1.06 [0.88-1.44] 1.42 [1.09-2.49] 1.32 [0.95-1.69] 
Qs (L/min/m2) 2.85 [2.34-3.65] 2.80 [2.43-3.55] 2.46 [2.17-2.81] 
Collateral flow (L/min/m2) 1.76 [0.70-2.90] 0.32 [0.0-1.81] 0.67 [0.31-1.56] 
PFD deviation (percentage 
points) 
12 [5-21] 9 [4-16] 8 [3-15] 
LPA stenosis (%) 39 [13-49] 47 [33-66] 32 [17-45] 
RPA stenosis (%) 20 [9-31] 35 [10-58] 19 [8-32] 
Overall PA stenosis (%) 31 [13-36] 38 [30-54] 22 [13-22] 
TCPC resistance (WU) 0.16 [0.13-0.29] 0.10 [0.07-0.21] 0.18 [0.13-0.22] 
HFD deviation (percentage 
points) 
21 [13-37] 17 [6-44] 13 [7-16] 
LT: lateral tunnel; ECC: extracardiac conduit; FU: follow up; BSA: body surface area; IVC/SVC: 
inferior and superior vena cava; LPA/RPA: left and right pulmonary artery; Qs: systemic return; 




Both Y-grafts and LT/ECC patients showed more balanced HFD as patients aged (Figure 
6-8). Y-grafts improved quicker than LT/ECC. The Y-grafts at timepoint 2 (36 month follow up) 
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were significantly more balanced than the LT/ECC group with an earlier follow up time (p=0.009), 
and more balanced, though not statistically significant, than the two LT/ECC groups with later 
follow up times (p=0.059 and p=0.209 respectively, Figure 6-8a). TCPC resistance was not 
significantly different between any two groups (Figure 6-9). Large variations in TCPC resistance 




Figure 6-8 HFD comparison of Y-grafts and LT/ECC patients. Results are represented as both a 
(a) bar chart and (b) line graph to better compare groups. Error bars represent standard error 
in (b) for clarity. P-value indicates significance of independent sample t-test. No other 
comparison was significant. Follow up time is indicated as number of months (##m). HFD: 





Figure 6-9 TCPC resistance comparison of Y-grafts and LT/ECC patients. Results are 
represented as both a (a) bar chart and (b) line graph to better compare groups. Error bars 
represent standard error in (b) for clarity. No statistical comparison between groups was 
significant. Follow up time is indicated as number of months (##m). TCPC: total cavopulmonary 




6.4.1 Cross-sectional comparison 
6.4.1.1 Y-Graft Hemodynamic Performance 
As expected, PFD deviation is relatively low and on average there is about a 25% difference in 
overall flow rates to the LPA and RPA. This flow split is determined partially by branch pulmonary 
artery stenosis as well as overall lung resistance.95  HFD deviation was higher and more variable 
than expected and will be discussed in the following section.  The effect of LPA stenosis on iPL 
is also an expected result. Blood accelerates through the stenosis region and then decelerates as 
the vessel returns to its original size according to the conservation of momentum principle. These 
changes in velocity result in an increased pressure drop across the TCPC (lower efficiency) which 
leads to an increased iPL. The LPA is a common site for stenosis and Figure 6-2 shows that the 
most severe LPA stenosis anatomies have the highest iPL.61  
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The distribution of TCPC resistance raises concern for a number of Y-graft patients.  In this study, 
Y-graft TCPCs are seen to have resistances as high as 4.7 Woods units, and this increased level of 
vascular resistance could lead to venous hypertension/congestion. Liver failure and protein-losing 
enteropathy are thought to be direct results of elevated Fontan venous pressures.34,52,53 The 
relatively even distribution of HFD deviation suggests that the Y-graft is not a “one size fits all” 
solution to accomplish evenly split hepatic flow to the lungs. While 13% of Y-graft patients had 
very balanced HFD, nearly a quarter of patients had >90% hepatic flow directed to either the left 
or right lung. The effectiveness of Y-graft use seems to be multi-factorial and extremely patient 
specific, suggesting the need for pre-operative, individual surgical planning via computational 
modeling.    
 
6.4.1.2 Representative Y-Graft Cases 
The ability of a Y-graft to evenly split hepatic flow is highly dependent on PFD, the location of 
branch PA stenosis and IVC/SVC flow collisions, among other factors. A difference in PFD can 
cause two Y-grafts with very similar anatomies to have drastically different HFDs. This can be 
seen in Figure 6-3, where Y2 and Y5 have PFDs of 24% and 65%, respectively. Despite similar 
anatomies and Y-grafts, the HFD for these cases are considerably different (48% and 81% to the 
LPA, respectively). A comparison between Y1 and Y4 illustrates the effect of IVC/SVC flow 
collision on HFD. Both cases have balanced PFD and similar sized PAs, but Y1 has a medially 
positioned SVC, while Y4’s SVC is positioned more superior to the left Y-branch. The SVC flow 
collision in Y4 forces some SVC flow into the left Y-branch which causes hepatic flow to 
preferentially course through the right Y-branch. The result is a very unbalanced HFD for Y4 (12% 
to the LPA) and relatively balanced HFD for Y1 (65% to the LPA).  
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Stenosis is commonly seen in Fontan anatomies;61 Y2, Y3, Y5 and Y6 all have severe stenosis in 
either the pulmonary arteries or Y-graft branches. For single SVC anatomies (Y2, Y5), mid-PA 
stenosis influences SVC flow which will preferentially follow the path of least resistance (in these 
cases towards the RPA). For an unbalanced PFD case, if the mid-PA stenosis is located on the 
same side as the PA receiving the majority of pulmonary flow, then the stenosis blocks most SVC 
flow and this PA receives the majority of its flow from the hepatics and will therefore have an 
unbalanced HFD (Y5).  However, the opposite is true if the stenosis is located on the low PFD 
side; in this case hepatic flow is able to move towards both PAs resulting in more balanced HFD 
(Y2). For bilateral SVC anatomies (Y3), mid-PA stenosis can “separate” the two SVC flows and 
HFD will be highly dependent on the individual SVC and overall PA flows. If SVC flows are 
similar and PFD is balanced, a balanced HFD is expected. Y6 shows a case with severe stenosis 
located in the left Y-branch, and as a result hepatic flow is very limited through the stenosed 
branch. With the full range of flow rates, flow ratios, pulsatilities, unique geometries and stenosis 
locations, the ability of a specific Y-graft to achieve balanced HFD may not be intuitive. Again, 
Y-graft performance needs to be evaluated on an individual basis and all of these factors must be 
considered.  
 
6.4.1.3 Y-graft vs LT/ECC 
Average TCPC resistance was approximately 3x higher for Y-grafts than LT/ECCs. The most 
apparent explanation stems from the geometry of the Y-graft itself. With commercially available 
Y-grafts, the diameter of the base of the Y-graft is evenly split between the two branches.  For 
example, a 20mm (diameter) Y-graft will have two 10mm (diameter) branches. A basic calculation 
reveals that preserving diameter does not preserve area; this design results in a 50% reduction in 
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cross-sectional area as blood moves into the Y-graft branches. In essence, Y-grafts have a built-in 
50% long segment “stenosis”. In order to preserve cross-sectional area, the Y-graft branch 
diameter must be r*sqrt(2), where r is equal to the radius of the Y-graft before it splits into the two 
branches. Additionally, resistance is inversely proportional to the fourth power of the radius 
(Poiseuille’s law). Therefore, blood traveling through 2 Y-branches with diameters half the size of 
the LT/ECC would analytically yield an 4x increase in resistance.  According to the results 
presented here, the reduction in diameter and cross-sectional area inherent to commercially 
available Y-grafts has a greater negative impact on TCPC resistance than the venous flow 
collisions inherent to LT/ECCs.  Therefore, “custom” Y-grafts which preserve cross sectional area 
as shown by Yang et al. may be the more promising option for successful Y-graft use, and may 
potentially provide an advantage over the LT/ECC Fontan pathway.43,44 
Overall, HFD deviation was not significantly different between graft types. Both graft types were 
highly variable. The most important observation is the discrepancy in the number of patients at 
both the lowest (ideal) and highest (poor) HFD deviation (Figure 6-4e). In this study, Y-grafts have 
almost twice as many poor differential cases as ideal cases, while LT/ECCs show the opposite 
trend. These results highlight the need for pre-operative planning with Y-graft use as well as the 
design of individualized Y-grafts which are tailored for a specific patient. Potential modifications 
such as the angle of insertion, branch size and overall shape could lead to better HFD performance 
on an individual basis.  A surgical modification already explored by surgeons includes “flaring” 
of the Y-graft branches at the anastomosis location. This allows the Y-graft branches to connect 




6.4.1.4 Additional Considerations 
Particle residence time (PRT) was investigated for its potential impact on flow-induced thrombus 
formation, as well as to provide quantitative information about flow stagnation.96,97 No differences 
between Y-grafts and LT/ECC were seen for minimum, mean or maximum residence times. As 
seen in Figure 6-4f, Y-graft iPL was more sensitive to LPA stenosis than LT/ECC iPL. PA stenosis 
may have a greater influence on the reduced flow through the closest Y-branch than it does on the 
total hepatic flow traveling through a LT/ECC connection. This difference would lead to a greater 
effect of stenosis on iPL for Y-grafts than LT/ECCs. 
Several additional comparisons between graft types are important to note. First, PFD was identical 
between graft types at 46% to the left lung, indicating that graft type does not affect PFD. 
Additionally, there was significantly more PA stenosis (p=0.02) in the LT/ECC cohort as seen in 
Table 6-1. Even with significantly more PA stenosis, which is known to increase resistance, the 
LT/ECC cohort still had lower TCPC resistance than the Y-grafts. This strengthens the finding 
that commercially available Y-grafts inherently create higher TCPC resistance. Finally, the 
LT/ECC group includes both intra-atrial and extracardiac connections, while Y-grafts are always 
extracardiac. In this study, 10 of the LT/ECCs were intra-atrial. To ensure that these results were 
a consequence of graft type and not the intra-atrial vs. extracardiac variation, a sub-comparison 
was performed between these two groups. No statistically significant differences were found in 
this sub-comparison for iPL (p=0.40), PFD (p=0.34), or HFD deviation (p=0.14), and therefore 
the comparative results presented here are due to graft choice and not the difference between LT 
or ECC. 
 
6.4.2 Serial Y-graft study 
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6.4.2.1 Hepatic Flow Distribution 
Both Y-grafts and LT/ECC patients showed more balanced HFD as follow up time 
increased. However, Y-grafts improved at a faster rate (Figure 6-8). The Y-grafts (at 36 month 
follow up) had an HFD deviation less than half of the LT/ECC group at 60 month follow up. In 
addition, no LT/ECC timepoint (even at 13 year follow up) was as balanced as the Y-graft cohort.  
In general, a more balanced HFD over time (for either graft type) may be explained in part 
by two main reasons: (i) more balanced overall pulmonary flow distribution and (ii) hepatic flow 
constituting a larger percentage of Qs as patients age.  Though HFD is multifactorial, one key 
component is pulmonary flow distribution. In most cases, as PFD becomes more balanced, HFD 
becomes more balanced. In this study, both patient cohorts showed more balanced PFD as age 
increased, though not statistically significant (Table 6-2,Table 6-3). Secondly, it is well known 
that the IVC receives a larger portion of Qs as patients age.98 As this percentage increases, graft 
positioning, flow interactions, and the location of stenosis etc. may have a diminished effect.  
To illustrate with an extreme example, if 100% of Qs originates from the IVC (which includes 
hepatic flow), IVC flow will travel to the LPA and RPA regardless of graft placement. In this 
scenario, HFD would be completely determined by PFD, which is seldom extremely unbalanced 
(PFD deviation averaged 11±8 in this study).  Therefore, as age and IVC flow increases it is 
expected that HFD will become more balanced regardless of graft type.  Though both of these 
factors occurred at similar rates for the Y-graft and LT/ECC groups, Y-grafts exhibited an 
accelerated improvement in HFD when compared with the LT/ECC group (Figure 6-8b). This 
suggests that using a Y-graft provides an advantage over LT/ECC connections in terms of 
achieving a balanced HFD. The accelerated improvmenet in HFD likely occurs because Y-grafts 
are an inherently better option for achieving a balanced HFD. In the immediate pre-operative state, 
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patients have similar HFD despite which graft was used. This early similarity occurs because the 
body has not yet adapted to the new Fontan connection and factors such as pleural effusions are 
common which may mask the true performance of the surgical option. However, as follow up time 
increases and the body adapts, the differences between Y-grafts and traditional connections 
become more clear.   
6.4.2.2 TCPC Resistance 
Even with the “built in” 50% stenosis inherent to the design of commercially available Y-
grafts, TCPC resistance was not significantly different between the Y-graft and LT/ECC groups.  
Overall PA stenosis was higher in the LT/ECC groups, but not to the extent of equaling the total 
(Y-graft + PA) stenosis seen in Y-graft patients. Therefore, avoiding caval flow collisions through 
Y-graft use must play a role in decreasing energy losses and lowering TCPC resistance. This 
encourages the use of a customized Y-graft design which would preserve cross-sectional area 
throughout the bifurcation.40 By combining a “stenosis-free” graft design with the ability to avoid 
caval flow collisions, it is reasonable to think that Y-grafts could offer lower TCPC resistance than 
the standard LT/ECC connections.  It remains unknown how TCPC resistance will differ between 
Y-grafts and LT/ECC connections at follow up times later than 31 months (our longest Y-graft 
follow up time). With increasing cardiac output as patients age, avoiding caval flow collisions may 
become a progressively more important factor. However, investigating this hypothesis will require 
longer-term follow up data.   
6.4.2.3 Future Y-graft Use 
While the cross-sectional study showed no significant difference in HFD between Y-grafts 
and LT/ECC, and significantly higher TCPC resistance in Y-grafts, these results may have been 
influenced by using the immediate post-operative state for Y-graft analysis. It is very challenging 
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to make long-term predictions of hemodynamics based on immediate post-operative MR data. 
Post-operative transient changes, such as fluid retention, pleural effusions, and acute changes to 
loading conditions all may have influenced the immediate post-operative scans. As more data 
emerge and further follow up information for these early Y-graft Fontan patients become available, 
the true utility in this technique will continue to be unveiled. Even though it is a more complex 
operation, with increasing experience the technical challenges of a bifurcated Fontan can be 
overcome, and the streamlining of caval flow may prove to be more beneficial for long-term 
hemodynamics.   
Based on the current data, Y-graft Fontan connections are a viable surgical option with 
comparable hemodynamic performance. After the immediate post-operative state, Y-grafts offered 
more balanced HFD than LT/ECC connections without sacrificing energy efficiency. Though 
longer follow up data on this unique cohort will be instructive, future Y-graft use may be a 
proactive step to balance HFD and reduce PAVM development. Additionally, as suggested in 
previous studies, the use of an area preserving Y-graft design may offer further hemodynamic 
benefits.40,43 As technology and biomaterials improve, the possibility to 3D print a Y-graft 
specifically designed for a patient may offer improved results. 
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7. SPECIFIC AIM 2A 
 
Purpose: To investigate the relationship between total cavopulmonary 
connection hemodynamics and Fontan associated liver failure. 
 




Specific Aim 2A will use CFD modeling to investigate potential relationships between 
Fontan hemodynamics and liver failure. This aim will assess if (a) liver fibrosis is correlated with 
concurrent TCPC hemodynamics (at the same time point), and if (b) prior TCPC hemodynamics 
are predictive of future liver failure. Through our collaboration with the Children’s Hospital of 
Philadelphia and their Single Ventricle Survivorship program, we have acquired concurrent MRI, 
catheterization and liver biopsy data for 33 Fontan patients.  In addition, we have serial data (at a 
time point prior to the liver biopsy) for 21 of these patients.  For each dataset, we will perform 
patient-specific simulations using MRI derived anatomy and blood flow waveforms. Fluid 
mechanic and anatomical metrics including pressure drop, TCPC resistance, energy loss, vessel 
size and percent stenosis will be calculated.  Percent collagen deposition, as a measure of liver 




This Specific Aim utilizes medical image processing, computational fluid dynamics, anatomy 
characterization and statistical analysis. Please refer to Chapter 4 for a detailed description of the 
methodology for each. 
7.2.1 Study Design 
This study includes two parts as shown in Figure 7-1. The first investiages the relationship 
between hemodynamics and liver fibrosis at the same time point, while the second part analyzes 
hemodynamic data collected more than 1 year prior to the liver biopsy to determine if 
hemodynamics are predictive of future liver fibrosis.  
 
Figure 7-1 Two-part study design of Specific Aim 2a. 
 
7.2.2 Patient Selection  
Thirty-three single ventricle patients after Fontan completion were studied with concurrent 
CMR, cardiac catheterization and liver biopsy. All subjects were evaluated as part of an 
institutional recommended clinical care protocol for elective comprehensive assessment who are 
more than 10 years from their Fontan operation.15 Indication for assessment was institutional 
recommendation for comprehensive surveillance, and not for any specific signs or symptoms of 
Fontan circulatory failure. No subject had any clinical signs or symptoms of hepatic dysfunction. 
This study cohort of 33 is a subset of a larger cohort of 67 patients who had catheterization and 
liver biopsy performed. Inclusion in the current cohort required that the cardiac catheterization, 
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MRI and liver biopsy were all performed within a six-month period. In most cases, CMR was 
obtained just prior to catheterization, and liver biopsy performed immediately following 
catheterization. Demographic data including age, gender, body surface area (BSA), Fontan type 
and Fontan duration was obtained for each patient. Fontan duration is defined as the time between 
the Fontan surgery and data collection. All patient data was obtained from the Children’s Hospital 
of Philadelphia and was collected under IRB approval (IRB 12-009791) with written informed 
consent. All patient data for the concurrent portion of the study can be found in Appendix F – 
Specific Aim 2A Cross-sectional Patient data. 
For part 2 of this aim (serial study), 21 single ventricle patients after Fontan completion 
were studied with CMR more than 1 year prior to liver biopsy. Similar to part 1, all liver biopsies 
were conducted as part of an institutional recommended clinical care protocol for elective 
comprehensive assessment who are more than 10 years from their Fontan operation.  Indication 
for assessment was an institutional recommendation for comprehensive surveillance, and not for 
any specific signs or symptoms of Fontan circulatory failure. No subject had any clinical signs or 
symptoms of hepatic dysfunction. Inclusion in the current cohort required that the CMR was 
performed more than 1 year prior to liver biopsy. Demographic data including age, gender, body 
surface area (BSA), Fontan type and duration of Fontan physiology was obtained for each patient. 
Fontan duration is defined as the time between the Fontan surgery and data collection. All patient 
data were obtained from the Children’s Hospital of Philadelphia and were collected under IRB 
approval (IRB 12-009791) with written informed consent. Ten of the 21 patients also had a CMR 
at the time of biopsy; these patients were included in a serial study investigating the relationship 
between changes in fluid mechanics and liver fibrosis.  All patient data for the serial part of the 





7.2.2.1 Hepatic Fibrosis Quantification 
Liver biopsies were obtained using ultrasound guided percutaneous needle biopsy. 
Percutaneous biopsy was chosen over a transvenous approach in order to obtain a more 
representative sample of liver tissue and eliminate sampling bias in which more severe fibrosis 
may, theoretically, be found surrounding the hepatic veins. Anticoagulation was reversed with 
protamine at completion of the cardiac catheterization and liver biopsy performed by an 
interventional radiologist, obtaining one or two sample cores. 
Quantitative determination of hepatic fibrosis was performed by an experienced 
pathologist using Sirius red staining for collagen with automated calculation of percent positive 
staining per slide.30,99  Slides were stained with Sirius red and digitally scanned using Aperio 
Scanscope CS-O (Leica Biosystems, Vista CA).  Whole slide image analysis with Color 
Deconvolution V9 algorithm was used to calculate quantitative percent collagen deposition by 
automated detection of the percentage of area containing Sirius red staining (Leica Biosystems, 
Vista CA).  For subjects with biopsy specimens on multiple slides, the percentage of Sirius red 
staining was averaged across all slides. 
 
7.2.2.2 Catheterization Protocol 
All subjects were in a fasting state for eight hours prior to the catheterization, as per 
institutional policy. The use of light sedation, deep sedation, or general anesthesia was at the 
discretion of the catheterization team. Original pressure tracings and data from cardiac 
catheterization were reviewed and measurements were repeated to assure consistency of data 
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interpretation for all study subjects. Protocol included obtaining a hemoglobin level 6-12 hours 
after liver biopsy with comparison to pre-biopsy level, and overnight observation in a post-
procedure recovery unit. 
 
7.2.2.3 Hemodynamic Metrics  
In addition to the hemodynamic metrics listed in the Methods chapter, two additional metrics were 
calculated in this study. Total ventricular power output was defined as the flow energy produced 
by the single ventricle in one cardiac cycle. This metric was calculated as 𝑃𝑜𝑤𝑒𝑟 = 𝐶𝑂 ∗ 𝑃 ,  
where the subscript ‘sv’ signifies single ventricle, CO is cardiac output and 𝑃 ,  is the average 
pressure of the single ventricle.  Ventricular power was converted to units of milliwatts. The 
percentage of total power output lost in the TCPC was calculated as 𝛸 = 100 ∗ , where PL 
is power loss in the TCPC.  
 
7.3 Results 
7.3.1 Concurrent Study (part 1) 
7.3.1.1 Demographic Data 
Patient demographic data is given in Table 7-1.  The cohort was balanced in terms of gender 
and Fontan type. Single ventricle morphology included 45% hypoplastic left heart syndrome 
(HLHS) and 55% non-HLHS.  Average patient age was 16.2±4.7 [7-26] years, with an average 
Fontan duration of 14.2±4.6 [5-24] years.  The average percent collagen deposition was 21.3±8.7 
[9-49] %, incorporating a wide range of hepatic fibrosis.  No significant correlations were found 
between percent collagen deposition and age, BSA or Fontan duration.  Percent collagen 
deposition was not significantly different when analyzed by gender, Fontan type or presence of 
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fenestration (Table 7-1).  The average time between CMR and liver biopsy was 14±27 days, with 
a range of 0-102 and median of 1 day. 
 







Age (years) 16.2±4.7 [7-
26] 
-0.055 0.766 
BSA (m2) 1.5±0.3 [0.76-
2] 
0.044 0.811 
Gender (male/female) 16/17 - 0.734 










15/18 - 0.457 
Presence of 
fenestration (yes/no) 
13/20 - 0.803 
Time between CMR and 
liver biopsy (days) 
14±27 [0-102] - - 
Correlations with percent collagen deposition are shown. Categorical variables show p-values for 
the appropriate independent samples test. Values are mean ± standard deviation [range]. BSA: 
body surface area; Fontan duration: time since Fontan procedure. 
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7.3.1.2 Fibrosis and Hemodynamics 
A significant, positive correlation was found between percent collagen deposition and 
indexed IVC flow rate (rho=0.624, p<0.001, Figure 7-2a).  Similarly, indexed IVC flow rate was 
significantly higher (p=0.008) in the upper tertile of percent collagen deposition scores compared 
to the lowest tertile (Figure 7-2b). Cardiac output was positively correlated with percent collagen 
deposition and approached statistical significance (rho=0.297, p=0.062, Table 7-2). No significant 
correlations were found between percent collagen deposition and caval or branch pulmonary artery 
pressures or flow rates. In addition, there were no correlations with pulmonary venous flow rates 
(Qp) or systemic to pulmonary collateral flow. Similarly, systemic vascular resistance (SVR), 
pulmonary vascular resistance (PVR), and IVC pulsatility index showed no significant correlations 








Figure 7-2 Effect of fibrosis on IVC flow and ventricle power output: (a) Correlation between 
IVC flow and percent collagen deposition; (b) Collagen deposition tertile comparison; (c) 














Table 7-2 Correlations between hemodynamics and percent collagen deposition.  





Cardiac Index (L/min/m2) 3.2±0.77 [1.6-5.4] 0.307 0.088 
Cardiac Output (L/min)† 4.7±1.3 [2.5-7.5] 0.297 0.062 
IVC flow (L/min/m2)* 1.4±0.42 [0.39-2.6] 0.624 <1e-3 
SVC flow (L/min/m2) 0.80±0.36 [0.22-1.8] 0.160 0.390 
LPA flow (L/min/m2) 0.91±0.27 [0.32-1.7] -0.105 0.575 
RPA flow (L/min/m2) 1.3±0.39 [0.71-2.4] 0.178 0.329 
LPV flow (L/min/m2) 1.3±0.32 [0.82-2.3] 0.037 0.849 
RPV flow (L/min/m2) 1.6±0.40 [1.0-3.1] 0.382 0.041 
Collateral Flow (L/min/m2) 1.07±0.71 [0.0-3.0] 0.091 0.625 
IVC pressure (mmHg) 12.3±2.5 [6-16] -0.038 0.840 
SVC pressure (mmHg) 12.2±2.4 [6-16] -0.051 0.787 
LPA pressure (mmHg) 11.8±2.6 [6-17] -0.154 0.417 
RPA pressure (mmHg) 11.8±2.4 [6-16] -0.096 0.607 
SVR (WU/m2) 20.7±8.3 [10.0-48.4] -0.136 0.472 
PVR (WU/m2) 1.4±0.6 [0.37-2.9] -0.247 0.181 
IVC pulsatility index (%) 54±35 [19-162] -0.159 0.401 
Values are mean ± standard deviation [range]. IVC: inferior vena cava; LPA: left pulmonary 
artery; LPV: left pulmonary vein; PVR: pulmonary vascular resistance; RPA: right pulmonary 
artery; RPV: right pulmonary vein; SVC: superior vena cava; SVR: systemic vascular resistance: 




7.3.1.3 Fibrosis and Ventricular Function 
Ventricular power output was positively correlated with percent collagen deposition 
(r=0.51, p<0.01, Figure 7-2c). Ventricular power output averaged 675±227 [253-1317] mW.  No 
significant correlations were seen between percent collagen deposition and end diastolic volume, 
end systolic volume, stroke volume or ejection fraction (Table 7-3). 
 
Table 7-3 Correlations between ventricular function and percent collagen deposition.  






106±33 [45-181] 0.0061 0.974 
End systolic volume 
(mL/m2) 
50±27 [7-125] 0.015 0.940 
Stroke Volume 
(mL/m2) 
56±14 [35-87] 0.143 0.460 
Ejection Fraction 
(%) 
55±12 [27-85] 0.038 0.846 
Ventricular power 




Values are mean ± standard deviation [range]. * signifies statistical significance, † signifies a log 
transformation of the data. A Pearson correlation was used for the transformed data. 
 
7.3.1.4 Fibrosis and the Total Cavopulmonary Connection  
LPA diameter was negatively correlated with percent collagen deposition and approached 
statistical significance (rho=-0.328, p=0.067, Table 7-4). There were no significant relationships 
between percent collagen deposition and IVC, SVC or RPA size, or the extent of caval or branch 
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pulmonary artery stenosis.  Flow efficiency through the TCPC showed no significant correlations 
with percent collagen deposition (Figure 7-3). All individual data point values can be found in 
Appendix F – Specific Aim 2A Cross-sectional Patient data. TCPC resistance averaged 0.41±0.35 
[0.10-1.63] WU. The percentage of total ventricular power output lost in the TCPC was 1.8±1.9 
[0.24-8.17] percent. Indexed TCPC power loss averaged 0.11±0.09 [0.03-0.48]. Particle residence 
time did not correlate with percent collagen deposition with an average of 0.68±0.20 [0.18-1.11] 
seconds, corresponding to 0.84±0.26 [0.18-1.25] cardiac cycles. Velocity field and pressure drop 
maps are shown for a representative low and high percent collagen deposition case in Figure 7-4. 
Velocity magnitudes and pressure drops were slightly higher in the more severe fibrosis case, 
however this figure shows only a single time point in the cardiac cycle. These figures were made 
at the first timepoint in the cardiac cycle. The full simulation data is available on the server and 
may be used to create images at any point in the cardiac cycle for any patient of interest.  Overall, 
no consistent, discernable differences in flow collisions, flow field features, streamlining, or 












Table 7-4 Correlations between TCPC geometry, energetics and percent collagen deposition.  




IVC diameter (mm/m2) 11.6±2.9 [6.4-21.4] -0.058 0.753 
SVC diameter (mm/m2) 9.4±2.5 [5.9-17.0] -0.142 0.438 
LPA diameter (mm/m2) 7.1±1.1 [4.8-9.6] -0.328 0.067 
RPA diameter (mm/m2) 7.4±2.1 [3.9-14.2] 0.016 0.933 
IVC stenosis (%) 33±13 [10-58] 0.012 0.946 
SVC stenosis (%) 29±15 [3-56] -0.180 0.324 
LPA stenosis (%) 51±18 [22-85] 0.112 0.543 
RPA stenosis (%) 33±14 [1-66] -0.025 0.892 
IVC area (cm2/m2) 1.58±0.61 [0.56-2.72] -0.025 0.892 
TCPC resistance (WU) 0.41±0.35 [0.10-1.62] -0.077 0.687 
TCPC PL (% of total power 
output) 
1.8±1.9 [0.24-8.2] 0.079 0.688 
TCPC iPL 0.11±0.09 [0.03-4.9] 0.062 0.746 
Particle residence time 
(s) 
0.68±0.20 [0.18-1.12] 0.186 0.307 
Values are mean ± standard deviation [range]. IVC: inferior vena cava; LPA: left pulmonary 







Figure 7-3 Relationship between TCPC energetics and liver fibrosis: Flow efficiency through the 
TCPC showed no significant correlations with percent collagen deposition. (a) TCPC resistance; 
(b) TCPC power loss (as percent of total power output); (c) indexed power loss; (d) particle 
residence time. TCPC = total cavopulmonary connection. 
 
 
Figure 7-4 Total cavopulmonary connection velocity and pressure fields. Velocity field and 
pressure drop maps are shown for a representative low and high percent collagen deposition 
case.  Overall, no consistent, discernable differences in flow collisions, flow field features, 






7.3.2 Serial Study (part 2) 
7.3.2.1 Demographic Data 
Patient demographic data is given in Table 7-5. The cohort was 80% extracardiac conduits, 
48% fenestrated and 38% male. Single ventricle morphology was composed of 66% hypoplastic 
left heart syndrome (HLHS) and 34% non-HLHS.  All patients had CMR data at a time point >1 
year before liver biopsy. Average patient age at CMR and biopsy was 11.6±5.9 [3-23] and 18.3±4.9 
[11-29] years respectively, with an average time between CMR and biopsy of 6.7±2.9 [2-11] years. 
Fontan duration averaged 9.1±5.5 [0-21] and 15.8±4.7 [9-28] years at CMR and biopsy 
respectively. The average percent collagen deposition was 25±12 [7-49] %, incorporating a wide 
range of hepatic fibrosis. No significant correlations were found between percent collagen 
deposition and age, BSA or Fontan duration.  Percent collagen deposition was not significantly 











Table 7-5 Patient demographic data (n=21).   
Mean±SD [range] Correlation 
coefficient (r) 
p-value 
Age at CMR (years) 11.6±5.9 [3-23] - - 
Age at biopsy (years) 18.3±4.9 [11-29] 0.19 0.423 
Time between CMR 
and liver biopsy (years) 
6.7±2.9 [2-11] - - 
Fontan duration at 
CMR (years) 
9.1±5.5 [0-21] - - 
Fontan duration at 
biopsy (years) 
15.8±4.7 [9-28] 0.33 0.151 
BSA at CMR (m2) 1.1±0.4 [0.6-2.0] - - 








17/4 - 0.341 
Presence of 
fenestration (yes/no) 
10/11 - 0.418 
Collagen Deposition 
(%) 
25±12 [7-49] - - 
Values are mean ± standard deviation [range]. BSA: body surface area; Fontan duration: 
time since Fontan procedure. All correlation coefficients and p-values represent partial correlations 
between values and hepatic fibrosis controlling for the time between CMR and biopsy. P-value for 
categorical variables represents independent sample t-test.   
 
7.3.2.2 Hemodynamics and ventricular function 
No significant correlations were seen between percent collagen deposition and cardiac 
output, vessel flow rates, collateral flow or IVC pulsatility index (Table 7-6). Similarly, no 
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ventricular function metric was significantly correlated, including end diastolic volume, end 
systolic volume, stroke volume and ejection fraction (Table 7-6).  
 
Table 7-6 Correlations between hemodynamics, ventricular function and percent collagen 
deposition.  





Cardiac Index (L/min/m2) 3.3±0.6 [1.9-4.5] -0.03 0.907 
Cardiac Output (L/min) 3.9±1.4 [1.8-6.8] -0.04 0.987 
IVC flow (L/min/m2) 1.5±0.4 [0.9-2.2] 0.19 0.434 
SVC flow (L/min/m2) 0.9±0.4 [0.2-1.7] -0.32 0.166 
LPA flow (L/min/m2) 1.0±0.3 [0.5-1.7]  -0.04 0.876 
RPA flow (L/min/m2) 1.1±0.3 [0.6-1.7] 0.07 0.790 
Collateral Flow (L/min/m2) 1.0±0.7 [0.0-2.5] 0.48 0.276 
IVC pulsatility index (%) 52±42 [8-146] 0.22 0.630 
End diastolic volume 
(mL/BSA1.3) 
70±23 [36-100] 0.33 0.424 
End systolic volume (mL/ 
BSA1.3) 
28±11 [11-40] 0.31 0.452 
Stroke Volume (mL/ 
BSA1.3) 
43±13 [26-62] 0.25 0.405 
Ejection Fraction (%) 62±6 [56-72] -0.13 0.775 
Values are mean ± standard deviation [range]. IVC: inferior vena cava; LPA: left pulmonary 
artery; RPA: right pulmonary artery; SVC: superior vena cava.  All correlation coefficients and p-




7.3.2.3 TCPC geometry and energetics  
TCPC resistance showed a positive correlation (r=0.54, p=0.026, Table 7-7) with percent 
collagen deposition (Figure 7-5a).  TCPC resistance averaged 0.19±0.12 [0.06-0.44] WU. No 
significant relationships were seen with other efficiency related metrics including indexed power 
loss and pressure drop, which averaged 0.04±0.03 [0.01-0.11] and 0.49±0.25 [0.20-1.00] mmHg 
respectively.  In terms of TCPC geometry, left pulmonary artery (LPA) stenosis averaged 32±26 
[0-87]% and showed a positive correlation (r=0.55, p=0.028, Table 7-7) with percent collagen 
deposition (Figure 7-5b).  Again, a conservative p=0.01 was used to determine significance to 
account for multiple testing. No other TCPC geometry metric, including vessel diameters or other 
measures of stenosis, were close to significant correlations with percent collagen deposition (Table 
7-7).   The streamlines and pressure drop for three representative cases of low, moderate and high 
percent collagen deposition with TCPC resistance and LPA stenosis noted are shown in Figure 
7-6. All individual patient data used to create these plots can be found in Appendix G – Specific 












Table 7-7 Correlations between TCPC geometry, energetics and percent collagen deposition.  




IVC diameter (mm/m2) 18.0±6.5 [9.4-32.2] -0.09 0.731 
SVC diameter (mm/m2) 13.8±4.9 [7.4-23.5] -0.10 0.682 
LPA diameter (mm/m2) 10.9±3.4 [6.2-19.6] -0.41 0.100 
RPA diameter (mm/m2) 11.7±4.8 [5.8-22.4] -0.22 0.369 
IVC stenosis (%) 21±12 [6-53] -0.15 0.546 
SVC stenosis (%) 10±13 [0-54] 0.13 0.629 
LPA stenosis (%) 32±26 [0-87] 0.55 0.028* 
RPA stenosis (%) 25±28 [0-84] -0.24 0.316 
TCPC resistance (WU) 0.19±0.12 [0.06-0.44] 0.54 0.026* 
TCPC iPL 0.04±0.03 [0.01-0.11] 0.40 0.138 
TCPC pressure drop (mm 
Hg) 
0.49±0.25 [0.20-1.00] 0.06 0.817 
Values are mean ± standard deviation [range]. IVC: inferior vena cava; LPA: left pulmonary 
artery; RPA: right pulmonary artery; SVC: superior vena cava; TCPC: total cavopulmonary 
connection. All correlation coefficients and p-values represent partial correlations controlling for 





Figure 7-5 Effect of Fontan performance and stenosis on liver fibrosis: (a) Correlation between 
TCPC resistance and percent collagen deposition; (b) Correlation between LPA stenosis and 
percent collagen deposition. Correlation coefficient and p-value represent partial correlation 
controlling for time between CMR and biopsy. LPA: left pulmonary artery; TCPC: total 
cavopulmonary connection; WU: Wood units. 
 
 
Figure 7-6 Velocity streamlines and pressure drop contours for representative (a) low, (b) 
moderate and (c) high fibrosis cases (in relation to this cohort). All panels use the same color 
scales shown in panel 3. TCPC resistance and LPA stenosis are noted for each patient. Resistance 




7.3.2.4 Serial CMR analysis 
 Ten of the 21 patients in this study had multiple CMRs (one >1 year prior to biopsy and 
another at the time of biopsy).  This allowed for a preliminary investigation of potential 
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relationships between hemodynamic changes over time and liver fibrosis. One patient experienced 
premature ventricular complexes throughout one of their CMR examinations and was therefore 
excluded.  Average time between serial CMRs was 7.3±3.3 [2, 12] years (Table 7-8). As seen with 
the full cohort in this study (Table 7-6), this subset of patients showed no significant relationship 
between IVC flow rate >1 year prior to biopsy and percent collagen deposition (Figure 7-7b). 
However, a significant, positive correlation (r=0.91, p=0.001, Table 7-8) was observed between 
the change in IVC flow rate (during the interval between the CMRs) and percent collagen 
deposition (Figure 7-7c). Similarly, an increase in TCPC resistance (r=0.83, p=0.022) showed a 
significant, positive correlation with percent collagen deposition. Importantly, these changes were 
not correlated to patient age, time between CMRs or Fontan duration. Finally, IVC flow rate at the 
time of biopsy was significantly related to percent collagen (r=0.68, p=0.044) deposition (Figure 
7-7d), agreeing with our previous work. Figure 7-7a is provided to give a better understanding of 
the timing of the CMRs with respect to the biopsy, as well as the changes and absolute values for 











Table 7-8 Correlations between changes in hemodynamic metrics over time with percent 
collagen deposition (n=9). 




Morphology (HLHS/other) 3/6 - - 
Gender (male/female) 3/6 - - 
Time between CMRs 
(years) 
7.3±3.3 [2, 12] - - 
BSA (m2) 0.37±0.32 [-0.6, 0.85] 0.56 0.190 
Cardiac Output (L/min) 0.94±1.0 [-0.15, 2.37] 0.71 0.072 
Cardiac Index (L/min/m2)  -0.32±0.43 [-1.0, 0.33] 0.05 0.912 
IVC flow (L/min/m2) -0.03±0.22 [-0.31, 0.30] 0.91 0.001* 
SVC flow (L/min/m2) -0.16±0.32 [-0.85, 0.14] 0.37 0.415 
LPA flow (L/min/m2) -0.24±0.37 [-1.06, 0.08] 0.48 0.277 
RPA flow (L/min/m2) 0.10±0.34 [-0.52, 0.59] 0.36 0.433 
Collateral flow (L/min/m2) 0.17±0.46 [-0.52, 1.03] -0.09 0.854 
IVC stenosis (%) 11±11 [-2, 24] 0.03 0.957 
SVC stenosis (%) 12±15 [-7, 45] -0.31 0.492 
LPA stenosis (%) 21±23 [-21, 50] 0.06 0.903 
RPA stenosis (%) 11±34 [-54, 55] -0.29 0.535 
TCPC resistance (WU) 0.13±0.11 [-0.003, 0.29] 0.83 0.022* 
iPL 0.05±0.05 [0.01, 0.157] 0.64 0.124 
TCPC pressure drop 
(mmHg) 
0.64±0.51 [0.07, 1.43] 0.73 0.062 
IVC pulsatility (%) -3±38 [-91, 36] -0.36 0.423 
Change is calculated as value at CMR2 – value at CMR1. Values are mean ± standard deviation 
[minimum, maximum].  IVC: inferior vena cava; LPA: left pulmonary artery; RPA: right 
pulmonary artery; SVC: superior vena cava; TCPC: total cavopulmonary connection. All 
correlation coefficients and p-values represent partial correlations controlling for the time between 





Figure 7-7 Relationship between percent collagen deposition and IVC flow rate. Changes in IVC 
flow rate over time are shown in (a). Each line represents an individual patient. Differences in 
correlations between percent collagen deposition and IVC flow rate were observed between time 
points before (b) and at the time of (d) biopsy. Additionally, the change in IVC flow rate (c) was 




Liver fibrosis is a serious complication of the current treatment strategy for Fontan 
survivors. In these patients, while achieving the benefits of reduced intra-cardiac mixing and 
increased oxygen saturation, this physiology comes at the obligatory cost of creating a state of 
chronically elevated central venous pressures. Given that venous congestion likely plays a primary 
role in this hepatopathy, we sought to investigate whether additional higher order variables such 
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as flow hemodynamics, efficiency, or pathway architecture might influence the degree of fibrosis 
seen by using CMR derived ventricular function, flows and computational flow dynamics.  
Our study is particularly valuable as we have the unique opportunity of analyzing 
contemporaneous liver biopsy data in conjunction with detailed blood flow characteristics in each 
patient. The use of an accurate, high-resolution liver fibrosis quantification technique is necessary 
when investigating potential causes and risk factors of liver fibrosis. In this study, liver biopsy 
samples were analyzed in a unique manner specific to Fontan disease, by quantifying percent Sirius 
Red collagen staining.30,99 This method of quantification allows for a more incremental, 
quantitative scale, which may be more sensitive to teasing out possible associative or causative 
processes than traditional, graded scoring systems developed for other (non-Fontan) fibrosis 
mechanisms. 
This study demonstrated that in single ventricle patients exposed to Fontan physiology for 
a mean of approximately 14 years, significant positive associations exist between inferior vena 
caval flow (measured supra-hepatic) and ventricular power output at the time of biopsy. In 
addition, there was a significant positive correlation with cardiac output.  
Interestingly, a positive association was seen between the degree of hepatic fibrosis and 
indexed IVC flow rate as well as cardiac output. We speculate that this is due to hepatic 
arterialization and thus increased hepatic venous return contributing to IVC flow and cardiac 
output. Hypervascular nodules and hepatic arterialization have been described in the patient with 
Fontan circulation, with localization of hypervascularity to the peripheral perfusion “watershed” 
areas of the liver.100 This may reflect adaptation and attempt towards increased blood flow to 
regions of hypoperfusion and/or relative hypoxia, perhaps somewhat similar to the phenomenon 
of aorto-pulmonary collateral flow seen.101  Liver angiogenesis and fibrogenesis have been linked, 
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with a complex interplay between the two processes based on the primary mechanism causing the 
fibrosis.102  Although the precise mechanism is unclear, hepatic fibrosis after Fontan operation 
may lead to increased hepatic blood flow, increased venous return and may thus be a source for 
excessive volume loading of the single ventricle, again similar to systemic to pulmonary collateral 
flow or valve insufficiency scenarios.  This notion requires further investigation. This idea 
dovetails with the finding of increased ventricular power output with increasing hepatic fibrosis. 
Progressive hepatic fibrosis may thus be a source for future ventricular failure. Interestingly, 
similar changes are seen in patients with alcoholic liver cirrhosis. Though the hepatic arterial buffer 
response is a complex system, scar tissue in the liver generally impedes flow from the portal vein 
and hepatic artery.103 However, this may lead to the phenomena of arterilization which provides 
alternate, lower-resistance routes for blood through through liver. This can result in an overall 
increase in blood flow through the liver.   
To investigate whether prior hemodynamics are associated with future fibrosis, the second 
part of this study included patients with CMR data obtained more than 1 year before liver biopsy. 
This study demonstrates that a significant, positive correlation exists between prior Fontan metrics 
(TCPC resistance and LPA stenosis) and future liver fibrosis in single ventricle patients after 
Fontan.  Hemodynamic metrics were measured approximately seven years prior to liver biopsy. 
Fontan duration at the time of biopsy was approximately 16 years (Table 7-5).  
With the TCPC positioned immediately downstream of the liver, increases in TCPC resistance 
and flow obstruction (LPA stenosis) may result in increased hepatic congestion. This worsened 
hemodynamic state may lead to progressive liver fibrosis over time, producing the positive 
correlations seen in this study. Though individual measurements of pulmonary vascular resistance 
(PVR) were not available for these patients at the time of CMR, PVR values reported in previous 
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studies suggest that the TCPC resistances calculated here are around 10% of PVR on average.104 
For the purposes of illustrating the variability between patients, if we assume a constant PVR of 2 
WU for all patients (Egbe et al), TCPC resistance would range from 3% to 22% of PVR in this 
study (the ratio of TCPC resistance to PVR ranged from 4% to 107% in our previous study (Trusty 
et al.) including individual PVR measurements).104,105  This approximation demonstrates the 
potential for TCPC inefficiencies to substantially affect total resistance downstream of the liver.  
These findings encourage the consideration of pre-procedural planning to improve TCPC 
performance. Though commonly used for preventing or correcting pulmonary arteriovenous 
malformations by optimizing hepatic flow distribution (HFD), surgical planning can similarly be 
used to compare potential surgical options and optimize energy efficiency.11,28,39 Furthermore, 
flow efficiency through a connection can be more difficult to visualize and predict than HFD since 
changes in velocity and pressure are nonlinear and not always intuitive.106  Therefore, pre-
procedural planning focused on flow efficiency may be even more informative for surgical 
decision making.  
Similarly, interventional strategies may prove beneficial for patients post-Fontan with LPA 
stenosis or high TCPC resistance or those that demonstrate clinical hepatic decline. The significant, 
positive correlation between LPA stenosis and fibrosis seen in this study suggests that early 
correction of vessel stenosis may reduce the progression of liver disease in these patients. Whether 
this is due to the effect of LPA stenosis on TCPC resistance or some other factor, interventions 
such as balloon dilation may be important considerations in this post-Fontan population.  Periodic 
monitoring of vessel stenosis may be useful to determine when or if these interventions are needed. 
Important inferences can be made by comparing results between this longitudinal study and 
our previous cross-sectional study. One of the main conclusions from the previous cross-sectional 
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study was the positive correlation between IVC flow rate and percent collagen deposition 
(rho=0.624, p<0.001), reinforced by a significantly higher IVC flow rate in the upper tertile of 
fibrosis patients (p=0.008).105  In the current study with IVC flow measured approximately 7 years 
prior to biopsy, no such relationship was observed (r=0.19, p=0.434). Though these results are the 
first of their kind and may serve only as preliminary results, they suggest that liver disease itself 
(fibrosis induced hepatic arterialization as hypothesized in our previous study) may be the cause 
of these significant differences in IVC flow at the time of biopsy. In addition, TCPC resistance 
and LPA stenosis showed significant correlations with fibrosis in this longitudinal study but not at 
the time of biopsy. This confirms our suspicion that hemodynamics at the time of biopsy may be 
more representative of the effects of liver disease rather than the cause.  
Finally, the serial CMR analysis for the subset of nine patients in this study provides a more 
direct view of any causal relationships.  In these nine patients, we see interesting changes in the 
correlations between IVC flow rate and percent collagen deposition over time. IVC flow rate 
showed no correlation with percent collagen deposition at a time point prior to biopsy 
(approximately 7 years before), but a significant relationship was seen in the change in IVC flow 
rate as well as the IVC flow rate at the time of biopsy (all flows indexed to BSA). These findings 
support the proposed mechanistic pathway illustrated in Figure 7-8. Data from this study suggests 
that an inefficient TCPC design and vessel stenosis may caused increased resistance to hepatic 
flow, therefore increasing pressure and resulting in increased hepatic congestion, contributing to 
the progression of liver fibrosis. In addition, the progression of liver disease may lead to hepatic 
arterialization (a compensatory mechanism) which decreases resistance to flow through the liver 
and leads to increases in IVC flow rate. Though the progression of liver disease in these patients 
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is undoubtedly a multifactorial issue, these data suggests that TCPC design and vessel stenosis are 
important contributing factors.  
The relationship between hemodynamics and liver fibrosis may seem like a “chicken and the 
egg” scenario. With numerous and complex mechanicsms involved in the process, it can be 
difficult to tease out the cause and effect. Our preliminary explanation given here stems from the 
observation that TCPC resistance is corrected with liver fibrosis prior to biopsy, but not at the time 
of biopsy, and that the opposite is true for IVC flow (correlated at the time of biopsy but not prior 
to biopsy). We do not multiple liver biopsy measurements for these patients, so we cannot address 
how fast the liver fibrosis progressed or when it happened exactly. We are making the assumption 
that the time point prior to biopsy (~7 years before) the liver was relatively healthy without much 
fibrosis. Based on this assumption, we are proposing that metrics evaluated prior to biopsy are 
potentially a cause of liver fibrosis and not a result of liver fibrosis (since we are assuming liver 
fibrosis was minimal at this early timepoint). In addition, if a given metric was not correlated at 
the early timepoint, but is correlated at the time of biopsy, we are proposing that this change in 
relationship is a result of the progressing liver fibrosis. This logic will not hold in all situations, 
but in this preliminary study we feel it serves the reader well to propose a mechanistic link between 
these observations.   
 
 
Figure 7-8 Proposed mechanism of the interaction between hemodynamics and liver fibrosis.  
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8. SPECIFIC AIM 2B 
 
Purpose: To evaluate the use of ventricular assist devices to support the Fontan 
circulation and prolong liver health as a bridge to heart transplantation. 
 
Hypothesis: Ventricular assist devices can decrease Fontan hepatic congestion by 
augmenting flow and decreasing inferior vena cava pressure. 
 
8.1 Overview 
Heart transplantation is currently the only option to fundamentally correct a failing Fontan 
heart. However, Fontan associated liver disease can be a contraindication to heart transplant, and 
combined heart and liver transplantation is extremely rare.  Therefore, the purpose of Specific Aim 
2B is to determine if VADs can be used to promote liver health in a failing Fontan patient until 
heart transplantation. In this aim we will use both experimental and computational modeling to 
determine if VADs are a viable option for right-sided Fontan support, and if VADs can decrease 
hepatic congestion in order to delay liver failure.  To accomplish this, we will test 4 currently 
available pumps (Circulite, VentriFlo, PediMag and CentriMag) in a previously designed and 
validated Fontan mock circulatory loop. The experimental loop will be tuned to match “failing” 
Fontan pressures and flows acquired from clinical data. During these experiments we will evaluate 
each pump’s ability to decrease hepatic pressure while increasing cardiac output. Additionally, the 
experimental data will be used to validate a mechanically assisted Fontan computational model.  
The computational model will then be used to investigate the effect of variations in cannula offset 
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and insertion angle, as well as address the generalizability of the experimental results across 
multiple patient anatomies.  
 
8.2 Methods 
This specific aim uses in vitro modeling to test several mechanical circulatory support 
devices in the context of a failing Fontan. Please refer to Chapter 4 for a detailed description of 
the mock circulatory loop, measurement techniques and devices tested. 
 
8.2.1 Study Design  
Four devices were tested in this specific aim. Each device following a similar experimental 
protocol as shown in Figure 8-1. A variety of cannulation strategies, baffle clamping methods and 
pumping parameters were investigated (depending on the individual device abilities and 
successes). These will be discussed in the following sections.  
 




8.2.2 Patient Model 
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Substantial effort was spent in a previous study to develop a patient specific model that matches 
the bulk compliance of the actual TCPC.80  This model represents a “standard” TCPC with two 
inlets and two outlets, a right-sided superior vena cava and typical levels of stenosis. The anatomy 
was segmented from CMR data under IRB approval (H092079). The TCPC model was constructed 
of transparent silicone with a bulk compliance of 1.36 mL/mmHg. Further details on the 
quantification of patient-specific compliance as well as the determination of the appropriate model 
wall thickness can be found in the study be Tree et al.80   
 
8.2.3 Cannula and Baffle Restriction Strategies 
Multiple cannula and baffle restriction strategies were tested including placing the VAD 
(1) in parallel with the Fontan baffle (inflow placed in the IVC near the diaphragm and egress 
located at the LPA/RPA confluence, Figure 8-2a), (2) in series with the Fontan baffle (same 
cannulation as (1) with baffle completely restricted, Figure 8-2c), and (3) performing a Fontan 
“takedown” and using the VAD as a true (albeit extracorporeal) right ventricle. 
Additionally, in an attempt to reduce potential recirculation, a Y-graft outflow cannula 
(inserting downstream in each pulmonary artery, Figure 8-2b) was tested in series and in parallel. 
The main difference between scenario 2 and 3 is that SVC flow can move directly into the 
LPA/RPA in scenario 2, therefore it is not a complete Fontan “takedown.” In scenario 3, all 
IVC/SVC flow must pass through the assist device before entering the pulmonary circulation. To 
experimentally achieve scenario 3, the pulmonary arteries were separated from the IVC/SVC using 
two clamps (Figure 8-2d).  In addition to these 3 scenarios, various levels of baffle restriction (0-
100%) were explored in the “in parallel” configuration.  A schematic of the TCPC and VAD with 
vessels and cannula labeled is shown in Figure 8-2e. Outflow cannula position will vary based on 
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cannulation strategy. The results and implications of these cannulation options are discussed 
further in the following sections.  
 
Figure 8-2 Cannulation strategies. (a) Ventricular assist device (VAD) in parallel with single 
outflow cannula. (b) VAD in parallel with Y-graft outflow cannula. (c) VAD in series (complete 
Fontan baffle restriction). (d) Fontan takedown configuration (vena cava separated from 
pulmonary arteries). (e) Schematic of total cavopulmonary connection and VAD with vessels and 
cannula labeled. Outflow cannula will vary based on cannulation strategy. 
 
8.2.4 Banding Designs 
A further investigation was performed looking into the effect of Fontan baffle banding 
design on hemodynamics. This was undertaken after realizing that complete baffle restriction was 
needed for certain devices.  Five banding designs were 3D printed for evaluation. Following 
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Poiseuille’s law, each band was designed to theoretically produce the same resistance to flow 
(resistance proportional to length/radius4). A description is shown in Figure 8-3.  The results and 
implications of these banding options are discussed further in the following sections. 
 
 
Figure 8-3 Effect of banding design on hemodynamics. (a) Effect of banding on pressure; (b) Theoretical 
relationship between banding length (L) and area to maintain resistance (r=radius); (c) Top and side views 
of the five custom banding designs; (d) Effect of banding design on SVC pressure (VAD rpms labeled above 
each bar). Banding is calculated as percent constriction by area. All points on the curve in (b) theoretically 
offer the same resistance.  The asterisk in (d) indicates that SVC pressure increase was measured at the 
point when IVC pressure was reduced by 10 mmHg.    
 
8.2.5 Experimental Protocol 
In this study, successful Fontan support was defined as the ability to simultaneously decrease 
IVC pressure (Fontan pressure) by 5 mmHg and increase CO to 4.25 L/min (a 0.75 L/min 
increase).107,108 These hemodynamic changes represent a significant improvement in the 
physiologic state of a patient. Patients with hemodynamics in this range are less likely to have 
133 
 
severe liver complications.  If both criteria were met, the VAD configuration was deemed 
successful. Identical failing Fontan baseline conditions were first established in each scenario. The 
VAD was then turned on and a change in Fontan pressures was observed (as expected). If the IVC 
pressure decreased (reduced venous congestion) and PA pressures increased (improved ventricular 
filling and increased preload), ventricle adaptation (a shift in the pressure volume loop) was 
modeled by increasing the output of the “single ventricle” pump until the PA pressures returned to 
their baseline values (Figure 8-1). This is based on the assumption that the baseline PA pressures 
represent their homeostatic values. The resulting hemodynamic conditions were then compared to 
the criteria for success. If unsuccessful, the VAD configuration/parameters were adjusted and the 
process was repeated. 
 
 
8.2.6 Computational Model 
In addition to in vitro testing of commercially available mechanical assist devices, 
computational methods were used to explore Fontan circulatory support across multiple patient 
anatomies and cannulation variations.  Importantly, computational methods were first validated by 
comparing with experimental results. The CentriMag device was modeled computationally after 
determining that it outperformed all other devices during in vitro testing. The CentriMag device 
was modeled computationally using a “fan” boundary condition in ANSYS Fluent. The pump 
performance curve from the instructions for use defining pressure and flow relationship for 
CentriMag was implemented into Fluent by fitting the performance curve with a third order 
polynomial. The coefficients for this curve were inputted into the fan boundary condition 
134 
 
parameters in Fluent. Computational fluid dynamics, anatomy and velocity segmentation methods 
followed those previously described in Chapter 4.  
Six patients were modeled computationally (Table 8-1). Patients were chosen to offer a 
wide range of anatomies including variations in vessel sizes and IVC-SVC offsets, a variety of 
diagnoses and both intracardiac and extracardiac Fontan connections. All patient data were 
received from the Children’s Hospital of Philadelphia with IRB approval (IRB: H05236). 
Cannulation options were modeling using SURGEM III. A baffle size of 10mm (diameter) was 
used as specified in the CentriMag IFU. Five unique combinations of insertion offset and insertion 
angle were modeled (all within the realm of surgical possibilities). Each position is spaced ½ 
cannula diameter horizontal or vertical from the other insertion locations.  Five cannulation angles 
were modeled. Angle “n” represents an angle normal to the surface of the vessel wall. Angle “j”, 
“l”, “p” and “r” are positioned 50 degress away from normal as indicated in Figure 8-4. Fifty 
degrees was chosen to investigate extreme differences in cannula insertions.  To focus on the most 
extreme possible cannulation insertions, specific combinations of position and angle were chosen 
to result in the most extreme differences in flow fields. For example, the combination of “ir” inserts 
the cannula to the “northeast” of the control (“en”) and angles the cannula towards the “northeast”, 
directing flow from the cannula to the “northeast” as much as possible. “en” serves as the control 
which represents the center position with an insertion angle normal to the vessel wall. The five 
cannulation variations investigated include “en”, “ir”, “gp”, “cl”, and “aj”. 
Table 8-1 Patient ID key for Specific Aim 2B. 
Study ID GT ID 
Patient 1 CHOP011B 
Patient 2 CHOP001B 
Patient 3 CHOP057A 
Patient 4 CHOP064A 
Patient 5 CHOP081A 





Figure 8-4 Cannulation options. A total of five options were investigated: “en”, “ir”, “gp”, “cl”, 
and “aj”.  
 
In addition, dye flow visualization techniques were utilized to better understand the fluid dynamics 
inside the TCPC. A 20% (by volume) solution of red dye was injected into the SVC at baseline failing 
Fontan conditions at various VAD rpms. A Phantom VEO 340L (AMETEK Vision Research, NJ, USA) 
high speed camera was used to record videos at 1000 frames per second to allow for a qualitative 
understanding of the flow fields within the TCPC.   
 
Results from the computational modeling include wall shear stress, pressure gain from the 
vena cava to pulmonary arteries, power added and hepatic flow distribution. Wall shear stress was 
averaged over the cardiac cycle and across the entire surface area of the TCPC. Pressure gain was 
defined as the average pressure increase from the vena cava to the pulmonary arteries averaged 
over the cardiac cycle. The equation is given below: 
𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑔𝑎𝑖𝑛 = 0.5 ∗ 𝑃 , + 𝑃 , − 𝑃 , − 𝑃 ,  
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where 𝑃 ,  , 𝑃 ,  , 𝑃 , , and 𝑃 ,  are the average pressure for the LPA, 
RPA, IVC and SVC, respectively, during the cardiac cycle. Power added was calculated using the 
same equation as commonly used for “power loss”:  
𝑃𝐿 = 𝑝 +
1
2
𝜌𝑣 𝑣 · 𝑑𝐴 − 𝑝 +
1
2
𝜌𝑣 𝑣 · 𝑑𝐴 
where p is the static pressure, ρ is the blood density, A is the area of the inlet/outlet and v the 
velocity at the respective inlets or outlets. However, in this situation power is being added to the 
system, therefore the “power loss” value is negative. The percentage of TCPC wall area greater 
than 150 Pa was calculated as a measure of hemolysis potential. 150 Pa was chosen as a 
conservative estimate of the WSS threshold for hemolysis.109 The percentage of wall area above 
150 PA is defined as 
% 𝐴𝑟𝑒𝑎 𝑎𝑏𝑜𝑣𝑒 150 𝑃𝑎 =  100 ∗
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑇𝐶𝑃𝐶 𝑤𝑎𝑙𝑙 𝑎𝑏𝑜𝑣𝑒 150 𝑃𝑎






8.3.1.1 CircuLite in parallel 
Figure 8-5 shows the mean pressure and flow rate changes induced by the VAD when 
placed in parallel with the Fontan connection (Figure 8-2a). The largest magnitude flow changes 
occur while running the VAD at 28,000 rpm, its fastest capable speed. At this speed, the IVC flow 
is increased by 0.07 L/min, but the SVC, LPA, and RPA flow rates decrease by 0.2, 0.06, and 0.07 
L/min, respectively. The largest magnitude pressure changes also occur at 28,000 rpm VAD 
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rotational speed. The IVC, SVC, and LPA pressures decrease by 2.22, 1.08, and 0.43 mmHg 
respectively, and the RPA pressure increases by 0.63 mmHg at this rotational speed. 
 
 
Figure 8-5 Fontan vessel mean flow rate (top) and pressure (bottom) values as a function of 
VAD rotational speed during the VAD in parallel scenario. The VAD flow rate is also shown for 
comparison. The shaded region defines areas of ideal circulatory support. 
 
Ultimately, these results fall short of decreasing IVC pressure by 5 mmHg and augmenting 
CO by 0.75 L/min. Furthermore, although the VAD output was able to reach 2.5 L/min, (Figure 
8-5) of flow, it only resulted in a negligible change in CO, suggesting significant recirculation. 
This was further confirmed by using a simple dye injection technique which demonstrated 




8.3.1.2 Restrictive banding  
In order to minimize the recirculation observed in the previous configuration, graduated 
restriction was applied to test if restrictive banding would reduce the recirculation and what degree 
of restriction was needed.Figure 8-6 shows the mean pressure and flow rate changes with 
increasing levels of IVC banding while operating the VAD at 28,000 RPM. Table 8-2 lists the 
baseline mean flow rates and pressures when the VAD is not operating, for reference.  
 
 
Figure 8-6 Flow rate (top) and pressure (bottom) changes as a function of baffle restriction %. 





Table 8-2 Fontan vessel flow rates and pressures at various VAD rotational speeds and baffle 
restriction levels during the baffle restriction examination scenario. 





IVC SVC LPA RPA VAD CO IVC SVC LPA RPA 
0 0 2.15 1.36 1.89 1.62 -- 3.51 16.78 14.96 12.18 19.17 
28000 0 2.13 1.35 1.84 1.64 2.29 3.48 16.43 14.95 11.70 19.81 
28000 50 2.14 1.36 1.84 1.66 2.48 3.50 16.16 14.65 11.57 19.72 
28000 80 2.19 1.36 1.85 1.70 2.41 3.55 13.29 15.16 11.75 20.12 
28000 90 2.52 1.30 2.00 1.82 2.09 3.82 -4.07 17.39 13.98 22.43 
 
It was found that restrictive banding did not affect the Fontan connection mean flow rates 
and pressures and by extension, the degree of recirculation, until 80% restriction was applied. A 
90% restriction caused nearly 0.4 L/min augmentation of CO, all of which was due to an increase 
in IVC contribution rather than recirculation. The same 90% restriction also caused 20.5 mmHg 
of pressure loss in the IVC, resulting in a negative pressure value and a physiologically collapsed 
vein. This suggested that separation of the SVC and IVC flow (with restrictive banding) reduced 
the preload for the VAD to the point where negative IVC pressure and suction events may become 





8.3.1.3 Circulite in series 
VAD in parallel and restrictive banding scenarios resulted in less than ideal Fontan 
circulation support. Therefore, in an attempt to avoid recirculation and optimize the VAD preload, 
placement of the VAD in series was explored. As mentioned above, this involved take-down of 
the Fontan; with the new SVC IVC confluence serving as the preload chamber. The unifocalized 
branch pulmonary arteries served as the receiving vessel for the egress cannula. Figure 8-7 shows 
the mean pressure and flow rate changes induced by the VAD when placed in series with the 
Fontan connection.  
 
Figure 8-7 Flow rate (top) and pressure (bottom) changes as a function of VAD rotational speed 
during the VAD in series scenario. Note that during this scenario the VAD flow is equal to the 





The results show that the failing Fontan baseline set for the VAD in parallel and restrictive 
banding methods was not maintained during the VAD in series scenario (0 RPM). The failing 
Fontan baseline set was established with the Fontan connection intact. Taking down the Fontan 
connection to place the VAD in series with the caval veins and the pulmonary arteries forces an 
altered baseline condition, though all model resistances and compliances remain consistent. When 
the VAD is engaged, CO increases from 0.7 L/min to 1.75 L/min. This flow limit is achieved at 
the maximum speed of 28000 rpm which is the operating limit for the device. Additionally, IVC 
and SVC pressure drop by 5.9 mmHg while pulmonary artery pressure increases only 2 mmHg. 
Mean caval pressure drops an appropriate amount to be considered successful, and the CO is 
augmented by the VAD by ~ 1 L/min. However, the absolute magnitude of the CO is lower than 
previous scenarios, and much lower than physiological values of CO for Fontan patient support. 
Thus, the VAD in series scenario also fails to successfully meet both the support criteria, mainly 





8.3.2.1 VentriFlo in parallel  
When positioning the VAD in parallel with the Fontan baffle, a consistent pressure drop 
was observed across all vessels (Figure 8-8a).  The pressure drop increased as VAD flow rate 
increased, with a pressure drop of approximately 4 mmHg as the VAD flow rate approached the 
total IVC flow rate.  Following the experimental protocol, the inability of this configuration to 
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increase PA pressures prevented ventricle adaptation and no CO augmentation was achieved 
(Figure 8-8b).  Values from selected experimental conditions are listed in Table 8-3. 
The consistent pressure drop across all Fontan vessels, without a downstream increase in 
the PA pressures, indicates a significant amount of recirculation through the Fontan baffle as seen 
in our previous work.60  Fluid exiting the egress cannula preferentially travels down through the 
Fontan baffle and back into the inflow cannula, effectively short-circuiting the Fontan connection 
and failing to add energy downstream in the PAs.  In an attempt to decrease this recirculation, a 
Y-graft outflow cannula was used in order to deliver the VAD outflow further downstream in the 
PAs (Figure 8-2b). However, the results from this option were nearly identical to the single outflow 
cannula. 
 
Figure 8-8 Hemodynamic changes caused by ventricular assist device (VAD) implementation. 
VAD in parallel: (a) mean pressures and (b) mean flow rates. Successful support achieved with 




Table 8-3 Hemodynamic measurements for ventricular assist device (VAD) configurations and 
parameter testing. 
VAD Configuration 
Average Flow Rate (L/min) 
Average Pressure 
(mmHg) 
VAD IVC SVC LPA RPA IVC SVC LPA RPA 
In parallel (single outflow 
cannula) 
0.0 2.0 1.4 1.7 1.7 14.0 15.2 10.9 12.6 
0.6 2.0 1.4 1.7 1.7 13.5 14.8 10.3 12.0 
0.9 2.0 1.4 1.7 1.7 12.7 14.1 9.3 11.1 
1.5 2.0 1.4 1.7 1.7 11.9 13.3 8.2 10.0 





Baseline 0.0 2.2 1.3 1.7 1.8 15.2 18.0 10.6 17.9 
Baseline with 
VAD 2.4 2.4 1.1 1.9 1.7 6.2 20.9 11.7 19.9 
Ventricle 
Adaptation 





Baseline 0.0 2.2 1.3 1.7 1.8 15.2 18.0 10.6 17.9 
70 bpm 2.3 2.3 1.0 1.6 1.7 2.9 25.0 14.4 27.5 
140 bpm 2.4 2.5 1.1 1.8 1.8 2.8 21.3 11.1 22.7 






Baseline 0.0 2.1 1.4 1.8 1.8 19.0 21.8 13.4 21.7 
20% 2.1 2.2 1.3 1.8 1.8 5.8 22.8 12.1 22.2 
33% 2.1 2.2 1.3 1.7 1.8 5.8 21.9 11.5 21.3 
50% 2.1 2.2 1.3 1.7 1.7 6.1 21.5 11.4 20.7 
The VAD was not in use during baseline measurements. Ejection vs filling time is indicated as 




8.3.2.2 VentriFlo in series  
A restrictive banding around the Fontan baffle was then investigated as a means to decrease 
recirculation.  The amount of restriction was iteratively increased from 0 to 100 percent (by area).  
Baffle restrictions up to 80% produced almost no hemodynamic differences when compared with 
the unrestricted option, and a 90% baffle restriction showed only minor differences in pressure 
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drop and flow augmentation. However, a complete restriction of the Fontan baffle was found to be 
a viable option.  
With complete baffle restriction (effectively placing the VAD in series with the Fontan 
baffle), a substantial pressure drop in the IVC of approximately 10 mmHg was observed, along 
with a simultaneous increase in PA pressures of 1-2 mmHg (Figure 8-8c).  These conditions 
promote ventricle adaptation, which was modeled by increasing CO until the PA pressures 
returned to their baseline values.  In this “adapted” state, the mean flow rates were increased for 
all vessels with a resulting total cardiac output of 4.25 L/min (Figure 8-8d) and an IVC pressure 
approximately 10 mmHg lower than the baseline value (Figure 8-8c), thus meeting the defined 
criteria for successful support.   
 
8.3.2.3 Complete Fontan “takedown” 
Under the preload and afterload conditions that exist in the Fontan “takedown” 
configuration, the VAD could output a maximum of only 3.2 L/min, which was less than the 
baseline cardiac output. Therefore, this configuration was not successful.   
 
8.3.2.4 VentriFlo pumping parameters 
Achieving successful support required iterating through many different combinations of 
pumping parameters including flow rate, frequency, stroke volume, and ejection vs filling ratio 
(E/F ratio).  During successful support, the VAD was operating at 160 bpm and a 66% E/F ratio, 
producing an output of 2.85 L/min with a stroke volume of approximately 17 mL.  In an attempt 
to better understand the effects of these individual variables, a parametric sweep of VAD frequency 
and E/F (ejection to filling time) ratio was performed while holding all other parameters constant 
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(using the cannulation shown in Figure 8-2c).  VAD frequency was varied between 70 and 160 
bpm (holding VAD flow rate constant), and significant differences were noted in mean vessel 
pressure with IVC pressure increasing and PA/SVC pressure decreasing (Figure 8-9a).  Varying 
the E/F ratio from 20% to 50% produced less significant hemodynamic changes than VAD 
frequency, with a maximum pressure drop of about 2 mmHg in the SVC/RPA (Figure 8-9b).   
 
 
Figure 8-9 Effect of pumping parameters on hemodynamics. (a) Effect of ventricular assist 
device (VAD) frequency on Fontan pressures. (b) Effect of VAD ejection vs filling time on 
Fontan pressures. These measurements were taken using the VAD in series cannulation strategy 
(Figure 8-2c). 
 
Altering VAD flow rate was inconsequential in the parallel configuration (affected only 
the amount of recirculation with no productive change in hemodynamics), and irrelevant in the 
Fontan takedown configuration (maximum VAD flow rate was less than the baseline cardiac 
output and therefore not a viable option).  However, when positioned in series, VAD flow rate is 
the most important pumping parameter to achieve favorable changes in hemodynamics. Following 
intuition, if the VAD flow rate is below the original IVC flow rate it effectively limits the flow and 
substantially increases all upstream pressures.  Conversely, if the VAD flow rate is greater than 
the original IVC flow rate it creates a “suction” and significantly decreases all upstream pressures. 
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Therefore, with a VAD flow rate greater than or equal to the original IVC flow rate, IVC pressure 
will decrease which may alleviate hepatic congestion, the hypothesized mechanicsm for Fontan 




8.3.3 PediMag  
As with the CircuLite and VentriFlo devices, significant amounts of recirculation through 
the Fontan pathway (FP) were observed with the PediMag™ device.  To reduce recirculation, 
various levels of FP banding were explored. Eighty percent FP restriction (by area) was required 
before any noticeable hemodynamic changes were observed (Figure 8-3a). Based on these 
findings, the impact of complete restriction of the Fontan pathway was assessed. With complete 
Fontan pathway restriction, PediMag™ was able to decrease IVC pressure by >10 mmHg while 
increasing PA pressures by approximately 2 mmHg at the baseline flow conditions (Table 8-4). 
Following the established experimental protocol, these favorable changes allow for ventricle 
adaptation, which was modeled by increasing cardiac output. PediMag™ easily surpassed the 
initial criteria for success, effectively maintaining decreased IVC pressure and increased PA 
pressures even up to a cardiac output of 5 L/min (Figure 8-10,Table 8-4). However, these 
improvements in hemodynamics were accompanied by an increase in SVC pressure of 
approximately 6 mmHg.  Elevated SVC pressures may affect cerebral blood flow, enlarged veins 





Table 8-4 Hemodynamic measurements for PediMag™ and CentriMag™ at the baseline and adapted 
states. The asterisk indicates that PediMag™ required complete Fontan pathway restriction.    
Device Condition 
 Average Flow Rate (L/min) Average Pressure (mmHg) 
VAD speed 
(rpms) 
CO IVC SVC LPA RPA IVC SVC LPA RPA 
PediMag* 
Baseline 0 3.5 2.1 1.4 1.76 1.74 16 16.6 14.0 15.2 
Baseline with 
VAD 
2400 3.5 2.3 1.2 1.75 1.75 5.2 19.3 15.9 17.8 
Ventricle 
adaption to 4 
L/min 
2500 4.0 2.5 1.5 2.0 2.0 8.7 19.7 15.1 17.7 
Ventricle 
adaption to 4.5 
L/min 
2750 4.5 2.8 1.7 2.25 2.25 10.0 21.0 14.1 18.1 
Ventricle 
adaption to 5 
L/min 
3000 5.0 3.1 1.9 2.5 2.5 10.1 22.2 13.1 18.4 
CentriMag 
Baseline 0 3.5 2.1 1.4 1.75 1.75 17.2 16.0 14.0 16.4 
Baseline with 
VAD 
2350 3.6 2.2 1.4 2.0 1.6 6.3 11.6 17.5 16.0 
Ventricle 
adaption to 4 
L/min 
2350 4.0 2.5 1.5 2.1 1.9 8.8 13.7 17.9 17.7 
Ventricle 
adaption to 4.5 
L/min 
2550 4.5 2.8 1.7 2.4 2.1 10.8 15.4 19.7 19.6 
Ventricle 
adaption to 5 
L/min 




Figure 8-10 Hemodynamic changes achieved using PediMag™. (a) average pressures and (b) average 
flow rates. PediMag™ rpms are indicated below each cardiac output. LPA and RPA flow rates are nearly 





8.3.4 CentriMag  
The need for higher output to overcome recirculation encouraged the testing of the 
CentriMag™ device.  As shown in Figure 8-11, CentriMag™ was able to produce the desired 
hemodynamic changes with no FP banding. IVC pressure decreased ~10 mmHg while the average 
PA pressure increased ~1.5 mmHg (Table 8-4). In addition, SVC pressure decreased by ~4 mmHg, 
overcoming a major limitation of the PediMag™ device. Following these favorable changes, 
ventricle adaption was modeled (Figure 8-12). As with PediMag™, CentriMag™ could easily 
support a cardiac output up to 5 L/min while maintaining decreased IVC pressure and increased 
PA pressures (Table 8-4).  Dye flow visualization techniques revealed that at high enough VAD 
output, SVC flow was pulled down through the FP and into the inflow cannula. This explains the 
decrease in SVC pressure seen with the CentriMag™ device while at the same time achieving 
increased forward flow through the pulmonary arteries.   
 
 
Figure 8-11 Effect of CentriMag™ rotational speed on Fontan pressures. This scenario required no 





Figure 8-12 Hemodynamic changes achieved using CentriMag™.  (a) average pressures and (b) average 
flow rates. This scenario required no banding of the Fontan pathway. CentriMag™ rpms are indicated 
below each cardiac output. 
 
 
8.3.5 Computational modeling 
8.3.5.1 Validation 
Computational methods were first validated using the in vitro results. Figure 8-13 and 
Table 8-5 show very good agreement between the in vitro and computational results in terms flow 
rate and pressure changes. Importantly, the VAD flow rate was only 2% different between the two 
modeling techniques, proving that our method to model the pump computationally is accurate. 
Additionally, the average pressure increase from the vena cavae to the pulmonary arteries (the 
most important pressure metric) was only 1% different between techniques, again confirming the 





Figure 8-13 Comparison of (a) flow rates and (b) relative pressure changes between in vitro and 
computational results.  
 
Table 8-5 Comparison of flow rates and relative pressure changes between in vitro and 
computational results. 
Flows (L/min) In vitro In silico 
IVC 2.3 2.3 
SVC 1.3 1.3 
LPA 2 2 
RPA 1.7 1.7 
FAD 8.8 9 
      
Pressure Increase 
(mmHg) In vitro In silico 
Average 7.8 7.9 
IVC to LPA 9.7 8.4 
IVC to RPA 11.2 12.3 
SVC to LPA 4.4 3.4 
SVC to RPA 5.9 7.4 
 
Dye flow visualization techniques were used to better understand the flow fields within the 
TCPC. Dye was injected only into the SVC. Figure 8-14 shows good agreement between the in 
vitro and computational results at various VAD speeds. Slow motion dye flow visualization videos 




Figure 8-14 Comparison of “streamlines” from the SVC between in vitro (top row) and 
computational (bottom row) results. This comparison is made with the VAD at 0, 500 and 2350 
rpms.  
 
8.3.5.2 Computational results  
Pump efficacy across different patient anatomies and different cannulations were 
investigated. Clinical data for the six patients modeled computationally is given in Table 8-6. 







Table 8-6 Patient clinical data for computational modeling. Patient 1 is the patient also used for 
in vitro experiments.   









Patient 1 21 F 1.69 HLHS, VSD LT 3.91 73/27 45/55 
Patient 2 16 F 1.23 HLHS LT 2.33 71/29 40/60 
Patient 3 21 F 1.6 TGA, VSD, 
TA 
ECC 4.24 73/27 60/40 
Patient 4 6 F 0.94 HLHS LT 1.6 64/36 55/45 
Patient 5 4 F 0.54 TGA, TA ECC 3.88 32/68 35/65 
Patient 6 17 M 1.65 HLHS ECC 4.87 70/30 20/80 
BSA: body surface area; HLHS: hypoplastic left heart syndrome; VSD: ventricular septal defect; 
TGA: transposition of the great arteries; TA: tricuspid atresia; LT: lateral tunnel; ECC: 
extracardiac conduit. 
 
The CentriMag pump increased pressure from the vena cavae to the pulmonary arteries in all 
patient anatomies. The pump was run at 2350 rpms for all patients to focus on the effect of patient 
physiology on pump performance. Median pressure increase was 5.78 [1.2-7.9] mmHg, HFD was 
52 [19-63] and the pump added 31 [19-47] mW of power. Average wall shear stress (WSS) across 
the entire TCPC wall was low for all anatomies at 29.5 [21-36] Pa with a maximum wall shear 
stress of 248 [167-337] Pa. The threshold of 150 Pa was chosen as a conservative wall shear stress 
for potential red blood cell damage.109 This level of wall shear stress would require an exposure 
time on the order of 102 seconds which exceeds the exposure time experienced within the TCPC. 
Even at this threshold, only 1% of the total wall area experienced a WSS above 150 Pa for patient 




















Patient 1 7.9 47 55 21 167 0% 
Patient 2 5.3 28 48 25 183 0% 
Patient 3 4.3 37 63 30 203 0% 
Patient 4 7.4 19 62 32 316 0% 
Patient 5 6.2 34 35 29 293 0% 
Patient 6 1.2 28 19 36 337 1% 
HFD: hepatic flow distribution; WSS: wall shear stress. 
 
Wall shear stress, SVC streamlines, and relative pressure changes for the six patients can be 
visualized in Figure 8-15, Figure 8-16and Figure 8-17 respectively.  
 
 






Figure 8-16 SVC streamlines for all patients. Streamlines are only seeded at the SVC. In each 
case, the VAD is pulling the SVC flow down through the Fontan pathway into the inflow cannula.  
 
 






The effect of cannula insertion was also investigated. Various cannula insertions were 
modeled on Patient 1. Table 8-8 shows the results across the five cannulation variations. Pressure 
increased from the vena cava to the pulmonary arteries in each scenario with a median of 5 [2-7.9] 
mmHg. The pump added 40 [21-57] mW of power and HFD was 45 [43-55]. Average wall shear 
stress was 24 [21-26] Pa with a maximum WSS of 168 [125-193] Pa. All cannulations had 0% 
wall area with a WSS above 150 Pa.  
 


















Cannulation 1 e n 7.9 47 55 21 167 0% 
Cannulation 2 a j 4.6 34 43 23 168 0% 
Cannulation 3 c l 2 21 52 26 176 0% 
Cannulation 4 g p 6.3 57 45 26 125 0% 
Cannulation 5 i r 5 40 44 24 193 0% 
 
Wall shear stress, SVC streamlines, and relative pressure changes for the five cannulations can be 














Figure 8-20 Relative pressure changes for all cannulation options. All figures use the same color 
scale.  
 
A summary of the results from both the inter-patient comparison as well as intra-patient 
comparison (different cannulations) is given in Figure 8-21. 
 





8.4.1 Device efficacy  
A wide range in device efficacy was observed across the four devices tested. The devices 
tested include implantable and extracorporeal devices, pulsatile and continuous flow devices, and 
devices designed for partial and full ventricular support. Importantly, the lack of a Fontan animal 
model requires benchtop testing to determine which devices may potentially be beneficial for 
patient use. As seen in this work, some devices are clearly not suitable for failing Fontan support 
and therefore no in vivo trials are needed which may put patients in danger. 
Overall, device efficacy improved with the output of the device. The HeartWare CircuLite 
VAD was the “weakest” of the devices tested and could not provide successful support in any 
scenario (in parallel, with Fontan pathway banding, Fontan takedown). Significant amounts of 
recirculation required Fontan pathway banding, which then resulted in a non-physiologic pressure 
drop in the IVC. In addition, when taking down the Fontan and positioning CircuLite as a true 
right ventricle, the VAD could not produce a full cardiac output and therefore this pump was not 
a successful option.  
The VENTRIFLO™ True Pulse Pump was more powerful than the CircuLite VAD.  
VENTRIFLO™ showed similar recirculation patterns through the Fontan pathway. Severe 
pathway restriction was again needed to produce hemodynamic changes. With complete pathway 
banding, VENTRIFLO™ was able to provide successful support up to a CO of 4.25 L/min. 
However, this was accompanied by an unacceptable increase in SVC pressure and requires 
complete pathway restriction which makes the patient completely dependent on the VAD, raising 
concerns in the case of device durability/failure. In the Fontan takedown scenario, VENTRIFLO™ 
could only output a maximum of 3.2 L/min, which is less than the baseline cardiac output.  
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This work underscores the challenges of supporting a failing Fontan physiology. Similar 
to our previous studies, significant amounts of recirculation through the Fontan pathway (FP) 
limited the effectiveness of the PediMag™ device and required complete clamping of the FP. In 
this scenario, PediMag™ was able to outperform any device previously tested and successfully 
supported the failing Fontan circulation up to a cardiac output of 5 L/min. However, this scenario 
resulted in increased SVC pressure. Use of CentriMag™ as a Fontan assist device overcame these 
shortcomings and successfully achieved the goals of support in a native Fontan without the need 
for restrictive banding. Importantly, the drop in IVC pressure and augmentation of cardiac output 
achieved using CentriMag™ was accompanied by a drop in SVC pressure as well. This is possible 
because even with recirculation through the Fontan pathway, CentriMag™ is powerful enough to 
still provide sufficient forward flow to the pulmonary arteries allowing for successful support. In 
addition, the recirculating flow is able to entrain SVC flow, effectively “pulling” SVC flow and 
therefore decrease SVC pressure.   These observations provide an important insight into the pump 
parameters needed for suitable Fontan assist devices.  
The number of patients living with complex congenital heart disease continues to increase, 
and patients with single ventricle physiologies palliated with the Fontan TCPC continue to survive 
longer. This however sets them up for the inevitable Fontan failure; currently with very limited 
options for rescue, including heart transplant. The essential subtypes of Fontan failure have been 
described as 1) primary ventricular failure and 2) failure of the Fontan circulation in the setting of 
preserved ventricular function and pressure. Failure of the systemic ventricle can manifest similar 
to heart failure in anatomically normal hearts with increased end-diastolic pressure, increased left 
atrial pressure and decreased cardiac output with or without decreased systolic function. In this 
situation, at failure of medical therapy, ventricular assist devices can be implanted in the standard 
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fashion (systemic ventricle to aorta). Assistance in this manner has been shown to provide relief 
from such types of Fontan failure as a bridge to transplantation. Both pulsatile devices (Berlin 
Excor, Thoratec PVAD) as well as continuous flow devices (HeartWare HVAD, CentriMag™) 
have been used to support the systemic ventricle with varying success. Arnaoutakis, Weinstein and 
Poh all report high mortality rates and adverse events.56,110,111 Therefore, although in theory 
supporting failing Fontan with ventricular dysfunction appears straightforward, the clinical 
experience is far from optimal.  
Supporting a failing Fontan with preserved ventricular function is even more challenging 
in our view. This is supported by the fact that there are a large number of Fontan patients that 
develop this pathophysiology with essentially only a few reports of attempts to support these 
patients mechanically.58,59  In addition, we believe that there may be under reporting of other 
unsuccessful attempts at such support. In all of the published attempts to support the Fontan side 
failure, modifications have been required in the form of a Fontan take down (Prêtre et al), vena 
cava banding (Rodefeld et al) or creation of a compliance chamber (Reardon and Lacour-
Gayet).58,59,112,113 One of our interests here was to assess the feasibility of offering successful 
support using off the shelf devices with no or minimal modification to the Fontan anatomy or MCS 
device.   
In light of these limitations and challenges associated with supporting failing single 
ventricle patients, specifically failing Fontan patients, development of devices that allow for the 
adaptability necessary for practical use is critical. The current study provides data to support the 
notion that a centrifugal pump such as CentriMag™ may be able to assist the failing Fontan 
physiology. The advantage of this pump design is its high output (designed for full cardiac support) 
as well as the cannulation options adaptable to the TCPC anatomy. Allowing for both an inflow 
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and outflow cannula to be custom sized as needed depending on the patient anatomy permits 
optimal positioning of these cannula.  
The devices investigated here offer paracorporeal support and are therefore not a long-term 
strategy. However, the study finding that CentriMag™ may be able to effectively support a failing 
Fontan circulation and potentially improve hemodynamics has important clinical implications. It 
provides an option for temporary relief of the failing Fontan scenario and the ability to optimize 
the patient prior to consideration for long term support or transplantation. CentriMag™ and 
PediMag™ have both been used as bridge to transplant devices in the pediatric population as 
LVADs.55 Their ability to support the failing Fontan circulation provides a novel and clinically 
relevant application.   
 For long term support, currently available durable intracorporeal continuous flow devices 
however have fixed, short, inflow cannula (metal) that necessitate positioning of the device 
proximate to the ventricle. Such proximate positioning as well as the straight metal cannula is not 
well suited for attachment to the Fontan conduit. This therefore necessitates design modifications 
that would allow for flexibility in cannula length and positioning, as well as device positioning 
due to significant variations in Fontan pathway anatomy and intrathoracic relationships. A 
conceptual design for such a pump is shown in Figure 8-22. Here the intracorporeal, durable 
centrifugal pump is anchored to the right hemidiaphragm with inbuilt anchoring hooks. 
Additionally, the device can be anchored to the chest wall. The inflow and outflow cannula made 
of flexible material such as Dacron™ can be custom sized and appropriately sutured to the Fontan 
conduit. The driveline is externalized to be connected to the controller and power source. A design 
such as this may be able to provide long term support for this group of patients as a bridge to 






8.4.2 Banding and cannulation strategies 
Various methods of banding and cannulation strategies were attempted throughout these 
experiments on all of the devices tested.  Even using advanced banding designs to account for 
restriction diameter and length, no banding strategy was more successful than a standard, narrow 
banding of 80% constriction by area. However, this would not be implemented clinically since 
80% constriction is not feasible. Therefore, complete pathway restriction was found to be the best 
option to achieve successful support with the VENTRIFLO™ and PediMag™ devices. 
Multiple cannulation strategies were attempted to reduce recirculation and avoid complete 
pathway restriction. Similar to the banding results, advanced cannulation techniques did not 
improve results and therefore are not worth the added complexity. Overall, advanced banding and 
cannulation strategies were superceded by using a pump powerful enough to overcome the effects 
of recirculation.  
 
8.4.3 Generalizability  
The computational analysis shows similar results across patient anatomies and cannula 
insertions. These are important findings that suggest failing Fontan support can be achieved using 
similar methods for different patients. The patients modeled were selected from a variety of 
diagnoses, anatomies and physiological conditions, and therefore give a decent representation of 
the range of Fontan patients that may need mechanical circulatory support. Though other unique 
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anatomies do exist, these patients give a preliminary understanding of the generalizability of VAD 
use in Fontan patients.  
In addition, results were very similar across cannulation options. This provides confidence 
that slight variations in surgical implementation will not cause drastic differences in the pump’s 
ability to support the failing Fontan. The cannula insertion options that were modeled span a 
generous set of offsets and angulations, and therefore should be representative of the full range of 
surgical variations that could exist. Figure 8-22 shows a conceptual design and placement of an 




Figure 8-22 Conceptual design and placement of an intracorporeal durable centrifugal pump for failing 




9. SUMMARY AND CLINICAL SIGNIFICANCE 
 
This thesis investigated four potential solutions to two of the most common forms of 
Fontan failure (PAVMs and liver disease). As the number of Fontan patients continues to grow 
with increased life expectancies, it is obvious that solutions are needed for these problems. Specific 
Aim 1 focused on PAVMs and investigated the two proposed solutions of surgical planning and 
Y-graft use to balanced hepatic flow distribution (the mechanism to prevent/correct PAVMs). 
Specific Aim 2 focused on liver disease and investigated the two proposed solutions of improving 
TCPC efficiency and using mechanical circulatory support to decrease hepatic congestion (the 
mechanism cause liver fibrosis progression).  
 
9.1 Surgical planning (PAVMs) 
An important accomplishment in this thesis was the evaluation of surgical planning 
prediction accuracy. Overall, HFD prediction error was 17±13%. This error was significantly 
reduced when predicting HFD for hepatic to azygous shunts. These results are vital for proper 
implementation of surgical planning into clinical practice and engineering improvements to the 
surgical planning process. 
Clinicians must evaluate the ranking of surgical options with the prediction error in mind.  
Aside from hepatic to azygous connections, the predicted HFD will be almost 20% off on average. 
Therefore, an option that has a predicted HFD to be very balanced, could potentially be unbalanced 
in either direction depending on surgical implementation and the change in flow rates from pre- to 
post-op conditions. Surgical planning can alert clinicians of extremely poor surgical options (i.e. 
all hepatic blood flow going to a single lung), where even a 20% error would still not be a 
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promising option. Again, with hepatic to azygous connections, surgical planning produced 
accurate predictions which can provide guidance to surgical decision making.  
Both improved surgical implementation and more accurate surgical planning methodologies 
are needed to increase surgical planning accuracy. As discussed in section 5.4, little intra-operative 
guidance is currently available to help surgeons replicate virtual surgical options. Even if surgical 
planning methodologies could perfectly predict HFD for a given option, this is not completely 
useful if the surgeons cannot exactly replicate the option. On the other hand, current surgical 
planning methodologies are not perfect, and refinements are needed. A combination of these two 
aspects is likely necessary to improve surgical planning predictions.  
As surgical planning improves, another serious barrier is the logistics of making this 
technology available to an increasing number of clinicians. Currently, our lab is heavily involved 
with CHOA and CHOP (plus other referring centers) on each of their surgical planning cases. A 
substantial amount of man hours and computational resources are needed for each surgical 
planning case, and therefore this is not a sustainable practice for widespread use.11  Potential 
avenues could include a surgical planning based company or internal positions within each hospital 
that are responsible for surgical planning analysis. In either case, funding/reimbursement methods 
pose a potential challenge.  
In the end, we do see that correction of unbalanced HFD leads to regression of PAVMs.  In 
each Fontan revision in this study, the previously diagnosed PAVMs did regress once surgical 
planning was used to create a more balanced HFD. This is encouraging and proves the importance 
of choosing a correct TCPC design for a given patient.  We see clearly that this must be decided 




9.2 Y-grafts (PAVMs) 
Overall, Y-grafts have proven to be a viable option for Fontan completion.  Though 
additional follow-up data is needed for more generalizable results, the significant improvement in 
HFD over time is very encouraging. The results from the initial post-operative state were not as 
positive, but again this may have been an artifact of not allowing the body sufficient time for 
adaptation.  
An important concern for Y-graft use is the increased number of sutures needed for three 
anastomosis sites instead of two. It is thought that this may be a potential cause of increased 
thrombus in these patients. Additionally, potential regions of extreme wall shear stress is another 
concern of Y-graft use. The validity of these concerns remains to be seen. 
As a proposed solution for preventing the formation of PAVMs, the true validation will come 
from long-term follow up of these patients and the determination if PAVMs form less often in 
patients with Y-grafts. While HFD is an important and quantifiable metric related to PAVM 
formation, the existence of lung malformations is the actual outcome that must be measured. 
Overall, our single-center Y-graft studies have shown that using Y-grafts are a clinically 
viable solution for Fontan completion, and that this option is not inferior to traditional Fontan 
options. As this patient cohort ages, further information can be gathered concerning potential 
thrombus issues and the intended benefits regarding PAVM formation.  If Y-grafts prove to be a 
solution to preventing PAVMs, then this commercially available option will likely become more 




9.3 TCPC efficiency (FALD) 
Fontan hemodynamics measured approximately 8 years prior to liver biopsy were found to 
be predictive of future liver disease. Specifically, TCPC resistance and LPA stenosis showed the 
strongest correlations with liver fibrosis. An important, proposed mechanistic pathway was 
developed by combining results from the serial and concurrent portions of this study.  
Data from this study suggests that an inefficient TCPC design and vessel stenosis may result 
in increased hepatic congestion, contributing to the progression of liver fibrosis. In addition, the 
progression of liver disease may lead to hepatic arterialization which decreases resistance to flow 
through the liver and leads to increases in IVC flow rate. Though the progression of liver disease 
in these patients is undoubtedly a multifactorial issue, these data suggest that TCPC design and 
vessel stenosis are important contributing factors. 
These findings have important clinical implications. The results encourage the consideration 
of pre-procedural planning to improve TCPC performance. Though commonly used for preventing 
or correcting pulmonary arteriovenous malformations by optimizing hepatic flow distribution 
(HFD), surgical planning can similarly be used to compare potential surgical options and optimize 
energy efficiency. Furthermore, flow efficiency through a connection can be more difficult to 
visualize and predict than HFD since changes in velocity and pressure are nonlinear and not always 
intuitive.(18)  Therefore, pre-procedural planning focused on flow efficiency may be even more 
informative for surgical decision making.  
Similarly, interventional strategies may prove beneficial for patients post-Fontan with LPA 
stenosis or high TCPC resistance or those that demonstrate clinical hepatic decline. The significant, 
positive correlation between LPA stenosis and fibrosis seen in this study suggests that early 
correction of vessel stenosis may reduce the progression of liver disease in these patients. Whether 
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this is due to the effect of LPA stenosis on TCPC resistance or some other factor, interventions 
such as balloon dilation may be important considerations in this post-Fontan population.  Periodic 
monitoring of vessel stenosis may be useful to determine when or if these interventions are needed.  
 
 
9.4 Mechanical circulatory support (FALD) 
In vitro testing proved very useful in evaluating the off-label use of various mechanical 
circulatory support devices. The CircuLite device was clearly not capable of supporting the Fontan 
circulation, and should therefore not be implemented in a patient. At its maximum output, the 
VentriFlo device was able to achieve our initial goals for successful Fontan support, and provides 
physiological, pulsatile flow which may prove necessary for proper perfusion. The PediMag 
device outperformed the VentriFlo device, with the ability to induce favorable hemodynamic 
changes and increase cardiac output up to 5 L/min (beyond our original goal).  
However, each of these previous devices had two major drawbacks: (1) an increase in SVC 
pressure accompanied any decrease in IVC pressure and (2) complete baffle restriction was 
required to produce positive hemodynamic changes. The first concern trades improved liver health 
for potentially dangerous conditions for brain function, while the second concern forces the patient 
to be completely dependent on the VAD (deadly in the event of device malfunction/failure).  
The CentriMag device was able to overcome both of these concerns. When run at a high 
enough output, the inflow of the CentriMag pump pulled flow from both the IVC and SVC, 
decreasing pressure in both vessels. The output from the pump was directed down the two 
pulmonary arteries, simultaneously increased both outlet pressures.  This was accomplished 
without any baffle restriction.  Following this favorable change in hemodynamics, ventricle 
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adaptation was modeled, and CentriMag was able to maintain these improved conditions up to a 
cardiac output of 5 L/min. Therefore, CentriMag was the most successful pump tested in this thesis, 
exceeding our original requirements for success.  
A number of cannulation strategies and banding designs were tested in this study. However, 
the most successful scenario (using CentriMag) required no banding or non-standard cannulation 
and therefore these alternatives may be less impactful. Another potential factor in pump efficacy 
is the difference between pulsatile and steady flow. Though most devices produce steady flow, 
opponents argue that pulsatile flow is necessary for proper perfusion and clearance throughout the 
body. Though not the focus of this work, the potential consequences of either device type during 
the bridge-to-transplant period may warrant future work. A final concern is the high flow rate of 
the CentriMag device required to produce the desired hemodynamic changes.  
Finally, there are two important clinical consideration to take from this specific aim. First, 
devices perform much different in these “off-label” scenarios and therefore performance curves 
published in the instructions for use will not be accurate. A new set of performance curves must 
be generated at the pressures of the intended use. Second, though the wall shear stress results did 
not indicate any concerns for hemolysis, blood damage within the pump is a potential problem 
which needs to be considered.  






10. LIMITATIONS AND FUTURE DIRECTIONS 
 
10.1 Specific Aim 1A (Surgical Planning) 
10.1.1 Limitations 
Though important conclusions can be drawn from this study, a more complete 
understanding of surgical planning accuracy and methodological needs with increased statistical 
power will require a substantial amount of data most likely through a multi-center grant. Acquiring 
post-operative data is unlikely without dedicated funds. Additionally, this study includes a broad 
range of follow up times and offers only a “snapshot” of the patients’ post-operative 
hemodynamics. If available, the inclusion of serial data in a similar study could offer a better 
understanding of hemodynamic changes over time. The predicted results in this study are 
representative of the specific surgical planning process used. Results may vary with other 
prediction techniques. However, this study employs one of the most advanced anatomy prediction 
methods and still concludes that post-operative anatomy prediction is a limiting factor, which is 
unlikely to change based on prediction technique. Finally, two experienced surgeons were 
involved in these surgical planning cases. While we see no differences in prediction accuracy 
between these two surgeons, it is possible that results may vary based on the surgeon involved.   
 
10.1.2 Future Directions 
A number of relatively basic and necessary questions remain: Are patient outcomes 
improved as a result of surgical planning? Does surgical planning reduce operating times?  Does 
surgical planning reduce clinical costs or the need for re-operations? Can surgical planning provide 
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useful insights even with patient growth and adaptation over time? To address these questions as 
well as evaluate current surgical planning methods, further validation must be a focus in the 
coming years.  A substantial, multi-center clinical trial randomizing the use of Fontan surgical 
planning and funding post-op data collection may be necessary to acquire the data required to 
answer these questions.  
Additionally, in order to refine the process of surgical planning, further validation is needed 
in order to determine which, if any, metrics are causal or correlated to long-term Fontan 
complications.  Future studies are needed to identify specific metrics that may be associated with 
liver disease, protein losing enteropathy and thromboembolic events among others. Furthermore, 
the various simulation fidelities (steady vs pulsatile, free-breathing vs breath-held etc.) can be 
assessed for their impact on these metrics.  Through this process, surgical planning can be 
improved and more substantially related to patient outcomes. 
Finally, the results of Specific Aim 1A show the need for improved anatomy and flow 
prediction. Future efforts should focus on the improvement of anatomy and flow prediction tools 
as well as the surgical option implementation process.  Little intra-operative guidance is currently 
offered as part of the surgical planning process. Some efforts have explored 3D printing and 
augmented/virtual reality as planning/guidance tools, but further refinements are needed.91–94  In 
addition, a current shortcoming of the surgical planning process is the lack of feedback and 
interaction with the surgeon. Future work should push for more surgeon involvement throughout 
the process. It is vital to understand how the surgeon prefers to view the proposed surgical options 
and what methods work best to guide the surgeon to replicate that option. This information will 
provide valuable improvements to the creation of potential surgical options as well as define the 




10.2 Specific Aim 1B (Y-grafts) 
10.2.1 Limitations 
In the first part of this study, the period of time between the Fontan operation and the MRI 
scan was not identical for all patients. Y-graft patients were scanned within one month of the 
surgery, while LT/ECC patients were scanned around 6 months after the operation. This difference 
in recovery time may lead to variations in the amount of physiological adaptation which could 
affect flow rates (as seen in the difference between systemic venous flows) and pulmonary vascular 
resistance and therefore TCPC resistance and HFD. Additionally, the spatial velocity profiles used 
at the inlets of the CFD domain are assumed to be parabolic, which are not identical to the spatial 
velocity profiles obtained from the MRI velocity segmentations. However, this assumption is 
expected to have only minimal effects on the bulk hemodynamic metrics.  
In the second part of this study (serial analysis), the small sample size limits the power of 
statistical analysis. However, even with the limited number of patients, a significant improvement 
in hepatic flow distribution was observed.  Additionally, the lack of a LT/ECC comparison group 
with identical follow up times required the use of several unique comparison groups. Though this 
does not allow for a direct comparison with serial LT/ECC data, choosing follow up times that 
straddle the Y-grafts can provide meaningful comparisons. Finally, it is important to note that all 
Y-graft patients in this study used commercially available Y-grafts, and results may differ with 
more customized designs. 
From a modeling perspective, this study focused only on the TCPC geometry and did not 
include interactions with the rest of the cardiovascular or pulmonary circulation. This localized 
TCPC modeling may omit significant global influences on the system. Finally, due to limited data, 
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the hepatic veins were not included in this modeling. The inclusion of the hepatic veins and their 
respective flow rates could potentially influence the mixing of hepatic factor with the IVC flow 
and therefore alter the presented HFD results. This study also assumes rigid walls in the CFD 
simulations. 
 
10.2.2 Future Directions 
Follow-up studies on an increased number of Y-graft patients is essential to thoroughly 
assess if Y-graft use is beneficial for these patients. Specifically, careful monitoring of pulmonary 
arteriovenous malformation progression is key since the motivation for this graft is to provide a 
balanced HFD and prevent PAVM formation. As more data is collected we will be able to better 
determine the benefits/shortcomings of Y-graft use. 
Additionally, the potential of thrombus formation and the use of customized Y-graft 
designs should be explored further. Previous studies have brought up concerns for clot formation 
in the Y-graft arms due to regions of low wall shear stress. Clinicians should pay close attention 
to possible clot formation during follow-up imaging studies. As mentioned by the Marsden group, 
a customized Y-graft design may provide benefits by preserving cross-sectional area throughout 
the graft. These potential benefits have not been analyzed on a patient cohort large enough to draw 
any conclusions.  
 
10.3 Specific Aim 2A (TCPC hemodynamics and liver disease) 
10.3.1 Limitations 
All results in the first part of Specific Aim 2A are based on concurrent CMR, 
catheterization, and liver biopsy data sets. As we demonstrate in this study, IVC flow rate is 
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associated with hepatic fibrosis. Therefore, hemodynamic metrics that are dependent on IVC flow 
rates may change as a result of fibrosis. Consequently, if prior flow rates or TCPC energetics 
(highly dependent on IVC flow rate) are a factor in future fibrosis progression (e.g. Fontan 
hemodynamics are predictive of future hepatic fibrosis), the use of concurrent data sets would not 
elucidate this relationship. This motivated the second part of Specific Aim 2A which analyzed 
CMR derived flow dynamics and CFD energetics at a time point prior to the liver biopsy.   
In addition, because the TCPC is created from non-compliant materials (such as Gortex) 
and 2-3 staged surgeries would indeed cause fibrosis around systemic venous pathway vessels, 
rigid modeling is an acceptable assumption. Some variability is expected with liver biopsy data 
based on heterogeneity of the disease as well as sampling bias, however the current method 
remains the best available. Finally, all blood flow characteristics of the TCPC circuit were obtained 
with the patient at rest, in a supine position. Fontan hemodynamics are different with the patient 
upright, ambulatory and in particular during exercise. Perhaps our finding of LPA size in 
association with liver fibrosis may indeed suggest that important TCPC flow disturbances might 
be discovered in association with fibrosis if study could be undertaken in a more natural active 
daily state or under provocative testing. 
 
10.3.2 Future Directions 
To further investigate the relationship between liver fibrosis and Fontan hemodynamics, it 
may be important to explore another method of liver fibrosis quantification.  There is an inherent 
sampling bias to liver biopsies from which these results were drawn. Before ruling out the 
possibility that Fontan hemodynamics play a role in liver fibrosis, comparisons with imaging or 
ultrasound derived liver scores should be investigated, as well as related biomarkers.   
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If in fact Fontan hemodynamics prove to not be a driving force in Fontan associated liver 
disease, genetics may be the next area of investigation. If genetics are determined to decide which 
patients will have liver disease, and to what extent, potential, preliminary screenings may prove 
useful to determine how to proactively treat susceptible patients. Though this solution will take a 
substantial amount of time and resources to come to fruition, it may be the best option.  
 
10.4 Specific Aim 2B (Mechanical circulatory support) 
10.4.1 Limitations 
Though frequently used, in vitro modeling cannot perfectly represent the human body. The 
use of lumped compliance and resistance modules will cause the performance of the loop to deviate 
somewhat from physiologic behavior. For example, the use of a piston pump cannot perfectly 
mimic the complex systolic and diastolic function of the single ventricle, which necessitates the 
simplified adaptation modeling as described and used in this study.  In addition, the Fontan 
circulatory loop employed in this study is not validated for all failing Fontan physiologies. In 
particular, the mock circulation used in this study is representative of failing Fontan patients 
suffering from chronic Fontan failure: right-sided flow congestion and elevated central venous 
pressures in the presence of a functioning single ventricle capable of increasing cardiac output. 
Current efforts are underway to include a detailed ventricle module in the mock circulation that 
allows for variations in failing Fontan type as well as improved adaptation modeling. Finally, the 
use of an extracorporeal device is not ideal as a long-term solution, as it severely limits the freedom 
of a patient.  However, the purpose of this study is to focus on MCS as a bridge-to-transplant which 
allows for relatively “short-term” dependence on the device.  Limited patient freedom may be a 




10.4.2 Future Directions 
An important next step to improve in vitro modeling of the cardiovascular system is to 
more accurately model the heart.  As stated earlier, a piston pump cannot replicate the complex, 
load dependent functioning of the heart, or naturally adapt to changes in the cardiovascular system. 
Therefore, future efforts should focus on this modeling component. This could be accomplished 
through the use of more advanced, artificial hearts whose output is a function of hemodynamic 
conditions with some level of adaptation, or may benefit from an ex vivo strategy where an actual 
heart is resuscitated and performs its usual pumping function. The use of a mechanical artificial 
heart is the more likely solution due to cost and logistics.  
To move forward with the pumps that were found to be successful candidates, both 
hemolysis and animal testing are important next steps.  Each pump included in this thesis has 
previously passed hemolysis testing for their intended uses. However, in the Fontan assist scenario 
hemodynamics and flow rates are much different than those in cardiac failure for which these 
devices have been tested. Therefore, hemolysis testing is a necessary requirement. As with most 
medical devices, the use of an appropriate animal model for further testing before human use may 
provide additional insights into device efficacy. Unfortunately, no Fontan animal model exists. At 
best, single ventricle animal models have only lasted several hours and the severe shock and 
extreme adaptation of the animal to this new physiology may not allow for useful results. This 
shortcoming is a major barrier to the testing of devices for Fontan use.  
Finally, the real validation for in vitro testing will only come once one of these pumps are 
implemented in an actual Fontan patient. This will most likely happen in a “compassionate use” 
circumstance where there are no alternative options and the patient is failing. It is difficult for a 
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device to be “successful” in this scenario since the patients is already failing, but this may be the 







From the many modes of Fontan failure, this thesis investigated potential solutions for 
pulmonary arteriovenous malformations and liver disease. These two specific complictions were 
chosen because (1) they are very common in the Fontan population, (2) they are thought to be 
hemodynamic driven and (3) through our clinical collaborations we have access to unique data 
sets that allow for a thorough analysis of these complications. Two potential solutions for each of 
these complications were evaluated. The use of surgical planning and Y-grafts were investigated 
as potential methods to balance HFD and correct/prevent pulmonary arteriovenous malformations, 
and improving TCPC efficiency and the use of mechanical circulatory support devices were 
investigated as methods to decrease hepatic congestion and reduce liver disease progression. A 
brief conclusion for each proposed solution is given below. 
 
11.1 Surgical planning 
Fontan surgical planning can provide accurate predictions of hepatic flow distribution, but 
prediction accuracy varies with graft type. Even with its limitations, surgical planning can provide 
important insights into surgical decision making which can result in more balanced hepatic flow 
distrubtion and therefore less risk of PAVMs. Surgical planning was successfully used in Fontan 
revision cases to “fix” unbalanced HFD and casue PAVMs to regress. Anatomical prediction was 
found to be a key methodological shortcoming in the surgical planning process. With continued 
improvements, surgical planning may be a useful tool to avoid pulmonary arteriovenous 





While we observed no difference in HFD during the immediate post-operative state, Y-grafts 
showed significantly more balanced hepatic flow distribution than traditional connections at a ~3 
year follow up. In addition, Y-grafts had similar TCPC resistance to traditional connections, 
showing no inherenet disadvantages to Y-graft use. Y-grafts have been shown to be a feasible 
clinical option and therefore this data suggests that Y-grafts will provide more balanced hepatic 
flow distrubtion and may reduce the risk of pulmonar arteriovenous malformations.  
 
11.3 Effect of TCPC design on liver disease 
No relationships were observed between TCPC efficiency and the extent of liver disease at 
the time of biopsy. However, significant relationships were seen between TCPC efficiency and 
LPA stenosis at a time point approximately 7 years prior to liver biopsy.  Furthermore, the change 
in IVC flow rate over time was a strong predictor of the extent of liver fibrosis. These findings 
suggest that an inefficient TCPC design and vessel stenosis may result in increased hepatic 
congestion, contributing to the progression of liver fibrosis. In addition, the progression of liver 
disease may lead to hepatic arterialization which decreases resistance to flow through the liver and 
leads to increases in IVC flow rate. The finding that Fontan metrics are associated with liver 
fibrosis encourages the consideration of pre-procedural planning and interventional strategies to 
improve TCPC performance and reduce vessel stenosis. 
 




Mechanical circulatory support devices were found to be a successful option to provide failing 
Fontan support by increasing cardiac output and reducing IVC pressure. This combination of 
hemodynamic changes would reduce hepatic congestion and potentially delay or stop the 
progression of liver disease.  The ability to provide successful support was highly dependent upon 
which device was used. We found that more powerful pumps alleviate the need for Fontan pathway 
banding and produce the most beneficial hemodynamic changes. Advanced banding and 
cannulation strategies did not significantly effect the hemodynamic changes associated with 
various devices and are therefore not worth the added complexity. Though successful support was 
achieved in this benchtop setting, further testing in vivo is needed to evaluate the true efficacy of 
these devices.  
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12. FUNDING SOURCES 
 
This work was funded in part by an NIH R01 grant (HL098252) focused on investigating the effect 
of Fontan hemodynamics on patient outcomes. Specific Aim 2B was also funded by the Michael 
P. Fisher Cardiac ICU research fund (Children’s Healthcare of Atlanta).  Finally, the work in 




APPENDIX A – COMPUTATIONAL METHODS 
Appendix A is separated into 6 sections describing the various computational methods used 
in this thesis. The sections are as follows: Mesh generation and CFD simulation set-up, Blood 
waveform processing, Flow field visualization, Anatomy characterization, CFD simulation post-
processing and anatomy comparison. 
 
Mesh generation and CFD simulation set-up 
 
This appendix contains the protocol for adding flow extensions, generating a mesh and CFD 
simulation set-up.  All of these components are completed using various modules in ANSYS 
Workbench.  
 
Credit: Dr. Alan Wei 
 
Flow Extensions 
In this tutorial, the ANSYS workbench is used. Major modules involved are:   
 ANSYS Design Module -- geometry; 
 ANSYS Meshing Module -- mesh; 
 FLUENT – simulation; 
Some Tips: 
 Anytime you see the lighting mark on any module, you may want to right-click to 
“Update” or “Generate” for the sake of proceeding.  
ANSYS Design Module – Geometry 
Firstly, open the ANSYS Workbench under the ANSYS folder 
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Drag the “Geometry” module to the workbench following the instruction in Figure 0-1. 
 




Double-click the question mark next to the “Geometry” to open the ANSYS Design Module.  
After the “Geometry” window is on, import the geometry file by clicking the button shown in 




Figure 0-2 Menu bar. 
Usually, the geometry should be IGES files. The module will ask about the metric unit; choose 
‘millimeter’ as usual.  
Make sure change the “Operation” to “Add Frozen”, and then “Generate” the geometry. The 
geometry will show on the screen, as shown in Fig.3.  
       (a)   (b) 
Figure 0-3 Add frozen operation. 
On the screen shown in Figure 0-3 (b) (which will be referred as ‘working screen’ in the following 
context), you can use your mouse to adjust the perspective of view. If you had any trouble and 
need to reset the view, the following buttons in the tool bar may help. (In the software, you can 




Figure 0-4 Menu selection. 
Now, you need to create the extension for all vessels. Get into “Create” and find “Extrude”, make 
sure: 
1. Your “Selection Filter: Faces” on the tool bar is enabled:  
 
Figure 0-5 Selection filters.  
2. Select all “faces” on the boundary of a vessel end, i.e.: 
 
Figure 0-6 Face selection. 
3.  “Operation” = “Add Frozen”; 
4. In order to get “Face Normal” for “Direction Vector”, you need to again enable 
“Selection Filter: Faces” mode and pick any face on the surface of certain boundary, 
as shown in Figure 0-7. When you click the “Direction Vector”, the software will 
automatically reset the “Selection Filter” to “Edges”, you may need to manually 




Figure 0-7 Vessel extensions.  
5. “Depth” for CFD simulations are: 
a. 10 times the diameter of the vessel 
b. The vessel diameter is equal to 2 ∗ √( ) where Avessel is the cross 
sectional area of the vessel. 
c. Once you generate a set of extensions, you can modify their length arbitrarily. 
Also, you can right-click and suppress them if you do not need them in the 
simulations. 




Figure 0-8 Generate part. 
As long as an extension is created, a new body under the tree outline of “Parts” should be 
generated. After extensions for all vessel ends are created, remember to change the names for all 
bodies: 
 
Figure 0-9 Rename parts.  
Highlight all of vessel parts (TCPC, IVC, LPA, RPA, RSVC, etc.), right click and “Form a 
new part”: 
 
Figure 0-10 Form new part.  




Figure 0-11 Make fluid domain.  
So far, you finished all steps for “Geometry”. You can close the “Geometry” module window and 




ANSYS Meshing Module - Mesh 
Go back to the ANSYS Workbench main panel and add a “Mesh” into the working flow. Follow 
the Figure 0-12 to connect the existing geometry to the meshing module. Then, double-click to 




Figure 0-12 Connect to mesh module. 
First, you need create “Named Selections”. “Named Selections” are the components that will 
eventually be converted into FLUENT as boundary conditions. Notice that any suppressed 
components will not be passed to FLUENT, though hidden ones will. In order to create the “Named 
Selection”,  right click the “Model” on very top of the project outline: 
 
Figure 0-13 Create named selections.  
It is always better to identify the body surface of the TCPC first. Right click all OTHER vessels 




Figure 0-14 Viewing options.  
Then, you need to use the “Box select”. It is on the tool bar.  (By default, it should be just the row 
under the menu bar and located in the nearly middle of your screen) 
 
Figure 0-15 Selction options.  
Now, you can hold the left button and draw a box on the working screen to include everything. 
And then switch to the “Single Select” and de-select (by holding “Ctrl”) boundaries that are not 




Figure 0-16 Select wall faces.  
Then, right click the highlighted surface, and find “Create Named Selection”: 
 
Figure 0-17 
You need to create “Name Selection” for 
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1. Original TCPC Body Wall, i.e. Figure 0-18 (a). 
a. Name = “tcpc_wall” 
2. All original TCPC vessel ends, i.e. Figure 0-18 (b). When you do these original 
vessel ends, you may still want to hide all extension bodies.  
a. Ex. “rsvc”,”ivc” 
3. Sidewalls of all vessel extensions, i.e. Figure 0-18 (c). 
a. Ex. “rsvc_ext_wall”,”ivc_ext_wall” 
4. Ends of all vessel extensions, i.e. Figure 0-18 (d). 
a. Ex. “rsvc_ext_end”,”ivc_ext_end” 
 
Figure 0-18 
You can use the name convention illustrated in Figure 0-19. Make sure that svc and associated 





Now, click the “Mesh” in the project outline and make sure: 





2. Modify Sizing 
a. Select all the vessel ends and divide them by 4 to get the average area.  
b. Use Matlab or Excel to calculate the average diameter by inserting the 
average area in the equation derived above. 
c. Go to “Mesh”  “Sizing” 
d. Set “Max Size” and “Max Face Size” as approximately daverage/4; also, set 
“Min Size” as daverage /40. Please approximate to the nearest number that 
can be divided by 3. In the above case, “Max Size” would be 0.0009 (m) 





3. Next, Right Click “Mesh” and “Insert  Sizing”. 
 
Figure 0-12 




b. Change “Element Size” to  daverage /40 
 
Figure 0-13 
4. Right Click “Mesh” and “Insert  Inflation”.  
 
Figure 0-14 
a. For ”Geometry”: Use the Body Select Tool to select the TCPC body as 
above.  
b. For “Boundary”: Use Face selecting tool to select the TCPC surface 
excluding vessel ends. You can Press Ctrl + A to select all surfaces and then 





c. For “Inflation Option”, select “Total Thickness”. Change “Number of 
Layers” to 10 and change “Growth Rate” to 1.05 
 
Figure 0-16 
d. Set “Maximum thickness” to  daverage /40 otherwise 
5. Right click “Mesh” and “Insert  Sizing” again 





b. For “Element Size”, use daverage /4
 
Figure 0-18 
6. Right click “Mesh” and “Insert  Sizing” 
a. Use the Face Select Tool to select all the extrusion ends 
 
Figure 0-19 
b. For “Element Size”, use daverage /4 







7. Right click “Mesh” and “Insert  Method” 
a. For “Geometry”, use Ctrl-A to select all of the bodies in the domain 
b. Change “Method” to “Tetrahedrons” 
c. [Optional, ask Alan before you do it] Change “Algorithm” to “Patch 
Independent” 
8. Then, right-click the “Mesh” and “Generate” (or “Update”). 
So far, you finished all steps for “Meshing”. Close the module and save the project.  
 
Computational Fluid Dynamic simulation set-up  
Fluent - Simulation  
Go back to the ANSYS Workbench main panel and add a “FLUENT” into the working flow. 
Connect “Mesh” to “Setup” under “Fluent” icon, shown in Figure 0-23. After the connection, a 




If everything goes fine, a check mark should appear. Now, double-click the “Setup” under 
“Fluent”. The Fluent start-up dialog should be pop-up. You can either select “Serial” mode (Figure 
0-24 (a)), which will run the simulation with single CPU, or “Parallel” mode (Figure 0-24 (b)), 





In Fluent main window, find the options bar on very left of the screen: 
1. “General”  “Time”  “Transient” 
 
Figure 0-25 
2. “Setting Up Domain” -> “Make Polyhedra” 
 
Figure 0-4 
a. After finished making polyhedra mesh, “Smooth/Swap”. Use default setting 
and click “Smooth”. Smooth for 1-2 times. 
 
Figure 0-5 





i. Make sure that the “Minimum Orthogonal Quality” is greater than 
0.3.  
ii. Make sure that “Maximum Ortho Skew” is less than 0.7. 
 
Figure 0-7 
c. Then, click “Reorder” -> “Domain” 
 
Figure 0-8 
3. “User-Defined”  “Scalars” 
 
Figure 0-9 






4. “Material”  “air”  “Create/Edit” 
 
Figure 0-11 
a. Change “Name” to “blood” 
b. In the “Properties” section, change the density and viscosity to blood 
properties: 
i. Blood density = 1060 kg/m3 
ii. Blood viscosity = 0.0034 kg/m*s 
 
Figure 0-12 
c. Click “Edit” After “UDS Diffusivity” 
i. Ensure that the Coefficient = 0 
  
Figure 0-13 
d. Click the “Change/Edit” and, then, “Close”.  















h. “Monitors”  “Residuals-Print, Plot”  “Edit”: change all “Absolute Criteria” 





i. “Solution Initialization”: enable the “Hybrid Initialization”, but do not click 
“Initialize”! And wait.  
 
Figure 0-24 
5. Save the case to “Setup.cas” in patient case folder (i.e. CHOP128A/) 
 
Figure 0-24 
Modifying UDF files 
1. The Setup Process is complete. Now, Open UDF folder and you should see the 





2. Open the “alan_udf_header.h” 
 
Figure 4-2 
a. Check Vessel Name and the number of vessels in the format of 
“VesselName[numVessel][20]” (Figure 4-2).  
b. Modify “VesselID” according to the format of “VesselID[numVessel]” and 
make sure the numbers correspond to the “ID” of original vessel in the 
“Boundary Conditions” section in Fluent (Figure 4-2, Figure 4-3). For 
example, the “ID” of IVC is 6, which corresponds to the first value of 





c. Check “OutletVessel” variable so that the value matches vessel name.  
i. 1 means the corresponding vessel is outlet 
ii. 0 means the corresponding vessel is inlet 
d. Modify “lpaID”, and “TCPC_SurfID” according to “ID” of original LPA end 




e. Modify “TCPC_VolID” according to the ID of Body Wall (TCPC) in the 





3. Open “alan_udf_header_extern.h”  
a. Check and if necessary, modify “VesselName” and the number of vessels in 
the format of “VesselName[numVessel][20]”.  
b. Modify “VesselID” according to the format of “VesselID[numVessel]”.  
 
Figure 4-6 
4. Open “RunUDFSim.jou” 
a. First line: change “rcd” to “rc”.  
b. Change the name of the case file to the name of your Fluent case file. 
i. For example, if you name your case “Setup.cas”, change the name 
appropriately in the journal file. 
c. In the second section, “define boundary conditions”, uncomment additional 
boundary conditions if these BCs are present in your case. (Figure 4-7) 
i. You can uncomment a line by removing the semicolon in front of it. 
ii. Do not uncomment the RPA line if you are not using the RPA as a 
velocity inlet. 
d. At the end of the journal file, change the value to the right of /solve/dual-
time-iterate to be 10,000 * full cycle time. (Figure 4-8) 
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i. For example, if the full cardiac cycle in your case is 0.9 seconds, 


















Blood waveform processing 
This appendix includes the custom MATLAB scripts for waveform processing including (i) 
scaling the waveforms and (ii) using FFT analysis to create the boundary condition file for CFD 
simulation. The FFT_FittedCurves.m script will call the other 2 functions. 
 
Waveform scaling 
%%code to convert matrix of time/flows from ml/s to kg/m3 and then scale outlets 
%%appropariately to maintain appropriate flow split 
%Also converts time to seconds and scales as needed to get integer number 
%of milliseconds. 
 
%%%this version scales each phase individually 
 
%%based on matrix with the following columns: (time is in milliseconds and 
%%flows are in mL/s) 
%% time ivc rsvc lsvc az lpa rpa rupa 
 
prompt = 'matrix of time/flows= '; 





%%calculate sum of inlets and outlets 
 
for i=1:length(mat) 
    inlets=sum(mat(i,2:5)); 
    outlets=sum(mat(i,6:8)); 
    factor=inlets/outlets; 
 
    %%scale outlets so total inlet equals total outlet FOR EACH PHASE 
    mat(i,6)=mat(i,6)*factor; 
    mat(i,7)=mat(i,7)*factor; 




%deal with time column 
 
















FFT analysis and creation of boundary condition file for simulations 
 







fft_num = 30; 
dt = 0.001; 
 
interp_enable = 1; 
interp_fft_number = 1024; %use how many points to interpolate the original curve. Better to make 
it 2^n 
interp_type = 'spline'; % spline is usually good. pchip is cubic interpolation; sometimes, it over 
smoothed the curve 
 
fft_plot_cycle = 2; %define how many cycles you want to plot for the fft curves 
 
% make sure ftime is NOT a full cycle! 
% Vessel ID: 
% Column     1  2  3  4  5  6       7       
8 
%           flow_time  IVC RSVC/SVC   LSVC  AZ  LPA  RPA 
 RUPA 
% 
%   Unit: flow_time in second, IVC ... are mass flow rates in kg/s 
ftime = [ 
Output from waveform scaling code. 
]; 
 




vname = {'ivc','rsvc','lsvc','az','lpa','rpa','rupa'}; 
Vessel_Good = mean(ftime); 
sizeftime = size(ftime); 
nd = sizeftime(1,1); 
vesselnum = sizeftime(1,2)-1; 
 
ftime(nd+1,1) = ftime(nd,1)+ftime(nd,1)-ftime(nd-1,1); 
vesselnum_good = 0; 
for i = 1:vesselnum; 
    ftime(nd+1,i+1) = ftime(1,i+1); 
    if Vessel_Good(i+1) ~= 0 
        vesselnum_good = vesselnum_good + 1; 
    else 
        vesselnum_good = vesselnum_good; 




nd = nd+1; 
 
ff = ftime(nd,1); 
 
for t = 1:interp_fft_number+1 
    newtime(t) = ftime(nd,1)/interp_fft_number*(t-1); 
end 
 
plot_loc = 1; 
 
for vesselID = 1:vesselnum 
    timecheck = ftime(:,1); 
    vfrcheck(:,vesselID) = ftime(:,vesselID+1); 
     
    % newvfr = spline(ftime(:,1),ftime(:,2),newtime); 
    newvfr(:,vesselID) = interp1(ftime(:,1),ftime(:,vesselID+1),newtime, interp_type); 
     
    FSfun_vfr(:) = newvfr(:,vesselID); 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    if interp_enable 
        FSfun = fscreate(newtime,FSfun_vfr,fft_num); 
    else 
        FSfun = fscreate(ftime(:,1),ftime(:,vesselID+1),fft_num); 
    end 
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    MeanValue(vesselID) = FSfun('avg'); 
    cosfun1 = FSfun('cosine'); 
    sinfun1 = FSfun('sine'); 
    for i = 1:fft_num 
        cosfun(i,vesselID) = cosfun1(i); 
        sinfun(i,vesselID) = sinfun1(i); 
    end 
     
     
    for t = 1:fft_plot_cycle*interp_fft_number+1 
        time_fft(t) = ftime(nd,1)/interp_fft_number*(t-1); 
        vfr_fft(t,vesselID) = MeanValue(vesselID); 
        for i = 1:fft_num 
            vfr_fft(t,vesselID) = vfr_fft(t,vesselID) + cosfun(i,vesselID)*cos(2*pi*i/ff*time_fft(t)) + 
sinfun(i,vesselID)*sin(2*pi*i/ff*time_fft(t)); 
        end 
    end 
     
    if interp_enable 
        SStot = 0.0; 
        SSres = 0.0; 
        for i = 1:interp_fft_number 
            SStot = SStot + (newvfr(i,vesselID)-MeanValue(vesselID))^2; 
            SSres = SSres + (newvfr(i,vesselID)-vfr_fft(i,vesselID))^2; 
        end 
        alan_r_squared(vesselID) = 1- SSres/SStot; 
    else 
        warning('interp_enable is diabled. no R^2, i.e. R^2 = 0\n'); 
        alan_r_squared(vesselID) = 0.0; 
    end 
     
     
     
    % calculate derivatives 
    d_vfr_fft = diff(vfr_fft(:,vesselID)); 
    d_time_fft = diff(time_fft); 
    for t = 1:fft_plot_cycle*interp_fft_number 
        d_vfr(t,vesselID) = d_vfr_fft(t)/d_time_fft(t); 
    end 
    d_vfr(fft_plot_cycle*interp_fft_number+1,vesselID) = d_vfr(1,vesselID); 
     
     
     
    % plots 
     
    if Vessel_Good(vesselID+1) ~= 0 
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        subplot(vesselnum_good,2,plot_loc); 
        plot_loc = plot_loc+1; 
        scatter(newtime,newvfr(:,vesselID)); 
        hold on; 
        scatter(ftime(:,1),ftime(:,vesselID+1),'filled','d'); 
        hold on; 
        plot(time_fft, vfr_fft(:,vesselID)); 
        hold off; 
        titlename = sprintf('%s Curves, R^2 = %f',vname{vesselID},alan_r_squared(vesselID)); 
        title(titlename); 
        subplot(vesselnum_good,2,plot_loc); 
        plot_loc = plot_loc+1; 
        scatter(time_fft, d_vfr(:,vesselID)); 
        titlename = sprintf('%s Derivative',vname{vesselID}); 
        title(titlename); 
    end 
end 
 
fname = sprintf('alan_FFT_BCs_header.h'); 
FFT_header = fopen(fname,'w'); 
fprintf(FFT_header,'#ifndef _ALAN_FFTBCs_HEADER_H_\n'); 
fprintf(FFT_header,'#define _ALAN_FFTBCs_HEADER_H_ 1\n'); 
 
fprintf(FFT_header,'/* '); 
for i = 1:vesselnum 





fprintf(FFT_header,'double alan_FFT_mean[%i] = {',vesselnum); 
for i = 1:vesselnum 
    if i ~= vesselnum 
        fprintf(FFT_header,'%f,',MeanValue(i)); 
    else 
        fprintf(FFT_header,'%f};\n',MeanValue(i)); 
    end 
end 
 
fprintf(FFT_header,'int fft_num = %i;\n',fft_num); 
fprintf(FFT_header,'double samplef = %f;\n',ftime(nd,1)); 
 
 
fprintf(FFT_header,'struct alan_FFT_const {\n\tdouble cos[%i];\n\tdouble 
sin[%i];\n};\n\n',fft_num, fft_num); 
  fprintf(FFT_header,'struct alan_FFT_const alan_FFT[%i] = {\n',vesselnum); 
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for i = 1:vesselnum 
    fprintf(FFT_header,'\t{\n'); 
    fprintf(FFT_header,'\t\t{'); 
    for j=1:fft_num 
        if j ~= fft_num 
            fprintf(FFT_header,'%e, ',cosfun(j, i)); 
        else 
            fprintf(FFT_header,'%e},\n',cosfun(j, i)); 
        end 
    end 
    fprintf(FFT_header,'\t\t{'); 
    for j=1:fft_num 
        if j ~= fft_num 
            fprintf(FFT_header,'%e, ',sinfun(j, i)); 
        else 
            fprintf(FFT_header,'%e}\n',sinfun(j, i)); 
        end 
    end 
    if i ~= vesselnum 
    fprintf(FFT_header,'\t},\n'); 
    else  
        fprintf(FFT_header,'\t}\n'); 
        fprintf(FFT_header,'};\n'); 
    end 
         
end 
 


















   error('At Least Two Input Arguments Required.') 
end 
if narg>2 && ischar(varargin{end}) && ... 
         ~any(strcmpi(varargin{end},{'odd','even'})) && ... 
         ~any(strcmpi(varargin{end},{'foh','zoh'})) && ... 
         (ischar(varargin{end-1}) && ~isequal(lower(varargin{end-1}),'tag')) 
   FSData.tag=varargin{end}; % grab tag provided 
   varargin(end)=[];          % strip tag from input 
   narg=narg-1; 
end 
switch class(varargin{1}) % find class of first input argument 
case {'double' 'single'} 
   if isequal(numel(varargin{1}),numel(varargin{2})) % fscreate(t,f,N,TYPE) 
      t=varargin{1}(:); 
      f=varargin{2}(:); 
      if narg>=3 && isnumeric(varargin{3}) 
         N=varargin{3}; 
         if fix(N)~=N || abs(N)~=N || N<1 
            error('FSCREATE:InputError','N Must be a Positive Integer.') 
         end 
      end 
      if ischar(varargin{end}) % Type is specified 
         Tref={'foh' 'zoh'}; 
         idx=strncmpi(varargin{end},Tref,1); 
         Type=char(Tref(idx)); 
         if isempty(Type) 
            error('FSCREATE:InputError','Unknown TYPE Argument.') 
         end 
      else 
         Type='foh'; 
      end 
      Kn=local_getFS(t,f,N,Type); 
      FSData.Kn=Kn; 
      FSData.T=t(end)-t(1); 
      FSfun=@(t) FourierSeries(FSData,t); 
   else                                                    % fscreate(Kn,T) 
      Kn=varargin{1}(:).'; 
      N=(length(Kn)-1)/2; 
      if N~=fix(N) || max(abs(conj(Kn(N:-1:1))-Kn(N+2:end)))>sqrt(eps) 
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         error('FSCREATE:InputError', ... 
            ['First Input Argument must be a valid Fourier Series\n', ... 
             'vector containing the complex exponential series\n', ... 
             'coefficients in increasing harmonic order with\n', ... 
             'K(-n)=conj(K(n)) where n is the harmonic number.']); 
      end 
      T=varargin{2}; 
      if numel(T)~=1 || T<=0 || ~isreal(T) 
         error('Second Input Argument Must be the Positive Scalar Period.') 
      end 
      FSData.Kn=Kn; 
      FSData.T=T; 
      FSfun=@(t) FourierSeries(FSData,t); 
   end 
case 'char'                                        % fscreate('WAVE',T,N,P) 
   wave=varargin{1}; 
   T=varargin{2}; 
   if narg==4 
      P=varargin{4}; 
   else 
      P=[]; 
   end 
   if narg>=3 && ~isempty(varargin{3}) 
      N=varargin{3}; 
      if fix(N)~=N || abs(N)~=N || N<1 
       error('FSCREATE:InputError','N Must be a Positive Integer.') 
      end 
   end 
   Kn=local_getwave(wave,T,N,P); 
   FSData.Kn=Kn; 
   FSData.T=T; 
   FSfun=@(t) FourierSeries(FSData,t);    
case 'function_handle' 
   if ~ischar(varargin{2}) 
      error('FSCREATE:InputError','Second Input Argument Must be a String.') 
   end 
   if narg==3 && ... 
      isa(varargin{3},'function_handle')     % fscreate(FSfunA,'Op',FSfunB) 
 
      FSfunA=varargin{1}; 
      NA=FSfunA('size'); 
      KnA=FSfunA('coef'); 
      FSData.T=FSfunA('period'); 
       
      FSfunB=varargin{3}; 
      NB=FSfunB('size'); 
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      KnB=FSfunB('coef'); 
       
      zAB=zeros(1,NA-NB); 
      zBA=zeros(1,NB-NA); 
      switch lower(varargin{2}) 
      case '+' 
         Kn=[zBA KnA zBA]+[zAB KnB zAB]; 
      case '-' 
         Kn=[zBA KnA zBA]-[zAB KnB zAB]; 
      case '*' 
         Kn=conv(KnA,KnB); 
         iDC=(length(Kn)+1)/2; 
         N=max(NA,NB); 
         Kn=Kn(iDC-N:iDC+N); 
      otherwise 
         error('FSCREATE:InputError','Unknown Mathematical Operator.') 
      end 
      FSData.Kn=Kn; 
      FSfun=@(t) FourierSeries(FSData,t); 
       
   else                    % fscreate(FSfun,'Op') or fscreate(FSfun,'Op',P) 
      FSfun=varargin{1}; 
      Kn=FSfun('coef'); 
      N=(length(Kn)-1)/2; 
      iDC=N+1; 
      T=FSfun('period'); 
      wo=2*pi/T; 
      if narg==3 
         P=varargin{3}; 
      end 
      switch lower(varargin{2}(1:min(2,length(varargin{2})))) 
      case 'ta'                              % tag 
         if ischar(P) 
            FSData.tag=P; 
         else 
            error('FSCREATE:InputError','Character String Tag Required.') 
         end 
      case 'di'                              % differentiate 
         Kn=1j*wo*(-N:N).*Kn; 
      case 'in'                              % integrate 
         nn=-N:N; 
         idx=nn~=0; 
         iKn=zeros(size(Kn)); 
         iKn(idx)=Kn(idx)./(nn(idx)*wo*1i); 
         iKn(iDC)=0; 
         Kn=iKn; 
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      case 'mi'                              % time mirror 
         Kn=Kn(end:-1:1); 
      case 'sm'                              % Exact Blackman smoothing 
         m=linspace(-pi,pi,length(Kn)); 
         Kn=Kn.*(7938 + 9240*cos(m) + 1430*cos(2*m))/18608; 
      case 'tr'                              % trim negigible elements 
         tol=sqrt(eps); 
         mKn=abs(Kn); 
         rKn=abs(real(Kn)); 
         iKn=abs(imag(Kn)); 
         b=mKn<tol*max(mKn); 
         Kn(b)=0;              % elements with small magnitude 
         b=rKn<tol*max(rKn) | rKn<tol*iKn; 
         Kn(b)=1i*imag(Kn(b)); % elements with small real part 
         b=iKn<tol*max(iKn) | iKn<tol*rKn; 
         Kn(b)=real(Kn(b));    % elements with small imaginary part          
      case 'ev'                              % Even part 
         Kn=real(Kn); 
      case 'od'                              % Odd part 
         Kn=1i*imag(Kn); 
      case 'ha'                              % Halfwave part 
         idx=rem(N,2)+1:2:length(Kn); 
         Kn(idx)=0; 
      case 'no'                              % no DC part 
         Kn(iDC)=0; 
      case 'dc'                              % set DC value 
         if narg==2 || numel(varargin{3})>1 
            error('FSCREATE:InputError','Scalar Third Argument P Required.') 
         end 
         Kn(iDC)=real(P); 
      case 'ad'                              % set DC value 
         if narg==2 || numel(varargin{3})>1 
            error('FSCREATE:InputError','Scalar Third Argument P Required.') 
         end 
         Kn(iDC)=Kn(iDC)+real(P); 
      case 'de'                              % delay 
         if narg==2 
            error('FSCREATE:InputError','Third Argument P Required.') 
         end 
         if ischar(P) 
            a1=angle(Kn(iDC+1))/(2*pi); 
            switch lower(P(1)) 
            case 'o' 
               d=a1+1/4; 
            case 'e' 
               d=a1; 
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            otherwise 
               error('FSCREATE:InputError','Unknown Delay Requested.') 
            end 
         else 
            d=P(1); 
         end 
         Kn=exp(-2j*pi*(-N:N)*d).*Kn; 
      case 'sc'                              % scale amplitude 
         if narg==2 || numel(varargin{3})>1 
            error('FSCREATE:InputError','Scalar Third Argument P Required.') 
         end 
         Kn=P*Kn; 
      case 'pe'                              % set period 
         if narg==2 || numel(varargin{3})>1 
            error('FSCREATE:InputError','Scalar Third Argument P Required.') 
         end 
         T=varargin{3}; 
      case 're'                              % resize 
         if narg==2 || numel(varargin{3})>1 
            error('FSCREATE:InputError','Scalar Third Argument P Required.') 
         elseif fix(P)~=P || abs(P)~=P || P<1 
            error('FSCREATE:InputError','P Must be a Positive Integer.') 
         end 
         if P>N     % pad with zeros 
            zpadd=zeros(1,P-N); 
            Kn=[zpadd Kn zpadd]; 
         elseif P<N % delete excess terms 
            Kn=Kn(iDC-P:iDC+P); 
         else % P=N no work 
            return 
         end 
      otherwise 
         error('FSCREATE:InputError','Unknown Operation Requested.') 
      end 
      FSData.Kn=Kn; 
      FSData.T=T; 
      FSfun=@(t) FourierSeries(FSData,t); 
   end 
otherwise 
   error('Unknown First Input Argument.') 
end % END of Primary Function 
%-------------------------------------------------------------------------- 
%-------------------------------------------------------------------------- 





   error('Period Must be Positive.') 
end 
if ~isreal(f) 
   error('Input Must be Real-Valued.') 
end 
if abs(f(1)-f(end))> eps*(1+abs(max(f)-min(f))) 











   Nl=length(f)-1; 
   idx=dt~=0; 
   m=zeros(Nl,1); 
   m(idx)=df(idx)./dt(idx); 
   b=f(1:end-1)-m.*t(1:end-1); 
   n=1:N; 
   mm=repmat(m,1,N); 
   bb=repmat(b,1,N); 
   t1=repmat(t(1:end-1),1,N); 
   t2=repmat(t(2:end),1,N); 
   nn=repmat(n,Nl,1); 
   Fp=sum((1j*(mm.*t2+bb)./(nn*wo)+mm./(nn*wo).^2).*exp(-1j*nn*wo.*t2) - ... 
          (1j*(mm.*t1+bb)./(nn*wo)+mm./(nn*wo).^2).*exp(-1j*nn*wo.*t1));    
   Kn=[conj(Fp(end:-1:1)) trapz(t,f) Fp]; 
case 'zoh' 
   n=1:N; 
   Ni=length(f)-1; 
   ff=repmat(f(1:end-1),1,N); 
   t1=repmat(t(1:end-1),1,N); 
   t2=repmat(t(2:end),1,N); 
   nn=repmat(n,Ni,1); 
 
   Fp=sum(1j*ff./(nn*wo).*(exp(-1j*nn*wo.*t2) - exp(-1j*nn*wo.*t1))); 
   Kn=[conj(Fp(end:-1:1)) trapz(t,f) Fp]; 
end 
%-------------------------------------------------------------------------- 








case 'squ'                                                     % squarewave 
   Kn(N+2:2:lkn)=-2j*(((1:2:N)*pi).^(-1)); 
   Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
case 'tri'                                                       % triangle 
   Kn(N+2:2:lkn)=4*(((1:2:N)*pi).^(-2)); 
   Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
case 'ful'                                        % fullwave rectified sine 
   Kn(N+1)=2/pi; 
   n=2:2:N;     
   Kn(N+3:2:lkn)=2./(pi*(1-n.^2)); 
   Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
case 'hal'                                        % halfwave rectified sine 
   Kn(N+1)=1/pi; 
   Kn(N+2)=-j/4; 
   n=2:2:N; 
   Kn(N+3:2:lkn)=1./(pi*(1-n.^2)); 
   Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
case 'dc'                                                  % dc or constant 
   Kn(N+1)=1; 
case 'sin'                                                      % sine wave 
   if lenP==1 
      n=P; 
   else 
      n=1; 
   end 
   if fix(n)~=n || n<1 || n>N 
      error('Harmonic Number Must be an Integer Between 1 and N.') 
   end 
   Kn=zeros(1,N); 
   Kn(n)=-1i/2; 
   Kn=[conj(Kn(end:-1:1)) 0 Kn]; 
case 'cos'                                                    % cosine wave 
   if lenP==1 
      n=P; 
   else 
      n=1; 
   end 
   if fix(n)~=n || n<1 || n>N 
      error('Harmonic Number Must be an Integer Between 1 and N.') 
   end 
   Kn=zeros(1,N); 
   Kn(n)=1/2; 
   Kn=[Kn(end:-1:1) 0 Kn]; 
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case 'saw'                                                       % sawtooth 
   if lenP==0                             % ideal sawtooth 
      Kn(N+2:lkn)=2j*(((1:N)*2*pi).^(-1)); 
      Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
   else                                   % finite fall time sawtooth 
      a=min(.4999,P(1)); 
      if a~=P(1) 
         warning('FSCREATE:InputError',... 
                 'Requested Fall Time Must be Less Than 1/2.') 
      end 
      t=[0 a .5 1-a 1]; 
      f=[0 -1 0  1  0]; 
      [dum,Kn]=fscreate(t,f,N); 
   end 
case 'rsa'                                               % reverse sawtooth  
   [dum,Kn]=fscreate('saw',T,N,P); 
   Kn=Kn(end:-1:1); 
case 'tra'                                                      % trapezoid 
   if lenP==0 
      p=2/3; 
   else 
      p=min(abs(P(1)),.999); 
   end 
   if lenP>0 && p~=P(1) 
      warning('FSCREATE:InputError',... 
              'Requested Duty Cycle Must Be Less Than 1.') 
   end 
   a=(1-p)/2; 
   b=1-a; 
   npi=(1:2:N)*pi; 
   jnpia=1j*a*npi; 
   jnpib=1j*b*npi; 
   Kn(N+2:2:lkn)=(( (1+1j*a*npi).*exp(-jnpia)... 
      - (1+jnpib).*exp(jnpia)... 
      + 1j*npi).*(npi.^(-2))./a... 
      + ( (1/a-1)*exp(jnpia)... 
      - exp(-jnpia) -1/a)*1j./npi); 
   Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
case 'pul'                                                     % Pulsetrain 
   if lenP==0 
      p=1/2; 
   else 
      p=min(abs(P(1)),.999); 
   end 
   if lenP>0 && p~=P(1) 
      warning('FSCREATE:InputError',... 
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              'Requested Duty Cycle Must Be Less Than 1.') 
   end 
   if lenP<2 || P(2)==0                 % ideal zero rise time pulse 
      Kn(N+1)=p; 
      arg=pi*p*(1:N); 
      Kn(N+2:lkn)=p*sin(arg)./(arg+eps); 
      Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
   else                                 % finite rise time pulse 
      r=min((1-p)/2-10*eps,abs(P(2))); 
      if r~=P(2) 
         warning('FSCREATE:InputError',... 
                 'Requested Rise Time Too Long.') 
      end 
      a=p/2; 
      t=[0 a a+r 0.5 1-a-r 1-a 1]; 
      f=[1 1  0   0    0    1  1]; 
      [dum,Kn]=fscreate(t,f,N); 
   end       
case 'bip'                                             % Bipolar Pulsetrain 
   if lenP==0 
      p=2/3; 
   else 
      p=min(abs(P(1)),.999); 
   end 
   if lenP>0 && p~=P(1) 
      warning('FSCREATE:InputError',... 
              'Requested Duty Cycle Must Be Less Than 1.') 
   end 
   if lenP<2 || P(2)==0                 % ideal zero rise time pulsetrain 
      a=(1-p)/2; b=1-a; 
      jnpi=(1:2:N)*pi*1j; 
      Kn(N+2:2:lkn)=(exp(-jnpi*b)-exp(-jnpi*a))./(-jnpi); 
      Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
   else                                 % finite rise time pulse 
      r=min((1-p)/4-10*eps,abs(P(2))); 
      if r~=P(2) 
         warning('FSCREATE:InputError',... 
                 'Requested Rise Time Too Long.') 
      end 
      a=p/4; 
      b=.25; 
      c=.75; 
      t=[0 b-a-r b-a b+a b+a+r 0.5 c-a-r c-a c+a c+a+r 1]; 
      f=[0   0    1   1    0    0    0    -1  -1   0   0]; 
      [dum,Kn]=fscreate(t,f,N); 
   end       
224 
 
case 's2s'                                           % sine to square morph 
   if lenP==0 
      p=1/2; 
   else 
      p=P(1); 
   end 
   if p<0 || p>1 
      error('FSCREATE:InputError',... 
            'Morphing Parameter Must be Between 0 and 1.') 
   end 
   if p==0                            % sine wave 
      Kn=zeros(1,N); 
      Kn(1)=-1i/2; 
      Kn=[conj(Kn(end:-1:1)) 0 Kn]; 
   elseif p==1                        % square wave 
      Kn(N+2:2:lkn)=-2j*(((1:2:N)*pi).^(-1)); 
      Kn(1:N)=conj(Kn(lkn:-1:N+2)); 
   else                               % morph between sine and square 
      kp=zeros(1,N); 
      b=(1-p)/2; 
      m=1:2:N; 
      bm=b*m; 
  kp(m)=(2*b/pi)*( 2i*bm.*exp(-1i*bm*pi)-1 )./(4*bm.^2-1)... 
           - 2i*cos(bm*pi)./(m*pi)... 
           + (2*b/pi)*( 1+ 2i*bm.*exp(1i*bm*pi))./(4*bm.^2-1); 
  Kn=[conj(kp(end:-1:1)) 0 kp]; 
   end      
otherwise 
      error('FSCREATE:InputError','Unknown Waveform Input.') 
end 
%-------------------------------------------------------------------------- 
% Fourier Series Function 
%-------------------------------------------------------------------------- 
function y=FourierSeries(FSData,t) 
% Fourier Series Evaluation and Manipulation using function handles 
% 
% This function gets called when FSfun(...) is issued where FSfun is a 
% function handle as returned by FSCREATE. 
 
Kn=FSData.Kn;           % FS coefficient vector 
wo=2*pi/FSData.T;       % fundamental frequency 
N=(length(Kn)-1)/2;     % highest harmonic 
iDC=N+1;                % index of dc component 
 
if isnumeric(t)                                   % Evaluate Fourier Series 
   nwo=wo*(1:N);     % positive harmonic indices 
225 
 
   ko=real(Kn(iDC));    % average value 
   tsize=size(t); 
   Knp=Kn(iDC+1:end).';    % positive frequency coefs 
   y=ko+2*(real(exp(1j*t(:)*nwo)*Knp))'; 
   y=reshape(y,tsize); 
elseif ~ischar(t) 
   error('Unknown Input Argument.') 
else                                                      % FSfun('string')  
   switch lower(t(1:min(3,length(t)))) 
   case 'tag' 
      y=FSData.tag; 
   case {'coe' 'kn'}                                   % coefficient vector        
      y=Kn;          
   case {'per' 't'}                                                % period 
      y=FSData.T; 
   case 'siz'                                    % size or highest harmonic 
      y=N; 
   case {'dc' 'ave' 'avg'}                            % dc or average value 
      y=Kn(iDC); 
   case 'msv'                                           % mean square value 
      y=real(Kn*Kn'); 
   case 'thd'                                   % total harmonic distortion 
      idx=iDC+[-1 1]; 
      fn=Kn(idx); 
      Kn(idx)=[]; 
      y=sqrt(real(Kn*Kn')/real(fn*fn')); 
   case 'one'                            % one-sided line amplitude spectra 
      y=abs([Kn(iDC) 2*Kn(iDC+1:end)]); 
   case 'pha'                                % one-sided line phase spectra 
      y=angle(Kn(iDC:end))*180/pi; 
   case 'sin'                                      % trig sine coefficients 
      y=-2*imag(Kn(iDC+1:end)); 
   case 'cos'                                    % trig cosine coefficients 
      y=2*real(Kn(iDC+1:end)); 
   case 'all'                              % return all data in a structure 
      y.tag=FSData.tag; 
      y.coef=Kn; 
      y.period=FSData.T; 
      y.size=N; 
      y.avg=Kn(iDC); 
      y.msv=real(Kn*Kn'); 
      idx=iDC+[-1 1]; 
      fn=Kn(idx); 
      Kn(idx)=[]; 
      y.thd=sqrt(real(Kn*Kn')/real(fn*fn')); 
      y.one=abs([Kn(iDC) 2*Kn(iDC+1:end)]); 
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      y.phase=angle(Kn(iDC:end))*180/pi; 
      y.sine=-2*imag(Kn(iDC+1:end)); 
      y.cosine=2*real(Kn(iDC+1:end)); 
   case {'spe' 'ste'}                                    % create stem plot 
      xdata=0:N; 
      subplot(2,1,1) 
      ydata=abs([Kn(iDC) 2*Kn(iDC+1:end)]); 
      stem(xdata,ydata) 
      ylabel('Amplitude') 
      xlabel('Harmonic Index') 
      title('Fourier Series Line Spectra Plot') 
      ydata=angle(Kn(iDC:end))*180/pi; 
      subplot(2,1,2) 
      stem(xdata,ydata) 
      ylabel('Phase') 
      xlabel('Harmonic Index') 
   case 'plo'                                            % create time plot 
      t=linspace(0,FSData.T,min(max(5*N,100),500)); 
      nwo=wo*(1:N); 
      ko=real(Kn(iDC)); 
      Knp=Kn(iDC+1:end).'; 
      ydata=ko+2*(real(exp(1j*t(:)*nwo)*Knp))'; 
      plot(t,ydata) 
      title('Fourier Series Plot.') 
   otherwise 
      error('Uknown Input Argument.') 














pname = 'C.jpg'; 






disp(['The x axis range is the period length of one cardiac cycle in seconds: Tcycle']); 
x_range =input('Type in the range of x axis -- Tcycle='); 








disp(['Choose one of the value markers shown on the y axis: Yvalue']); 
y_range =input('Type in the range of y axis -- Yvalue='); 
































    Point(i,2)=(DataY(1,2)-Point(i,2))/Y_Step; 

















MeanValue = FSfun('avg'); 
a = FSfun('cosine'); 
b = FSfun('sine'); 
save Waveform MeanValue a b 










Flow field visualization – streamline coloring 
This appendix includes the protocol to color streamlines by outlet vessel. It involves  
MATLAB and Tecplot. Content includes (i) general protocol, (ii) MATLAB script and (iii)  
Tecplot macro.  
 
General protocol 
1. Create a cross section near the bottom of the IVC 
2. Create streamlines from that cross section. 
3. Using the slice from plane tool, determine some threshold to determine what streamlines 
are exiting through one of the PAs.  For example, if streamlines going to the lpa all have 
x vales greater than 0.028 at some point on the streamline, you can use that as your 
threshold. 
4. Data - Extract – Streamtraces (do NOT concatenate into one zone) 
5. File – write data file – point data, asci 
a. Select all streamlines, and only the x/z/y coordinate you are using as your 
threshold to write to the data file. 
6. Drag and drop the data file into the workspace in matlab.  Matlab will open up an import 
GUI, just select all and click import. 
7. Run matlab code (VesselStreamlines.m) 
a. Will produce a variable called “allOneString” 
8. Make a TecPlot macro that changes the color of a streamline.  Copy and paste the 
“allOneString” variable into the macro where it specifies which zone changes color.  
9. When the macro runs, it will change every zone number included in “allOneString” to 
whatever color you have specified.  This will include all the streamlines that exit either 




%% code to determine which streamlines to go either the LPA/RPA.   
% Outputs a variable called StreamLines that gives the steamline IDs of the 
% streamlines that go to whichever vessel you specified. 
 
%%Must load in streamline data from Tecplot: 
%     1. Create streamlines from IVC 
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%     2. Write data file (ascii, point).  Write only one variable  
%      (whichever variable you are using as the threshold. 
%     3. Drag and drop data file into matlab workspace. 
%     4. Import window opens in matlab.  Select all...import selection. 
%     5. Change name of variable to data. 
 
%%To run code: 
%     1. fill out the following two lines of code (number of streamlines and threshold, then run. 
 
NumberOfStreamlines=500;  %number of streamlines you exported from Tecplot 
threshold=.0166;  %%set this number based on vessel, you can use any x/y/z threshold 
 
streamlineList=[];  %%initialize vector for list of streamlines 
 
vesselID = data(11);  %11 
datalength=data(12); %12 
start=15; %15 
finish=start+datalength-1; %14 used to be 15 
 
for in=1:NumberOfStreamlines; 
    for i=start:finish; 
        %vesselID=4+in;  %%added this 
        if data(i)>threshold 
            streamlineList=[streamlineList vesselID]; 
        end 
    end 
     
    if in<NumberOfStreamlines 
        vesselID=data(i+2);   
        datalength=data(i+3); 
        start=i+6; 
        finish=i+6+datalength-1; 
        %in=in+1; 
    end 
end 
 
StreamLines = unique(streamlineList); 
 
StreamsCommas = StreamLines; 
allOneString = sprintf('%.0f,' , StreamsCommas); 
allOneString = allOneString(1:end-1);% strip final comma 
 







# Created by Tecplot 360 build 14.0.2.35002 
$!VarSet |MFBD| = 'C:\Users\Phillip\Documents' 




















The following protocol is used to measure vessel dimensions using vascular modeling toolkit 
(VMTK) and MATLAB. A custom MATLAB script is included below (VesselMeasurements_v3) 
which analyzes the output from VMTK and calculates the average, minimum and maximum vessel 
diameters, as well as percent stenosis for each vessel. This appendix includes (i) the protocol, (ii) 
custom VMTK script, and (iii) custom MATLAB code. 
 
Protocol 
1. Prepare anatomy file (Geomagic) 
a. Load .igs file, convert to polygons (menu button) 
b. Remove boundaries and subdivision points 
c. Decimate - 40,000 triangles 
d. Cut off vessel ends to make hollow 
e. Save as .stl file (name as Patient1_hollow.stl) 
2. Open VMTK code (VesselMeasurements_v3) 
3. Change path/filename of the .stl file in the VMTK code (line 1) 
4. Change path of where to store the temporary .stl file (surface.stl) 
5. Change paths of where to store the output files (there are 4 of these) 
6. Run the VMTK code 
a. VMTK will ask you to specify inlets and outlets, you must go in this order (each 
has one inlet and 2 outlets): 
i. IVC to LPA and RPA  
ii. SVC to LPA and RPA 
iii. LPA to IVC and SVC 
iv. RPA to IVC and SVC 
b. VMTK will output .dat files named IVCtoPAs, SVCtoPAs, LPAtoVCs and 
RPAtoVCs (these are the files that matlab will read) 
7. Open MATLAB script (ComputeVessel_sizes_v3.m).  This script needs to be in the same 
directory as the outputted VMTK files. 
8. Change name in MATLAB file (line 17). 
9. Run the code. Code will spit out a warning if the number of cross sections used to 
calculate vessel dimensions was less than 50.  This can happen either because the vessel 
is very short, or because there is a problem.  Always check which of these is the case if 
you get a warning (ex:  “IVC indices are low!”) 
10. Matlab will output a file (in the same directory as the code and VMTK outputs) that gives 




**NOTE:  this code is currently set up to only deal with 4 vessel cases. If there are more than 4 
vessels, this code can still be used the same way to get measurements for the 4 vessels, but cannot 
measure additional vessels. 
 
VMTK script  
##Must go in correct order!!! 
##IVC to PAs, SVC to PAs, LPA to VCs, RPA to VCs 
 
vmtksurfacereader -ifile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/LB05_hollow.stl -
ofile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/surface.stl 
 
vmtksurfacereader -ifile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/surface.stl --pipe 




vmtksurfacereader -ifile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/surface.stl --pipe 




vmtksurfacereader -ifile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/surface.stl --pipe 




vmtksurfacereader -ifile C:/Users/Phillip/Desktop/vmtk_trial/new/version_v3/surface.stl --pipe 






%%%code to read in centerline/area data from vmtk and then gives average, 
%%%minimum and maximum vessel sizes, along with stenosis calculations. 
%%%Warning will display on screen if using less than 50 cross sections to 










%tol=.1;  %parameter to decide how far centerlines need to be apart before 
%terminating the vessel 
tol=.5; 
 
sep=.01;  %parameter to decide when the first centerline stops and the 2nd one begins 
%sep=.005; 
 

















% ivcLPA = importdata('IVCtoLPA.dat'); 
% ivcLPAsize=ivcLPA.data(:,10); %gets only vessel size column 
%  
% ivcRPA = importdata('IVCtoRPA.dat'); 




while sqrt( (IVCtoPAs.data(ind,1)-IVCtoPAs.data(ind+in-1,1))^2+(IVCtoPAs.data(ind,2)... 
        -IVCtoPAs.data(ind+in-1,2))^2+(IVCtoPAs.data(ind,3)-IVCtoPAs.data(ind+in-1,3))^2 ... 
        )<tol;   %this specifies that when centerlines are more than 0.1 mm apart that we have left the 
IVC 





































% svcLPA = importdata('SVCtoLPA.dat'); 
% svcLPAsize=svcLPA.data(:,10); %gets only vessel size column 
%  
% svcRPA = importdata('SVCtoRPA.dat'); 




while sqrt( (SVCtoPAs.data(ind,1)-SVCtoPAs.data(ind+in-1,1))^2+(SVCtoPAs.data(ind,2)... 
        -SVCtoPAs.data(ind+in-1,2))^2+(SVCtoPAs.data(ind,3)-SVCtoPAs.data(ind+in-1,3))^2 ... 
        )<tol;   %this specifies that when centerlines are more than 0.1 mm apart that we have left the 
SVC 



















%%LPA section  
% lpaIVC = importdata('LPAtoIVC.dat'); 
% lpaIVCsize=lpaIVC.data(:,10); %gets only vessel size column 
%  
% lpaSVC = importdata('LPAtoSVC.dat'); 
% lpaSVCsize=lpaSVC.data(:,10); %gets only vessel size column 
 
















while sqrt( (LPAtoVCs.data(ind,1)-LPAtoVCs.data(ind+in-1,1))^2+(LPAtoVCs.data(ind,2)... 
        -LPAtoVCs.data(ind+in-1,2))^2+(LPAtoVCs.data(ind,3)-LPAtoVCs.data(ind+in-1,3))^2 ... 
        )<tol;   %this specifies that when centerlines are more than 0.1 mm apart that we have left the 
LPA 




































while sqrt( (RPAtoVCs.data(ind,1)-RPAtoVCs.data(ind+in-1,1))^2+(RPAtoVCs.data(ind,2)... 
        -RPAtoVCs.data(ind+in-1,2))^2+(RPAtoVCs.data(ind,3)-RPAtoVCs.data(ind+in-1,3))^2 ... 
        )<tol;   %this specifies that when centerlines are more than 0.1 mm apart that we have left the 
RPA 






















OverallStenosis =100- (minLPAsize+minRPAsize+minIVCsize)/(avgLPAsize 
+avgRPAsize+avgIVCsize)*100; 
 
if IVCind <50 
    %disp('IVC Indices are Low!') 
    warndlg(sprintf('IVC indices are low!')) 
end 
 
if SVCind <50 
    %disp('SVC Indices are Low!') 
    warndlg(sprintf('SVC indices are low!')) 
end 
 
if LPAind <50 
    %disp('LPA Indices are Low!') 
    warndlg(sprintf('LPA indices are low!')) 
end 
 
if RPAind <50 
    %disp('RPA Indices are Low!') 




%%write text file 
fileID = fopen(sprintf('%s_vessel_measurements.txt',name),'w'); 
fprintf(fileID, 'Vessel sizes (mm)'); 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID,['IVC_d_avg' '\t' 'IVC_d_min' '\t' 'SVC_d_avg' '\t' 'SVC_d_min' '\t' 'LPA_d_avg' '\t' 
'LPA_d_min' '\t' 'RPA_d_avg' '\t' 'RPA_d_min']); 
fprintf(fileID, ['\n' '\n']); 
 






fprintf(fileID, ['\n' '\n' '\n' '\n']); 
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fprintf(fileID, ['Stenosis (percent)']); 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID, ['IVC_stenosis' '\t' 'SVC_stenosis' '\t' 'LPA_stenosis' '\t' 'RPA_stenosis' '\t' 'Overall 
Stenosis']); 
fprintf(fileID, ['\n' '\n' ]); 
 
formatSpec = ['%5.2f' '\t' '%5.2f' '\t' '%5.2f' '\t' '%5.2f' '\t' '%5.2f']; 
fprintf(fileID, formatSpec,IVCstenosis, SVCstenosis,LPAstenosis,RPAstenosis,OverallStenosis); 
 
 
fprintf(fileID, ['\n' '\n' '\n' '\n']); 
fprintf(fileID, 'Smallest IVC area (cm2)= '); 
 




fprintf(fileID, ['\n' '\n' '\n' '\n']); 
fprintf(fileID, 'Number of cross sections to determine dimensions= '); 
 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID, ['IVC #' '\t' 'SVC #' '\t' 'LPA #' '\t' 'RPA #' ]); 
fprintf(fileID, ['\n' '\n' ]); 
 
formatSpec = ['%5.0f' '\t' '%5.0f' '\t' '%5.0f' '\t' '%5.0f' ]; 

















CFD simulation post-processing 
 The following appendix includes the post-processing MATLAB code used to calculate  
 
power loss, index power loss, resistance and hepatic flow distribution.  This code was also used  
 
to check the convergence of these metrics over multiple cardiac cycles. This code must be in the  
 
same directory as the PLnHFD files outputted from Fluent.  Instructions are given within the first  
 




%%code that does post-processing on PLnHFD output files from Fluent. Checks 
%%HFD convergence, calculates and checks power loss convergence, calculates 
%%iPL, pressure drop,and resistance.  Also gives flow rates (L/min) to 
%%make sure they are correct. 
 
%Instructions: 
%     (1) drag and drop all PLnHFD output files into same directory as code 
%     (2) delete last cycle output file (it should be an empty file 
%     (3) Need to have patient's BSA, know which vessels the patient has 
%     (4) Name patient 









%%output file column numbers differ based on how many vessels 
prompt = 'What type of case is this? 1: 4 vessel,2: lsvc, 3: az, 4:lsvc and az, 5:rupa, 6:rupa and lsvc   
'; 
option = input(prompt); 
 
prompt = 'Patient BSA =  '; 
BSA = input(prompt); 
 
 
fnames = dir('*.out'); 
numfids = length(fnames); 
vals = cell(1,numfids); 
[~,index] = sortrows({fnames.date}.'); fnames = fnames(index); clear index 
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for K = 1:numfids 








%%specify which columns have the various flows/PL (depends on what vessels 
%%are present (determined by user input to prompt). Also calculate flow 





    %%option 1: standard 4 vessel case 
    QivcCol=2; QsvcCol=5; QlpaCol=3; QrpaCol=4; PLcol=20; 
     
    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qs=Qivc+Qsvc; 
    FlowRates=[Qivc Qsvc 0 0 Qlpa Qrpa 0] 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs 0] 
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 
     
elseif option==2    
    %%option 2: lsvc 
    QivcCol=2; QsvcCol=5; QlpaCol=3; QrpaCol=4; QlsvcCol=6; PLcol=24; 
     
    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qlsvc = -mean(w(:,QlsvcCol))*60*1000; 
    Qs=Qivc+Qsvc+Qlsvc; 
    FlowRates=[Qivc Qsvc Qlsvc 0 Qlpa Qrpa 0] 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs 0] 
     
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 ||Qlsvc<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 
     
elseif option==3    
    %%option 3: az 
    QivcCol=2; QsvcCol=5; QlpaCol=3; QrpaCol=4; QazCol=6; PLcol=24; 
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    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qaz = -mean(w(:,QazCol))*60*1000; 
    Qs=Qivc+Qsvc+Qaz; 
    FlowRates=[Qivc Qsvc 0 Qaz Qlpa Qrpa 0] 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs 0] 
     
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 ||Qaz<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 
     
elseif option==4   
    %%option 4: lsvc and az 
    QivcCol=2; QsvcCol=5; QlpaCol=3; QrpaCol=4; QlsvcCol=6; QazCol=7; PLcol=28; 
    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qlsvc = -mean(w(:,QlsvcCol))*60*1000;   Qaz = -mean(w(:,QazCol))*60*1000; 
    Qs=Qivc+Qsvc+Qaz+Qlsvc; 
    FlowRates=[Qivc Qsvc Qlsvc Qaz Qlpa Qrpa 0] 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs 0] 
     
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 || Qlsvc<0 || Qaz<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 
     
elseif option==5    
    %%option 5: rupa 
    QivcCol=2; QsvcCol=5; QlpaCol=3; QrpaCol=4; QrupaCol=6; PLcol=24; 
    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qrupa = mean(w(:,QrupaCol))*60*1000; 
    FlowRates=[Qivc Qsvc 0 0 Qlpa Qrpa Qrupa] 
    Qs=Qivc+Qsvc; 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs Qrupa/Qs] 
     
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 || Qrupa<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 
     
elseif option==6  %%put all column 1 for now 
    %%option 6: rupa and lsvc 
    QivcCol=1; QsvcCol=1; QlpaCol=1; QrpaCol=1; QlsvcCol=1; QrupaCol=1; PLcol=1; 
    Qivc = -mean(w(:,QivcCol))*60*1000;Qsvc = -mean(w(:,QsvcCol))*60*1000;Qlpa = 
mean(w(:,QlpaCol))*60*1000;Qrpa = mean(w(:,QrpaCol))*60*1000;  %%in L/min 
    Qlsvc = -mean(w(:,QlsvcCol))*60*1000;    Qrupa = mean(QrupaCol)*60*1000; 
    Qs=Qivc+Qsvc+Qlsvc; 
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    FlowRates=[Qivc Qsvc Qlsvc 0 Qlpa Qrpa Qrupa] 
    OutletFlowSplit=[Qlpa/Qs Qrpa/Qs Qrupa/Qs] 
     
    if Qivc<0 || Qsvc<0 || Qlpa<0 || Qrpa<0 || Qlsvc<0 || Qrupa<0 
        warndlg(sprintf('Check Normal Vector Directions!!')) 
    end 





    a=vals{1,K}.data; 
    PL_temp=-1000*mean(a(:,PLcol)); %multiply by 1000 to get mW 











subplot(2,2,4) %plot percentage change over the final 5 cycles 
convValuesPL = []; 
for i=fliplr(0:5) 
    d=(PL(end-i)-PL(end-i-1))/PL(end-i-1)*100; 
    convValuesPL=[convValuesPL d]; 
end 
plot(convValuesPL) 














    a=vals{1,K}.data; 
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    if option==1||2||3||4; 
         
    [rows,columns]=size(a); 
    flux_it_LPA_temp=[]; 
    flux_it_RPA_temp=[]; 
    for count=1:rows 
        %calculate total flux of scalar for LPA 
        flux_it_lpa= a(count,end-2)*a(count,3); 
        flux_it_LPA_temp=[flux_it_LPA_temp flux_it_lpa]; 
         
         
        %calculate total flux of scalar for RPA 
        flux_it_rpa= a(count,end-1)*a(count,4); 
        flux_it_RPA_temp=[flux_it_RPA_temp flux_it_rpa]; 
         
    end 
         
    total_flux_LPA = sum(flux_it_LPA_temp); 
    total_flux_RPA = sum(flux_it_RPA_temp); 
     
    %calculate HFD by calculating ratio of LPA to total fluxes 
        hfd_temp = round(100*total_flux_LPA/(total_flux_LPA+total_flux_RPA)); 
         
     
     
    HFD = [HFD hfd_temp]; 
     
    elseif option==5   %%%%%for rupa and 2 inlets 
     
    [rows,columns]=size(a); 
    flux_it_LPA_temp=[]; 
    flux_it_RPA_temp=[]; 
    flux_it_RUPA_temp=[]; 
    for count=1:rows 
        %calculate total flux of scalar for LPA 
        flux_it_lpa= a(count,end-3)*a(count,3); 
        flux_it_LPA_temp=[flux_it_LPA_temp flux_it_lpa]; 
         
         
        %calculate total flux of scalar for RPA 
        flux_it_rpa= a(count,end-2)*a(count,4); 
        flux_it_RPA_temp=[flux_it_RPA_temp flux_it_rpa]; 
         
        %calculate total flux of scalar for RUPA 
        flux_it_rupa= a(count,end-1)*a(count,6); 
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        flux_it_RUPA_temp=[flux_it_RUPA_temp flux_it_rupa]; 
         
    end 
         
    total_flux_LPA = sum(flux_it_LPA_temp); 
    total_flux_RPA = sum(flux_it_RPA_temp); 
    total_flux_RUPA = sum(flux_it_RUPA_temp); 
     
    %calculate HFD by calculating ratio of LPA to total fluxes 
        hfd_temp = 
round(100*total_flux_LPA/(total_flux_LPA+total_flux_RPA+total_flux_RUPA)); 
         
     
     
    HFD = [HFD hfd_temp]; 
        
        
    end 









subplot(2,2,2) %plot percentage change over the final 5 cycles 
convValues = []; 
for i=fliplr(0:5) 
    c=(HFD(end-i)-HFD(end-i-1))/HFD(end-i-1)*100; 
    convValues=[convValues c]; 
end 
plot(convValues) 



























%%write text file 
fileID = fopen(sprintf('%s_PostProcess.txt',name),'w'); 
fprintf(fileID,name); 
fprintf(fileID, ['\n' '\n']); 
 
fprintf(fileID, '------------Hepatic Flow Distribution------------'); 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID,['HFD for last 10 cycles']); 
fprintf(fileID, ['\n' '\n']); 
 
formatSpec = ['%5.0f']; 




fprintf(fileID, ['\n' '\n' ]); 
fprintf(fileID, ['HFD convergence (percent)']); 
fprintf(fileID, ['\n']); 
 
formatSpec = ['%5.2f']; 
fprintf(fileID, formatSpec,convValues);  %%write HFD convergence values 
 
 
fprintf(fileID, ['\n' '\n' '\n' '\n']); 
fprintf(fileID, '-------------------Power Loss-------------------'); 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID,['Power Loss for last 10 cycles']); 
fprintf(fileID, ['\n' '\n']); 
 
formatSpec = ['%5.2f']; 






fprintf(fileID, ['\n' '\n']); 
fprintf(fileID, ['PL convergence (percent)']); 
fprintf(fileID, ['\n']); 
 
formatSpec = ['%5.1f']; 




fprintf(fileID, ['\n' '\n' '\n' '\n']); 
fprintf(fileID, ['---------------Flow Rates (L/min)---------------']); 
fprintf(fileID, ['\n' '\n']); 
 
fprintf(fileID, ['IVC' '\t' 'RSVC' '\t' 'LSVC' '\t' 'AZ' '\t' 'LPA' '\t' 'RPA' '\t' 'RUPA']); 
fprintf(fileID, ['\n' '\n' ]); 
 




fprintf(fileID, ['\n' '\n' '\n'  ]); 
fprintf(fileID, ['---------------Outlet Flow Split---------------']); 
fprintf(fileID, ['\n' '\n']); 
fprintf(fileID, ['LPA'  '\t' 'RPA'  '\t' 'RUPA' ]); 
fprintf(fileID, ['\n' '\n']); 
 
formatSpec = ['%5.2f']; 













This appendix describes the protocol to compare differences between two TCPCs. This 
could be used for two different patients, for one patient at two different time points, or for a 








2. Use the “Best-fit alignment” feature to allow Geomagic to register the two anatomies. 
(This is an important step to account for differences in coordinate systems between 




3. Using the “trim” feature in Geomagic, trim all vessels to end at the same location for both 
anatomies.  
 
4. Decimate to approximately 20,000 triangles for each anatomy.  (A higher number of 
triangles is unnecessary and slows down the Cloud Compare calculations.) 
5. Delete the coordinate systems for each anatomy. (CSYS 1) 
 
6. Export each anatomy as a .stl file.  
7. To compare the grafts by themselves, “trim” the graft from the TCPC of each anatomy 
and save the graft as a .stl.  (DO NOT register the grafts to one another, this would 
“erase” important positioning differences between the two TCPCs. 
 
8. Open Cloud Compare.  
9. Open the two .stl files (either both TCPCs or both grafts). 






11. Click the “Compute cloud/mesh distance” button.  
 
 
12. The program will make several estimations. Uncheck the “signed differences” option. 
Click “Compute”.  
 
 






14. The “trace a polyline by point-clicking” option can be used to make manual 
measurements.  Simply click the two points you want to measure the distance between, 
then right click and press enter. The polyline now shows up in the “Tree” menu. Click on 
it to view coordinates, length etc.  
 
 
Figure 0-26 Comparison of grafts. Distance apart is indicated by color. The white line shows a 






APPENDIX B – EXPERIMENTAL METHODS 
 
LabVIEW virtual instrument 
The LabVIEW virtual instrument used to control the pulsatile piston pump, trigger imaging 
systems, and record pressure and flow measurements was composed of an active waveform display 
on the left-hand side and various control panels on the right with different display, calculations, 
calibration, and output settings. Figure 0-1 shows the panel with display settings. Figure 0-2 shows 
the panel with calculations settings. Figure 0-3 shows the panel with calibration settings. Figure 
0-4 shows the panel with output settings. 
 
 
Figure 0-1 LabVIEW virtual instrument with plot display settings panel. The Plot 1 and Plot 2 
curves settings are used to display different channels in the plots on the left. The two plots in the 





Figure 0-2 LabVIEW virtual instrument with calculations settings panel. The Resistance 
Calculation Input and Mean/Pulsatility Channel boxes are used to specify the input channel 
number (0-15) for the calculations displayed below. The analysis period displays the time, in 




Figure 0-3 LabVIEW virtual instrument with calibration settings panel. This panel is used to 
specify the linear relationship between the analog input signal (V) and its respective metric value 
(L/min or mmHg) using a gain (G) and offset (O) for each channel. The DO Force Null? button 
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can be used to force all readings to zero by modification of their respective offset values. All values 
can also be altered manually. 
 
 
Figure 0-4 LabVIEW virtual instrument with output settings panel. The trigger and pump filepath 
boxes specify the custom waveform file location (.csv format) on the computer hard drive. The 
multiplier and period boxes (above and below) specify the custom waveform amplitude gain and 
time period, respectively. The input and output channels boxes specify the DAQ devices and 
channels used. The Input/Output Rate box specifiys the data sampling and created waveform 
frequency. The Samples to Read box specifies the number of samples (at the Input/Output Rate box 






APPENDIX C – SPECIFIC AIM 1A PATIENT DATA 
 
This appendix contains all raw data (flow rates, birth and surgery dates, HFD prediction errors etc) 
for all patients included in Specific Aim 1A. The Georgia Tech patient IDs are also given for 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX D – SPECIFIC AIM 1B CROSS-
SECTIONAL PATIENT DATA 
This appendix contains all data for all patients included in the cross-sectional portion of Specific 
Aim 1B (30 Y-graft and 30 LT/ECC patients).  The posterior views for a variety of the Y-graft 


















CHOA_Y2B ygraft 9 F 4.9798 3.08 0.899 0.02807
CHOA_Y3 ygraft 2 M 5.6085 0.79 0.53 0.65113
CHOA_Y4 ygraft 3 M 0.7201 1.448 0.73 0.02576
CHOA_Y4B ygraft 6 M 2.1768 1.438 0.935 0.13041
CHOA_Y5 ygraft 2 F 1.3269 0.85 0.5 0.11007
CHOA_Y8 ygraft 14 M 3.525 3.2509 1.523 0.04849
CHIOA_Y9 ygraft 3 M 4.8748 1.38 0.512 0.09908
CHOA_Y10 ygraft 2 F 5.8903 1.39 0.554 0.13717
CHOA_Y13 ygraft 3 M 0.479 1.27 0.598 0.01704
CHOA_Y14 ygraft 1.5 M 2.8018 1.59 0.562 0.04486
CHOA_Y15 ygraft 2 F 25.9811 1.58 0.503 0.3396
CHOA_Y17 ygraft 2 F 0.4464 1.76 0.521 0.00453
CHOA_Y19 ygraft 4 M 7.9623 1.47 0.709 0.25676
CHOA_Y21 ygraft 3 F 0.9444 0.7026 0.54 0.1618
CHOA_Y22 ygraft 2 F 3.0074 1.8598 0.57 0.03095
CHOA_Y23 ygraft 3 F 8.1206 0.9711 0.553 0.55258
CHOA_Y24 ygraft 2 M 0.0147 1.994 0.539 0.00049
CHOA_Y25 ygraft 3 F 0.1116 1.413 0.553 0.00247
CHOA_Y26 ygraft 3 M 16.9388 1.5912 0.591 0.299
CHOA_Y27 ygraft 4 F 24.2854 1.7596 0.66 0.39568
CHOA_Y28 ygraft 2 M 6.96 0.8738 0.544 0.629
CHOA_Y29 ygraft 4 M 17.8996 1.9376 0.651 0.2125
CHOA_Y30 ygraft 5 M 8.9636 2.088 0.65 0.08477
CHOA_Y31 ygraft 3 M 0.1672 0.623 0.61 0.05243
CHOA_Y32 ygraft 4 M 11.9254 1.6 0.751 0.33461
CHOA_Y34 ygraft 6 M 2.6768 1.7946 0.895 0.0756
CHOA_Y35 ygraft 3 F 27.4868 1.656 0.626 0.48333
CHOA_Y36 ygraft 4 F 7.3748 2.22 0.768 0.08101
CHOA_Y37 ygraft 3 F 5.8173 1.42 0.647 0.17331




















SVC033 ECC 4 M 4.5606 2.6177 0.81 0.03399
SVC040 LT 3 M 1.2396 1.4598 0.62 0.03121
SVC043 ECC 4 M 3.3148 1.9872 0.69 0.04098
SVC047 ECC 4 M 10.3004 2.138 0.61 0.07992
SVC051 ECC 3 M 1.98 1.9709 0.64 0.02159
SVC057 LT 3 M 0.7987 1.6684 0.61 0.01304
SVC058 ECC 3 M 3.1517 2.5939 0.59 0.01281
SVC059 ECC 4 M 9.2832 1.7594 0.75 0.19538
SVC062 ECC 4.5 M 1.6099 1.7568 0.71 0.0305
SVC063 ECC 2 F 1.2165 1.3881 0.65 0.03916
SVC070 ECC 3 M 4.1322 2.3678 0.51 0.0165
SVC075 LT 2 F 2.2418 2.6856 0.58 0.00793
SVC078 ECC 2 M 2.2371 2.2557 0.56 0.01246
SVC079 ECC 3 M 4.2784 2.4183 0.91 0.05105
SVC083 ECC 5 M 2.8171 2.0857 0.62 0.02432
SVC085 ECC 4 M 1.602 1.6998 0.62 0.02555
SVC093 ECC 3 M 3.6621 3.0816 0.71 0.01285
SVC100 LT 3 F 13.2363 2.7563 0.69 0.06132
SVC112 ECC 3 M 5.0149 2.8064 0.63 0.01835
CHOP042B ECC 3 F 3.0329 1 0.62 0.23757
CHOP051B ECC 4 M 1.8381 1.4743 0.63 0.04639
CHOP054A LT 4 F 0.6955 2.0442 0.46 0.00351
CHOP081A ECC 3 F 9.0232 1.5345 0.54 0.14839
CHOP085A LT 2 M 2.2176 1.2016 0.5 0.06512
CHOP086A ECC 6 F 32.3467 3.7103 0.81 0.08467
CHOP087A LT 5 M 19.2336 1.9333 0.81 0.35586
CHOP109B ECC 4 M 6.4896 2.6612 0.65 0.02965
CHOP064A LT 6 F 0.4898 1.2614 0.94 0.04394
CHOP148A LT 4 M 7.0043 1.7705 0.73 0.13705
























CHOA_Y2B 38 12 66 16 0.47192 2.15 2.39
CHOA_Y3 33 17 18 32 4.76287 2.03 3.83
CHOA_Y4 34 16 55 5 0.25071 2.50 3.42
CHOA_Y4B 36 14 78 28 0.98427 3.20 3.43
CHOA_Y5 74 24 38 12 0.91827 1.44 2.88
CHOA_Y8 49 1 38 12 0.50799 4.14 2.72
CHIOA_Y9 30 20 5 45 1.3106 1.46 2.85
CHOA_Y10 35 15 25 25 1.68895 1.50 2.71
CHOA_Y13 80 30 37 13 0.17759 0.92 1.54
CHOA_Y14 46 4 47 3 0.62284 1.84 3.27
CHOA_Y15 64 14 64 14 5.23494 2.23 4.44
CHOA_Y17 55 5 12 38 0.07508 1.35 2.59
CHOA_Y19 52 2 37 13 2.61246 1.78 2.51
CHOA_Y21 7 43 77 27 1.03308 1.07 1.98
CHOA_Y22 25 25 0 50 0.4956 1.74 3.05
CHOA_Y23 44 6 6 44 4.76196 1.72 3.12
CHOA_Y24 56 6 48 2 0.00199 1.95 3.61
CHOA_Y25 48 2 72 22 0.03091 1.41 2.56
CHOA_Y26 60 10 65 15 3.95385 2.16 3.66
CHOA_Y27 32 18 29 21 5.1768 1.55 2.35
CHOA_Y28 51 1 1 49 4.95889 1.08 1.98
CHOA_Y29 47 3 92 42 3.10382 2.14 3.29
CHOA_Y30 49 1 89 39 1.33639 1.63 2.50
CHOA_Y31 84 34 99 49 0.26278 0.66 1.08
CHOA_Y32 65 15 81 31 3.49843 2.60 3.46
CHOA_Y34 41 9 86 36 0.74388 1.75 1.96
CHOA_Y35 40 10 83 33 6.27448 1.74 2.78
CHOA_Y36 38 12 69 19 1.14923 2.12 2.76
CHOA_Y37 24 26 48 2 1.86659 1.20 1.85
























SVC033 45 5 19 31 0.5391 4.38 5.40
SVC040 28 22 40 10 0.36065 2.04 3.29
SVC043 69 19 72 22 0.57919 2.42 3.51
SVC047 58 8 40 10 1.37458 3.17 5.20
SVC051 31 19 43 7 0.32622 2.92 4.56
SVC057 44 6 51 1 0.17503 2.12 3.47
SVC058 35 15 21 29 0.27637 3.20 5.43
SVC059 38 12 70 20 2.24921 3.33 4.45
SVC062 71 21 45 5 0.37035 2.13 3.00
SVC063 24 26 1 49 0.41038 3.03 4.66
SVC070 40 10 15 35 0.37589 1.86 3.66
SVC075 58 8 63 13 0.18028 2.69 4.63
SVC078 55 5 29 21 0.24621 2.26 4.03
SVC079 60 10 23 27 0.66574 2.59 2.85
SVC083 32 18 6 44 0.4015 4.38 7.06
SVC085 45 5 28 22 0.34376 2.82 4.54
SVC093 44 6 7 43 0.2738 3.80 5.35
SVC100 41 9 45 5 1.20216 2.72 3.95
SVC112 55 5 26 24 0.40115 3.26 5.17
CHOP042B 77 27 48 2 1.8804 2.08 3.35
CHOP051B 79 29 61 11 0.53277 1.95 3.09
CHOP054A 21 29 19 31 0.07656 2.05 4.45
CHOP081A 38 12 18 32 2.06929 3.88 7.18
CHOP085A 35 15 40 10 0.76795 1.60 3.20
CHOP086A 36 14 33 17 1.90325 2.83 3.50
CHOP087A 35 15 69 19 4.16819 2.69 3.32
CHOP109B 51 1 14 36 0.59563 2.63 4.04
CHOP064A 55 5 77 27 0.28936 1.61 1.72
CHOP148A 42 8 43 7 1.63116 2.47 3.39






























CHOA_Y2B 9.78 9.36 10.89 10.18 187.21 167.11 8.42 12.61
CHOA_Y3 5.91 3.19 8.82 8.05 167.02 111.23 70.75 16.64
CHOA_Y4 7.71 6.57 9.02 8.45 151.47 123.20 27.45 12.25
CHOA_Y4B 10.28 9.23 9.44 7.59 163.64 119.94 19.46 35.30
CHOA_Y5 8.50 7.05 7.94 7.21 212.50 159.69 31.19 17.58
CHOA_Y8 18.29 16.88 13.17 12.91 261.87 232.75 14.85 3.92
CHIOA_Y9 5.70 3.74 6.78 5.81 120.24 73.23 56.84 26.57
CHOA_Y10 5.10 4.19 7.90 7.19 125.49 98.17 32.75 17.19
CHOA_Y13 7.59 6.96 7.22 6.20 144.06 114.12 15.93 26.15
CHOA_Y14 6.06 4.81 10.03 9.25 191.96 151.76 37.14 15.02
CHOA_Y15 6.85 5.35 5.73 4.75 124.51 79.88 38.96 31.40
CHOA_Y17 8.71 7.75 7.28 6.63 194.15 156.63 20.88 17.09
CHOA_Y19 6.66 5.28 7.22 6.36 106.98 75.67 37.23 22.49
CHOA_Y21 5.36 4.19 10.65 10.47 206.59 184.97 38.96 3.25
CHOA_Y22 4.01 3.12 6.15 5.18 74.21 50.46 39.27 28.90
CHOA_Y23 4.28 2.54 5.77 4.32 73.36 35.74 64.71 43.91
CHOA_Y24 5.67 4.30 5.86 5.34 96.79 68.52 42.50 16.78
CHOA_Y25 6.03 5.34 4.48 4.08 80.16 64.13 21.60 17.11
CHOA_Y26 5.44 4.52 6.52 4.52 95.80 54.31 31.12 51.81
CHOA_Y27 4.22 3.16 7.07 6.55 80.65 62.95 43.76 14.18
CHOA_Y28 5.08 2.84 3.32 3.04 53.16 24.91 68.85 16.31
CHOA_Y29 7.00 6.27 5.64 4.92 97.51 76.60 19.78 24.00
CHOA_Y30 6.86 5.70 6.49 6.11 107.75 84.41 30.90 11.32
CHOA_Y31 7.93 5.97 7.07 5.87 145.33 90.27 43.33 31.04
CHOA_Y32 6.10 5.39 7.21 6.88 93.37 79.88 22.11 8.97
CHOA_Y34 7.06 6.36 9.37 7.87 120.86 89.86 18.99 29.43
CHOA_Y35 5.94 4.83 7.65 6.64 117.79 84.51 33.94 24.83
CHOA_Y36 8.61 7.88 6.17 4.89 114.70 87.87 16.32 37.19
CHOA_Y37 4.22 3.55 6.33 5.47 70.26 51.61 29.19 25.38






























SVC033 8.48 5.53 10.20 9.13 170.50 110.46 57.48 19.83
SVC040 9.21 5.85 9.43 7.42 219.93 113.13 59.59 38.04
SVC043 10.21 7.63 9.25 8.81 215.97 154.69 44.10 9.19
SVC047 6.26 5.02 7.93 7.83 131.55 111.39 35.74 2.61
SVC051 7.54 5.74 10.49 9.67 204.86 155.32 42.01 14.97
SVC057 12.43 9.10 10.01 7.20 327.97 173.32 46.36 48.37
SVC058 8.65 5.90 10.62 9.61 249.95 169.25 53.48 18.23
SVC059 9.01 6.91 8.26 7.17 156.59 103.89 41.21 24.68
SVC062 9.76 9.02 11.40 8.94 248.94 178.41 14.43 38.52
SVC063 7.59 6.74 7.47 6.97 137.16 113.57 21.17 13.11
SVC070 6.94 5.29 9.11 7.18 201.81 122.53 41.88 37.78
SVC075 8.08 5.55 10.81 9.47 246.55 163.24 52.74 23.20
SVC078 9.78 9.35 8.72 7.79 240.71 207.64 8.65 20.15
SVC079 9.23 8.98 8.64 6.52 137.89 106.25 5.36 43.01
SVC083 8.21 6.40 8.65 8.36 180.17 140.57 39.13 6.54
SVC085 9.17 8.52 9.38 8.51 217.87 183.79 13.67 17.53
SVC093 10.87 9.00 9.00 8.83 220.30 175.79 31.45 3.82
SVC100 9.61 4.77 9.84 7.62 215.25 92.03 75.36 39.96
SVC112 9.27 7.35 10.21 8.13 237.30 149.68 37.19 36.70
CHOP042B 9.82 5.97 4.37 4.27 146.33 68.33 63.02 4.16
CHOP051B 9.24 8.01 8.30 7.02 192.29 141.52 24.74 28.46
CHOP054A 12.20 8.58 13.67 10.07 573.09 298.72 50.61 45.69
CHOP081A 8.90 6.45 12.69 10.58 349.38 223.34 47.57 30.41
CHOP085A 7.07 4.05 7.95 7.35 177.65 110.72 67.15 14.35
CHOP086A 7.67 6.47 11.28 10.39 180.39 145.31 28.82 15.12
CHOP087A 10.38 5.91 15.25 12.62 329.93 188.24 67.51 31.58
CHOP109B 9.47 7.21 9.00 6.47 206.14 113.41 42.00 48.28
CHOP064A 10.35 6.39 10.08 8.32 174.29 91.88 61.92 31.84
CHOP148A 7.80 6.14 7.77 6.14 130.37 81.08 38.00 37.61






















CHOA_Y2B 10.74 0.53 0.18 2.68 0.35 0.51 0.28 39.36
CHOA_Y3 33.40 1.60 0.82 2.82 1.46 1.08 0.40 73.98
CHOA_Y4 18.67 1.41 0.74 3.08 0.85 0.16 0.19 17.45
CHOA_Y4B 26.70 2.46 1.84 2.86 2.49 2.64 0.31 147.62
CHOA_Y5 24.85 1.43 0.72 2.87 1.01 1.05 0.31 68.03
CHOA_Y8 11.12 1.04 0.37 3.46 0.65 0.27 0.40 33.59
CHIOA_Y9 39.10 1.19 0.38 3.55 0.56 0.61 0.51 55.95
CHOA_Y10 21.77 0.84 0.33 2.26 0.67 0.57 0.39 48.14
CHOA_Y13 20.79 1.38 0.85 2.34 0.91 0.24 0.42 33.05
CHOA_Y14 20.94 1.21 0.34 2.97 0.91 0.73 0.29 50.81
CHOA_Y15 35.84 1.13 0.41 2.74 0.74 2.31 0.46 138.24
CHOA_Y17 19.32 0.91 0.04 2.57 0.60 2.40 0.31 135.17
CHOA_Y19 29.27 1.35 0.42 3.76 0.98 1.16 0.62 89.19
CHOA_Y21 10.47 1.17 0.08 3.23 0.65 1.19 0.83 101.06
CHOA_Y22 31.99 0.24 0.13 0.29 0.27 0.25 0.46 35.80
CHOA_Y23 51.28 1.03 0.45 2.26 0.53 0.67 0.33 50.21
CHOA_Y24 29.21 2.88 0.91 8.87 1.95 1.19 0.52 85.39
CHOA_Y25 20.00 0.81 0.37 2.58 0.45 0.33 0.64 48.28
CHOA_Y26 43.30 0.73 0.27 2.41 0.35 0.35 0.25 29.76
CHOA_Y27 21.94 1.03 0.09 1.97 0.84 1.47 0.28 87.74
CHOA_Y28 53.13 2.29 0.52 140.28
CHOA_Y29 21.44 0.75 0.38 1.81 0.48 0.33 0.34 33.65
CHOA_Y30 21.66 0.94 0.19 2.93 0.78 0.64 0.45 54.55
CHOA_Y31 37.88 1.68 0.88 2.81 1.16 0.80 0.90 85.00
CHOA_Y32 14.45 1.40 0.45 3.02 0.89 0.37 0.28 32.51
CHOA_Y34 25.65 0.38 0.53 45.59
CHOA_Y35 28.25 1.39 0.65 2.88 0.68 1.56 0.23 89.67
CHOA_Y36 23.39 0.99 0.34 4.04 0.43 0.24 0.31 27.41
CHOA_Y37 26.55 0.58 0.14 2.35 0.43 0.51 0.45 47.90






















SVC033 35.21 0.77 0.24 3.06 0.38 0.32 0.34 32.78
SVC040 48.56 0.96 0.37 2.35 0.48 0.68 0.45 56.51
SVC043 28.37 1.16 0.44 2.80 0.73 0.17 0.35 26.18
SVC047 15.32 0.76 0.00 2.48 0.11 0.20 0.19 19.63
SVC051 24.18 0.87 0.24 3.87 0.38 0.41 0.66 53.57
SVC057 47.15 1.11 0.32 2.59 0.83 0.59 0.53 56.04
SVC058 32.29 0.99 0.32 3.00 0.40 0.50 0.34 41.74
SVC059 33.66 0.64 0.18 2.53 0.25 1.06 0.38 71.75
SVC062 28.33 1.59 0.65 3.01 1.67 0.81 0.50 65.06
SVC063 17.20 0.94 0.35 2.49 0.45 0.40 0.54 47.00
SVC070 39.29 0.79 0.26 2.78 0.35 0.25 0.33 28.91
SVC075 33.79 1.33 0.33 3.24 0.41 0.69 2.94 181.50
SVC078 13.73 0.93 0.35 2.15 0.41 0.45 0.34 39.59
SVC079 22.95 0.77 0.38 2.34 0.48 0.25 0.35 29.93
SVC083 21.97 1.16 0.54 2.64 0.60 0.57 0.27 42.08
SVC085 15.64 1.29 0.55 2.80 0.89 0.70 0.29 49.91
SVC093 20.20 0.81 0.31 2.34 0.38 0.29 0.37 33.13
SVC100 57.24 0.83 0.23 3.68 0.37 0.64 0.55 59.60
SVC112 36.92 0.93 0.30 3.19 0.42 0.47 0.15 31.16
CHOP042B 53.30 1.82 0.14 4.60 1.50 2.29 0.44 136.76
CHOP051B 26.40 1.19 0.57 2.79 0.66 0.29 0.91 60.22
CHOP054A 47.88 1.32 0.48 3.59 0.53 0.44 0.37 40.75
CHOP081A 36.07 1.51 0.53 2.76 0.86 3.41 0.21 180.92
CHOP085A 37.67 1.00 0.63 2.83 0.74 0.62 0.42 52.13
CHOP086A 19.45 0.68 0.17 3.15 0.35 0.40 1.16 78.07
CHOP087A 42.94 1.27 0.47 3.87 0.66 0.44 0.37 40.51
CHOP109B 44.98 0.79 0.28 2.82 0.36 0.70 0.24 47.02
CHOP064A 47.28 1.48 0.66 4.30 0.90 0.30 0.59 44.26
CHOP148A 37.81 1.20 0.28 3.80 0.59 1.05 0.52 78.37









Ygraft 4 8 5 6 7 
LT/ECC 9 5 8 5 3 








Ygraft 13 7 2 3 5 
LT/ECC 23 5 2 0 0 
Data used to make Figure 6-2 and 6-4. 
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APPENDIX E – SPECIFIC AIM 1B LONGITUDINAL 
PATIENT DATA 
This appendix contains all data for all patients included in the longitudinal portion of Specific Aim 
1B. This includes 10 Y-graft patients with two serial time points, as well as three unique ECC 
control groups which each have 10 unique patients.  The Y-graft data are presented first, follow 
























Y1 CHOA_Y5 3.51 42.14 2 1 1 0.5 6 days 0.016
Y2 CHOA_Y13 3.23 38.70 1 2 1 0.6 12 days 0.032
Y3 CHOA_Y14 3.75 45.04 1 2 1 0.59 45 days 0.123
Y4 CHOA_Y26 3.24 38.83 1 2 1 0.62 14 days 0.038
Y5 CHOA_Y27 3.01 36.13 2 1 1 0.62 7 days 0.019
Y6 CHOA_Y32 2.44 29.26 2 2 1 0.75 23 days 0.063
Y7 CHOA_Y36 1.22 14.59 2 2 1 0.8 7 days 0.019
Y8 CHOA_Y37 0.32 3.82 2 1 2 0.65 9 days 0.0246
Y9 CHOA_Y40 3.02 36.24 2 2 1 0.6 7 days 0.019
Y10 CHOA_Y42 2.50 30.00 1 2 1 0.81 30 days 0.082














Y1 CHOA_Y5 12/9/2010 2 0.118 0.008 0.064 0.058 14 36
Y2 CHOA_Y13 5/1/2012 3 0.27 0.015 0.103 0.112 54 4
Y3 CHOA_Y14 5/10/2012 1.6 0.964 0.025 0.221 0.309 68 18
Y4 CHOA_Y26 8/22/2013 3 4.147 0.075 0.703 1.146 63 13
Y5 CHOA_Y27 10/10/2013 4 1.215 0.11 0.604 0.575 48 2
Y6 CHOA_Y32 3/17/2014 4 0.73 0.035 0.184 0.246 92 42
Y7 CHOA_Y36 7/29/2014 4 2.935 0.043 0.307 0.636 68 18
Y8 CHOA_Y37 8/14/2014 3 1.087 0.055 0.343 0.41 37 13
Y9 CHOA_Y40 10/2/2014 3 0.937 0.053 0.352 0.385 44 6


























Y1 CHOA_Y5 1.53 3.06 0.45 0.556 0.638 0.19 77 27 1.006 0.524
Y2 CHOA_Y13 3.28 5.467 0.37 0.61 0.732 0.183 80 30 0.98 2.3
Y3 CHOA_Y14 1.84 3.119 0.39 0.72 0.37 0.37 50 0 1.11 0.73
Y4 CHOA_Y26 2.4 3.871 0.55 0.97 0.85 0.61 58 8 1.52 0.88
Y5 CHOA_Y27 2.36 3.806 0.255 0.44 0.27 0.44 38 12 0.695 1.665
Y6 CHOA_Y32 2.6 3.467 0.39 0.8 0.59 0.88 40 10 1.19 1.41
Y7 CHOA_Y36 2.26 2.825 0.2 1.25 0.83 1.14 42 8 1.45 0.81
Y8 CHOA_Y37 1.7 2.615 0.6 0.6 0.3 0.9 25 25 1.2 0.5
Y9 CHOA_Y40 1.34 2.23 0.28 0.82 0.44 0.57 44 6 1.1 0.24
Y10 CHOA_Y42 2.3 2.84 0.4 1.1 0.7 0.7 50 0 1.5 0.8

















Y1 CHOA_Y5 18.293 18.09 13.12 13.12 9.076 7.785 8.59 8.59
Y2 CHOA_Y13 24.453 23.627 19.727 17.969 9.424 9.336 9.464 8.456
Y3 CHOA_Y14 16.028 15.411 12.356 12.208 6.683 6.18 11.5 11.5
Y4 CHOA_Y26 17.385 17.139 13.406 13.201 5.871 5.46 7.534 5.019
Y5 CHOA_Y27 15.568 8.103 10.36 9.713 4.355 3.701 7.379 6.911
Y6 CHOA_Y32 19.634 17.318 17.692 16.985 7.056 6.561 8.021 7.791
Y7 CHOA_Y36 16.404 15.297 11.011 10.107 9.488 8.917 7 6.6
Y8 CHOA_Y37 12.118 11.88 12 12 4.729 3.774 7.635 6.988
Y9 CHOA_Y40 20.575 19.110 15.409 13.193 6.905 6.104 6.760 6.284


















Y1 CHOA_Y5 2.208 0 26.436 0 13.946 13.946
Y2 CHOA_Y13 6.643 17.028 1.861 20.172 11.056 11.056
Y3 CHOA_Y14 7.547 2.368 14.467 0 3.652 3.652
Y4 CHOA_Y26 2.813 3.028 13.486 55.635 39.713 39.713
Y5 CHOA_Y27 72.91 12.104 27.772 12.278 16.281 16.281
Y6 CHOA_Y32 22.194 7.837 13.551 5.661 9.103 9.103
Y7 CHOA_Y36 13.047 15.745 11.678 10 11.475 11.475
Y8 CHOA_Y37 3.889 0 36.3 16.223 21.79 21.79
Y9 CHOA_Y40 13.733 26.698 21.862 13.576 18 14.46
Y10 CHOA_Y42 1.101 12.925 6.988 56.145 42 20.8
















Y1 CHOA_Y5 0.78 6/13/2014 5 1.784 0.058 0.328 0.513 28 22
Y2 CHOA_Y13 0.81 7/22/2015 6 1.124 0.023 0.146 0.271 49 1
Y3 CHOA_Y14 0.98 2/9/2016 5 2.067 0.024 0.143 0.364 49 1
Y4 CHOA_Y26 0.87 11/15/2016 6 0.73 0.022 0.111 0.191 52 2
Y5 CHOA_Y27 0.7 10/13/2016 7 0.618 0.033 0.183 0.226 65 15
Y6 CHOA_Y32 1.01 8/23/2016 6 3.547 0.017 0.127 0.451 71 21
Y7 CHOA_Y36 0.88 10/16/2015 5 1.637 0.022 0.144 0.326 52 2
Y8 CHOA_Y37 0.7 12/8/2014 3 0.822 0.04 0.23 0.292 43 7
Y9 CHOA_Y40 0.86 10/10/2017 6 1.290 0.042 0.171 0.315 53 3




































Y1 CHOA_Y5 4.21 5.40 0.87 0.83 0.79 0.55 59 9 1.70 0.51 2.51
Y2 CHOA_Y13 2.50 3.09 1.09 1.38 1.00 0.60 63 13 2.48 0.44 0.02
Y3 CHOA_Y14 4.00 4.08 1.10 1.60 1.00 1.20 45 5 2.70 0.41 1.30
Y4 CHOA_Y26 2.10 2.41 0.70 1.00 0.80 0.90 47 3 1.70 0.41 0.40
Y5 CHOA_Y27 2.20 3.14 0.40 0.90 0.50 0.60 45 5 1.30 0.31 0.90
Y6 CHOA_Y32 3.60 3.56 1.40 2.00 1.40 1.90 42 8 3.40 0.41 0.20
Y7 CHOA_Y36 2.70 3.07 0.90 1.20 1.00 1.20 45 5 2.10 0.43 0.60
Y8 CHOA_Y37 2.40 3.43 0.56 0.71 0.21 0.74 22 28 1.27 0.44 1.13
Y9 CHOA_Y40 1.70 1.97 0.90 0.89 0.70 0.44 61 11 1.80 0.50 0.00
Y10 CHOA_Y42 3.20 3.05 1.10 1.60 1.30 1.10 52 2 2.70 0.41 0.50




























Y1 CHOA_Y5 17.69 16.89 10.46 10.37 8.75 6.75 7.10 6.90 9 2 40 6 27
Y2 CHOA_Y13 21.32 21.14 21.19 20.75 9.98 9.00 8.99 8.49 2 4 19 11 15
Y3 CHOA_Y14 17.65 16.54 13.51 13.39 10.30 10.07 12.16 12.16 12 2 5 0 2
Y4 CHOA_Y26 21.99 21.61 13.04 12.83 9.33 8.91 11.49 11.24 3 3 9 4 6
Y5 CHOA_Y27 17.95 17.70 13.75 13.39 7.79 7.66 7.81 7.34 3 5 3 12 7
Y6 CHOA_Y32 20.95 20.38 27.36 26.72 9.38 7.80 10.08 8.00 5 5 31 37 34
Y7 CHOA_Y36 18.26 17.85 12.80 12.12 13.15 12.49 10.86 10.10 4 10 10 14 11
Y8 CHOA_Y37 15.50 15.18 15.18 15.17 5.37 4.89 7.80 6.20 4 0 17 37 30
Y9 CHOA_Y40 17.29 16.76 17.05 15.12 10.40 9.85 10.92 10.00 6 21 10 16 13


























SVC043 1 CBF CHOP 2 0.43 5.19 1 2 1
SVC059 1 CBF CHOP 2 0.59 7.13 1 2 1
SVC063 1 CBF CHOP 2 0.67 8.09 2 1 1
SVC075 1 CBF CHOP 1 0.54 6.48 2 1 1
SVC085 1 CBF CHOP 2 0.64 7.73 1 2 1
SVC112 1 CBF CHOP 2 0.72 8.58 1 1 1
CHOP081A 1 R01 CHOP 2 0.46 5.49 2 2 1
LB13_2 1 Serial liver CHOP ? 0.01 0.12 2 2 2
LB18_2 1 Serial liver CHOP 2 0.54 6.48 2 1 2
LB23_1 1 Serial liver CHOP 2 2.15 25.80 2 1 2
CHOP026A 2 R01 CHOP 1 4.48 53.79 2 1 1
CHOP016A 2 R01 CHOP 2 4.62 55.43 1 1 2
CHOP018A 2 R01 CHOP 1 5.38 64.50 1 2 2
CHOP024A 2 R01 CHOP 5.36 64.31 2 2 2
CHOP082A 2 R01 CHOP 2 5.30 63.60 1 2 2
CHOP088A 2 R01 CHOP 2 5.60 67.20 2 2 2
LB19_1 2 Serial liver CHOP 2 4.35 52.20 2 1 1
LB20_2 2 Serial liver CHOP 2 5.21 62.52 1 1 2
LB24_1 2 Serial liver CHOP 2 5.85 70.20 1 1 1
LB25_1 2 Serial liver CHOP 2 3.86 46.32 1 1 1
LB03_1 3 Serial liver CHOP 1 16.04 192.48 2 1 2
LB05_1 3 Serial liver CHOP 2 12.27 147.24 2 1 2
LB06_5 3 Serial liver CHOP 2 12.64 151.68 1 2 1
LB07_3 3 Serial liver CHOP 2 11.98 143.76 2 2 1
LB08_1 3 Serial liver CHOP 2 15.58 186.96 1 2 2
LB09_2 3 Serial liver CHOP 2 11.76 141.12 2 1 1
LB12_1 3 Serial liver CHOP 2 16.32 195.84 2 1 2
LB15_2 3 Serial liver CHOP 2 13.48 161.76 2 1 1
LB21_1 3 Serial liver CHOP 2 13.11 157.32 1 2 2




















SVC043 1 0.69 4 2.29 0.0283 0.2610 0.5186 86 36
SVC059 1 0.75 4 9.1 0.1915 1.3229 2.3275 51 1
SVC063 1 0.65 2 0.61 0.0196 0.1425 0.1978 3 47
SVC075 1 0.58 2 0.72 0.0025 0.0449 0.1206 64 14
SVC085 1 0.62 4 0.9 0.0144 0.1402 0.2383 16 34
SVC112 1 0.63 3 2.54 0.0093 0.1451 0.4073 26 24
CHOP081A 1 0.54 3 0.52 0.0086 0.0994 0.1525 12 38
LB13_2 1 0.62 3 3.4 0.0310 0.3651 0.7476 67 17
LB18_2 1 0.58 3 1.04 0.0155 0.1696 0.2824 41 9
LB23_1 1 0.66 5 1.11 0.0278 0.2150 0.3280 33 17
CHOP026A 2 0.83 6 1.91 0.0298 0.1987 0.4132 58 8
CHOP016A 2 0.83 6 2.13 0.0086 0.0896 0.2931 3 47
CHOP018A 2 0.68 7 0.58 0.0030 0.0377 0.0992 51 1
CHOP024A 2 0.74 7 1.15 0.0077 0.0796 0.2029 52 2
CHOP082A 2 0.87 7 0.93 0.0099 0.0703 0.1715 61 11
CHOP088A 2 1.25 8 0.66 0.0160 0.0533 0.1258 28 22
LB19_1 2 0.8 6 1.400893 0.0403 0.2302 0.3810 7 43
LB20_2 2 1 7 4.459021 0.0374 0.2391 0.6927 3 47
LB24_1 2 1 9 1.532863 0.0264 0.1329 0.3027 57 7
LB25_1 2 0.63 6 1.062668 0.0097 0.1119 0.2314 27 23
LB03_1 3 1.53 20 1.627477 0.0198 0.0636 0.2158 57 7
LB05_1 3 1.29 14 5.228602 0.0386 0.1834 0.6569 36 14
LB06_5 3 1.6 14 5.269497 0.0548 0.1743 0.6428 33 17
LB07_3 3 1.57 24 6.914106 0.0571 0.2012 0.7911 66 16
LB08_1 3 1.96 16 7.033888 0.0238 0.0841 0.5159 57 7
LB09_2 3 1.02 15 2.080923 0.0317 0.1617 0.3892 61 11
LB12_1 3 1.48 17 2.581938 0.1105 0.2434 0.5318 37 13
LB15_2 3 1.63 15 7.873656 0.0648 0.2173 0.8775 31 19
LB21_1 3 1.68 15 9.057736 0.0357 0.1470 0.7740 62 12
























SVC043 1 2.42 3.51 0.57 1.41 1.36 0.62 69 19
SVC059 1 3.33 4.45 0.88 0.87 0.47 0.76 38 12
SVC063 1 3.03 4.66 0.64 0.75 0.50 1.56 24 26
SVC075 1 2.69 4.63 0.82 1.87 0.67 0.48 58 8
SVC085 1 2.82 4.54 0.52 1.16 0.70 0.85 45 5
SVC112 1 3.26 5.17 0.84 1.96 0.70 0.56 55 5
CHOP081A 1 3.88 7.18 0.32 1.22 0.52 0.85 38 12
LB13_2 1 2.10 3.39 0.53 0.75 1.70 0.40 81 31
LB18_2 1 2.40 4.14 0.94 0.72 0.76 0.64 54 4
LB23_1 1 2.00 3.03 0.74 0.79 0.58 0.92 39 11
CHOP026A 2 3.10 3.74 0.79 0.80 0.64 0.96 40 10
CHOP016A 2 3.27 3.94 2.23 1.71 1.00 2.94 25 25
CHOP018A 2 2.63 3.87 2.03 1.84 1.37 1.87 42 8
CHOP024A 2 2.55 3.45 2.14 1.31 1.15 1.55 43 7
CHOP082A 2 2.47 2.84 1.56 0.88 0.96 1.47 40 10
CHOP088A 2 3.12 2.50 1.47 0.89 1.28 1.09 54 4
LB19_1 2 3.63 4.53 1.05 0.69 0.53 0.91 37 13
LB20_2 2 5.39 5.39 1.16 1.70 0.63 2.40 21 29
LB24_1 2 3.60 3.60 1.10 1.10 1.00 1.10 48 2
LB25_1 2 1.76 2.79 1.17 0.89 0.61 0.67 48 2
LB03_1 3 3.90 2.55 2.52 0.88 1.43 1.79 44 6
LB05_1 3 4.50 3.49 1.68 0.94 1.40 2.20 39 11
LB06_5 3 7.60 4.75 2.50 1.40 1.70 1.30 57 7
LB07_3 3 4.74 3.02 3.04 1.05 1.83 1.78 51 1
LB08_1 3 6.75 3.44 4.30 2.10 3.09 3.29 48 2
LB09_2 3 3.90 3.82 1.43 0.98 1.09 0.75 59 9
LB12_1 3 4.94 3.34 1.84 0.34 0.70 1.48 32 18
LB15_2 3 4.90 3.01 2.77 1.70 1.40 3.40 29 21
LB21_1 3 6.02 3.58 3.46 0.93 2.79 2.47 53 3



































SVC043 1 1.99 0.29 0.44 16.67 15.28 11.45 10.42 10.21 7.63 9.25 8.81
SVC059 1 1.76 0.50 2.11 14.37 13.53 13.92 13.00 9.01 6.91 8.26 7.17
SVC063 1 1.39 0.46 0.97 14.53 12.17 11.39 10.78 7.59 6.74 7.47 6.97
SVC075 1 2.69 0.31 1.54 16.95 13.74 11.25 8.80 8.08 5.55 10.81 9.47
SVC085 1 1.70 0.31 1.26 16.38 15.10 9.61 7.01 9.17 8.52 9.38 8.51
SVC112 1 2.81 0.30 1.99 16.31 15.26 13.96 13.34 9.27 7.35 10.21 8.13
CHOP081A 1 1.53 0.21 2.50 20.03 17.97 15.07 14.06 8.90 6.45 12.69 10.58
LB13_2 1 2.10 0.25 0.00 12.80 12.20 7.50 6.90 8.30 8.30 5.30 5.10
LB18_2 1 1.67 0.57 0.74 18.70 18.10 10.70 9.70 10.20 9.80 7.50 7.50
LB23_1 1 1.53 0.48 0.47 18.50 17.20 10.70 10.70 12.90 5.50 11.30 9.40
CHOP026A 2 2.08 0.38 1.50 19.98 18.73 13.80 11.76 9.38 4.47 9.25 7.75
CHOP016A 2 3.27 0.68 0.00 15.73 12.80 14.16 13.47 7.09 4.54 11.59 10.81
CHOP018A 2 2.63 0.77 0.00 17.72 16.71 12.28 11.66 11.60 8.72 10.09 8.60
CHOP024A 2 2.55 0.84 0.00 16.88 14.94 14.96 13.09 10.72 5.80 13.11 8.85
CHOP082A 2 2.44 0.64 0.03 19.86 19.05 15.68 14.92 14.96 10.41 11.83 11.79
CHOP088A 2 2.36 0.62 0.76 18.99 18.49 33.51 28.84 12.53 10.31 25.49 15.97
LB19_1 2 2.17 0.48 1.46 17.20 15.40 9.90 9.20 8.70 5.10 7.20 7.20
LB20_2 2 2.86 0.40 2.54 17.00 15.50 23.50 21.90 6.50 5.10 16.60 10.70
LB24_1 2 2.20 0.50 1.40 20.60 18.30 13.30 13.00 10.70 8.70 17.00 9.60
LB25_1 2 1.76 0.66 0.00 17.90 16.50 14.70 14.50 9.40 8.60 13.10 10.20
LB03_1 3 3.40 0.74 0.51 22.40 15.40 15.30 14.10 13.80 9.90 14.00 13.90
LB05_1 3 2.62 0.64 1.88 16.60 15.10 16.40 16.40 11.70 10.00 11.60 11.60
LB06_5 3 3.90 0.64 3.70 16.20 16.00 13.80 13.10 15.10 13.60 9.30 8.50
LB07_3 3 4.09 0.74 0.65 18.30 14.50 12.70 12.70 13.00 11.20 9.90 9.40
LB08_1 3 6.40 0.67 0.35 20.20 19.60 17.90 17.70 18.60 17.70 13.80 12.50
LB09_2 3 2.41 0.59 1.49 22.30 17.50 15.30 13.10 12.20 9.70 11.50 7.80
LB12_1 3 2.18 0.84 2.76 15.20 13.50 11.00 10.50 9.10 6.80 11.60 10.10
LB15_2 3 4.50 0.62 0.40 19.60 15.80 17.70 16.50 13.10 7.60 10.80 8.90
LB21_1 3 5.00 0.69 1.02 15.70 14.40 16.70 16.70 13.80 13.80 12.90 11.60
























SVC043 1 16 17 44 9 28
SVC059 1 11 13 41 25 34
SVC063 1 30 10 21 13 17
SVC075 1 34 39 53 23 34
SVC085 1 15 47 14 18 16
SVC112 1 12 9 37 37 37
CHOP081A 1 20 13 48 30 36
LB13_2 1 9 17 0 8 2
LB18_2 1 6 17 9 0 5
LB23_1 1 13 0 82 31 60
CHOP026A 2 12 27 77 30 54
CHOP016A 2 34 9 59 13 26
CHOP018A 2 11 10 43 27 37
CHOP024A 2 22 23 71 55 61
CHOP082A 2 8 9 52 1 32
CHOP088A 2 5 26 32 61 55
LB19_1 2 20 14 65 0 38
LB20_2 2 17 13 38 58 37
LB24_1 2 21 4 33 68 39
LB25_1 2 16 3 16 40 23
LB03_1 3 53 14 49 1 25
LB05_1 3 17 0 27 0 14
LB06_5 3 3 9 20 16 19
LB07_3 3 37 0 25 10 20
LB08_1 3 6 2 10 18 12
LB09_2 3 39 27 37 54 45
LB12_1 3 21 8 43 24 32
LB15_2 3 35 14 67 32 53
LB21_1 3 16 0 0 20 9
MRI1 3 18 25 38 32 36
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APPENDIX F – SPECIFIC AIM 2A CROSS-
SECTIONAL PATIENT DATA 
 
This appendix contains data for all patients included in the cross-sectional portion of Specific Aim 


































MRI1 CHOP_F1 17.34 2 12 2 2002 13 2 3
MRI3 CHOP_F3 20.28 1 9 1 2002 12 2 2
MRI4 CHOP_F4 19.13 1 13 1 1998 15 1 2
MRI5 CHOP_F5 20.00 1 5 2 2006 7 1 1
MRI6 CHOP_F6 22.93 2 22 2 1989 26 2 2
MRI7 CHOP_F7 9.36 1 10 3 2002 10 2 2
MRI11 CHOP_F11 36.55 2 14 1 1998 16 1 1
MRI12 CHOP_F12 18.52 2 18 2 1994 22 1 2
MRI14 CHOP_F14 14.04 2 24 2 1988 26 2 2
MRI15 CHOP_F15 18.22 2 17 3 1995 18 1 1
MRI16 CHOP_F16 14.28 2 15 2 1997 17 1 2
MRI17 CHOP_F17 20.14 1 16 1 1996 19 2 2
MRI18 CHOP_F18 49.43 2 17 2 1995 19 2 2
MRI19 CHOP_F19 12.65 1 17 1 1995 18 2 2
MRI20 CHOP_F20 14.92 2 14 3 1998 16 1 1
MRI22 CHOP_F22 22.32 1 20 2 1993 21 1 2
MRI25 CHOP_F25 19.74 2 15 3 1998 18 1 1
MRI27 CHOP_F27 12.09 2 9 2 2004 12 2 1
MRI28 CHOP_F28 12.59 2 11 2 2002 13 1 1
MRI29 CHOP_F29 13.51 1 18 1 1996 18 2 2
MRI31 CHOP_F31 18.25 1 10 1 2003 13 2 1
MRI32 CHOP_F32 22.62 1 18 2 1996 19 1 2
MRI33 CHOP_F33 17.14 2 19 2 1995 20 1 2
MRI34 CHOP_F34 25.69 2 7 2 2007 10 2 1
MRI35 CHOP_F35 18.97 2 15 1 1999 17 2 2
MRI36 CHOP_F36 36.24 2 18 2 1996 20 1 1
MRI39 CHOP_F39 37.78 1 10 2 2005 12 2 1
MRI41 CHOP_F41 32.88 1 11 1 2004 12 2 1
MRI42 CHOP_F42 20.00 1 9 1 2006 10 1 1
MRI44 CHOP_F44 16.38 2 11 3 2004 14 1 1
MRI45 CHOP_F45 26.35 1 12 1 2003 15 1 1
MRI46 CHOP_F46 19.05 1 21 1 1994 24 2 2


































MRI1 CHOP_F1 1.09 0.738 9.871 0.1218 549 129 23.56 1.80 1.020 0.753
MRI3 CHOP_F3 0.758 0.719 10.010 0.0963 455 186 40.92 2.20 0.881 0.633
MRI4 CHOP_F4 1.515 0.77 34.000 0.4853 416 214 51.47 8.17 1.039 0.800
MRI5 CHOP_F5 1 0.69 11.903 0.1380 702 234 33.31 1.70 1.067 0.736
MRI6 CHOP_F6 1.58 0.819 4.378 0.0605 613 413 67.42 0.71 1.126 0.922
MRI7 CHOP_F7 0.993 0.565 1.166 0.0387 344 122 35.38 0.34 1.021 0.577
MRI11 CHOP_F11 1.82 0.799 7.428 0.0820 1317 486 36.90 0.56 0.991 0.792
MRI12 CHOP_F12 1.88 0.734 7.767 0.0631 891 414 46.48 0.87 1.200 0.881
MRI14 CHOP_F14 1.59 0.923 6.070 0.1050 633 377 59.49 0.96 0.811 0.749
MRI15 CHOP_F15 1.9 0.828 6.052 0.0317 839 354 42.15 0.72 0.401 0.332
MRI16 CHOP_F16 1.6 0.835 5.260 0.0398 1049 467 44.50 0.50 0.820 0.685
MRI17 CHOP_F17 1.3 0.75 3.119 0.0398 595 277 46.57 0.52 0.920 0.690
MRI18 CHOP_F18 1.66 1 16.1 0.1129 762 351 46.08 2.11 0.181 0.181
MRI19 CHOP_F19 1.28 0.702 8.041 0.1263 593 325 54.80 1.36 1.036 0.727
MRI20 CHOP_F20 2 1.244 22.6 0.3637 253 313 123.56 8.93 0.391 0.486
MRI22 CHOP_F22 1.78 0.951 14.696 0.1106 783 444 56.65 1.88 0.839 0.798
MRI25 CHOP_F25 1.57 1.035 9.917 0.1267 889 500 56.20 1.12 1.010 1.045
MRI27 CHOP_F27 1.19 1.04 10.6 0.0778 456 201 44.15 2.32 0.479 0.498
MRI28 CHOP_F28 1.32 0.905 13.856 0.1147 608 174 28.69 2.28 0.741 0.671
MRI29 CHOP_F29 1.53 1.054 1.28 0.0763 497 224 45.14 0.26 1.058 1.115
MRI31 CHOP_F31 1.35 0.709 6.519 0.0739 531 212 39.99 1.23 0.948 0.672
MRI32 CHOP_F32 2 0.963 39.99 0.0637 1109 875 78.87 3.61 1.020 0.982
MRI33 CHOP_F33 1.92 0.923 5.293 0.0852 735 410 55.76 0.72 0.810 0.748
MRI34 CHOP_F34 1.06 0.687 0.854 0.0579 343 129 37.74 0.25 0.867 0.596
MRI35 CHOP_F35 1.66 0.706 12.559 0.1189 688 445 64.70 1.83 0.971 0.686
MRI36 CHOP_F36 1.856 0.901 7.310 0.0563 782 273 34.97 0.93 0.291 0.262
MRI39 CHOP_F39 1.434 0.803 5.278 0.1415 613 288 46.95 0.86 0.839 0.674
MRI41 CHOP_F41 1.39 0.6 19.900 0.1321 709 317 44.71 2.81 1.246 0.748
MRI42 CHOP_F42 1.369 0.937 49.477 0.3730 784 272 34.70 6.31 0.561 0.526
MRI44 CHOP_F44 1.877 0.772 16.8 0.0909 814 511 62.79 2.06 0.583 0.450
MRI45 CHOP_F45 1.3 1.11 5.100 0.0410 727 318 43.72 0.70 0.661 0.734
MRI46 CHOP_F46 1.99 0.632 6.63 0.0722 1.031 0.651































MRI1 CHOP_F1 16 16 16 16 67 67 101 8
MRI3 CHOP_F3 14 14 14 14 87 52 70 87 9
MRI4 CHOP_F4 12 12 11 11 80 59 69 80 6
MRI5 CHOP_F5 15 15 13 15 85 50 65 85 9
MRI6 CHOP_F6 14 12 12 12 105 65 80 105 7
MRI7 CHOP_F7 15 15 15 15 82 62 70 84 10
MRI11 CHOP_F11 13 13 13 11 121 50 80 120 9
MRI12 CHOP_F12 12 11 12 12 100 66 80 114 9
MRI14 CHOP_F14 9 9 9 9 105 60 78 104 10
MRI15 CHOP_F15 6 6 6 6 80 53 63 84 7
MRI16 CHOP_F16 13 13 13 9 95 50 65 95 8
MRI17 CHOP_F17 12 12 12 12 85 55 65 85 12
MRI18 CHOP_F18 9 8 7 8 100 60 70 100 4
MRI19 CHOP_F19 12 12 12 12 83 57 69 114 7
MRI20 CHOP_F20 14 14 14 13 94 60 73 100 9
MRI22 CHOP_F22 15 14 14 14 95 55 70 93 10
MRI25 CHOP_F25 16 16 15 15 125 80 95 130 12
MRI27 CHOP_F27 12 12 10 12 85 50 60 85 8
MRI28 CHOP_F28 10 10 10 10 75 50 60 82 7
MRI29 CHOP_F29 11 11 11 85 50 70 88 9
MRI31 CHOP_F31 14 13 13 12 70 44 55 75 9
MRI32 CHOP_F32 10 10 10 10 95 60 72 100 4
MRI33 CHOP_F33 12 12 12 12 110 70 85 110 10
MRI34 CHOP_F34 12 12 12 12 85 54 68 89 11
MRI35 CHOP_F35 8 8 8 8 92 57 70 90 6
MRI36 CHOP_F36 11 11 10 11 90 45 62 100 7
MRI39 CHOP_F39 10 11 10 10 81 55 67 85 7
MRI41 CHOP_F41 9 9 8 9 88 56 70 97 5
MRI42 CHOP_F42 13 13 12 13 91 57 70 92 6
MRI44 CHOP_F44 15 15 17 15 106 70 83 106 12
MRI45 CHOP_F45 15 15 14 14 95 51 67 95 14
MRI46 CHOP_F46 15 15 14 15











































MRI1 CHOP_F1 0.611 1.647 1.64 17.44 1.50 16.00 19.69 18.06 0.37 0.04 0.03
MRI3 CHOP_F3 0.852 1.958 1.36 13.80 1.80 18.20 16.01 21.12 0.62 0.06 0.06
MRI4 CHOP_F4 1.494 4.781 1.06 27.27 0.70 18.00 29.82 19.69 1.41 0.05 0.05
MRI5 CHOP_F5 0.792 2.060 1.05 20.90 1.05 20.90 22.74 22.74 0.75 0.04 0.04
MRI6 CHOP_F6 0.178 0.592 2.37 33.02 1.50 20.90 35.57 22.51 0.08 0.01 0.01
MRI7 CHOP_F7 0.158 0.288 2.88 34.26 2.90 34.50 37.30 37.56 0.05 0.00 0.00
MRI11 CHOP_F11 0.215 0.848 1.46 44.41 0.80 24.40 46.08 25.32 0.15 0.00 0.00
MRI12 CHOP_F12 0.176 0.784 1.88 41.36 1.00 22.00 43.42 23.09 0.09 0.00 0.00
MRI14 CHOP_F14 0.284 0.881 1.50 40.70 0.94 25.60 42.49 26.72 0.19 0.01 0.01
MRI15 CHOP_F15 0.101 0.524 1.03 29.22 0.54 15.38 30.35 15.97 0.10 0.00 0.00
MRI16 CHOP_F16 0.141 0.577 1.92 24.80 1.20 15.50 26.86 16.79 0.07 0.01 0.01
MRI17 CHOP_F17 0.156 0.468 2.47 16.90 1.90 13.00 19.53 15.02 0.06 0.01 0.01
MRI18 CHOP_F18 0.390 1.681 2.54 33.20 1.53 20.00 36.13 21.76 0.15 0.01 0.01
MRI19 CHOP_F19 0.472 1.306 2.94 24.32 2.30 19.00 27.74 21.67 0.16 0.02 0.02
MRI20 CHOP_F20 0.743 2.749 3.40 23.50 1.70 11.75 27.64 13.82 0.22 0.03 0.03
MRI22 CHOP_F22 0.340 1.500 2.85 17.91 1.60 10.06 21.10 11.85 0.12 0.02 0.02
MRI25 CHOP_F25 0.386 1.313 2.04 52.91 1.30 33.70 55.34 35.25 0.19 0.01 0.01
MRI27 CHOP_F27 0.413 1.403 3.42 20.87 2.87 17.54 24.70 20.76 0.12 0.02 0.02
MRI28 CHOP_F28 0.509 1.781 2.11 20.57 1.60 15.58 23.19 17.57 0.24 0.02 0.02
MRI29 CHOP_F29 0.144 0.288 0.57 38.25 0.37 25.00 38.96 25.47 0.25 0.00 0.00
MRI31 CHOP_F31 0.286 0.917 1.35 18.90 1.00 14.00 20.54 15.21 0.21 0.02 0.01
MRI32 CHOP_F32 0.281 2.249 2.00 30.00 1.00 15.00 32.28 16.14 0.14 0.01 0.01
MRI33 CHOP_F33 0.184 0.662 1.73 57.60 0.90 30.00 59.51 31.00 0.11 0.00 0.00
MRI34 CHOP_F34 0.171 0.256 0.64 51.33 0.60 48.42 52.14 49.19 0.27 0.00 0.00
MRI35 CHOP_F35 0.372 1.449 2.49 38.18 1.50 23.00 41.04 24.72 0.15 0.01 0.01
MRI36 CHOP_F36 0.162 0.731 3.16 20.00 1.70 10.78 23.32 12.56 0.05 0.01 0.01
MRI39 CHOP_F39 0.380 0.950 2.01 34.42 1.40 24.00 36.80 25.67 0.19 0.01 0.01
MRI41 CHOP_F41 0.589 2.296 1.67 22.24 1.20 16.00 24.50 17.62 0.35 0.03 0.02
MRI42 CHOP_F42 1.626 6.017 1.51 22.70 1.10 16.58 25.83 18.87 1.08 0.07 0.07
MRI44 CHOP_F44 0.291 1.482 3.38 67.57 1.80 36.00 71.24 37.95 0.09 0.00 0.00
MRI45 CHOP_F45 0.187 0.656 1.17 22.10 0.90 17.00 23.46 18.04 0.16 0.01 0.01
MRI46 CHOP_F46 0.169 0.710 4.48 2.25 4.65 2.33 0.04 #DIV/0! 0.04






























MRI1 CHOP_F1 3.6 3.30 2.70 3.50 1.30 1.38 1.10 0.90 0.90 1.60 2.00 1.50
MRI3 CHOP_F3 3.42 4.51 2.30 2.45 0.80 1.43 1.15 1.15 0.65 1.09 1.19 1.26
MRI4 CHOP_F4 3.45 2.28 3.20 3.50 1.10 1.76 2.07 1.45 1.21 1.69 1.99 1.49
MRI5 CHOP_F5 5.4 5.40 2.60 5.40 1.90 1.90 1.20 1.70 0.63 2.40 3.10 2.30
MRI6 CHOP_F6 3.89 2.46 3.33 4.14 1.24 2.74 2.34 0.99 1.28 2.16 2.27 1.87
MRI7 CHOP_F7 2.66 2.68 1.82 2.05 1.12 1.02 1.10 0.72 0.32 0.70 1.14 0.82
MRI11 CHOP_F11 7.29 4.01 3.94 5.96 1.50 3.20 2.83 1.11 1.92 1.32 3.26 2.70
MRI12 CHOP_F12 5.18 2.76 4.46 5.18 1.16 2.73 2.63 1.13 1.72 2.83 2.82 2.36
MRI14 CHOP_F14 4 2.52 3.10 4.00 1.30 2.44 2.27 0.81 1.73 1.21 1.93 2.05
MRI15 CHOP_F15 6.6 3.47 5.20 5.00 0.96 2.80 2.81 2.30 2.10 2.20 2.50 2.50
MRI16 CHOP_F16 7.3 4.56 4.10 5.70 1.20 3.80 2.80 1.30 1.30 3.20 3.40 2.30
MRI17 CHOP_F17 4.5 3.46 3.00 3.30 1.10 2.20 1.50 0.79 1.00 1.10 1.70 1.60
MRI18 CHOP_F18 5.15 3.10 4.31 4.72 1.10 2.63 2.72 0.64 1.92 1.90 2.39 2.33
MRI19 CHOP_F19 3.48 2.72 2.77 2.78 1.00 2.45 1.87 0.90 0.99 1.44 1.64 1.14
MRI20 CHOP_F20 1.67 0.84 3.70 4.42 1.19 2.35 2.18 1.52 2.13 1.48 2.27 2.15
MRI22 CHOP_F22 5.5 3.09 4.41 4.91 1.10 3.48 2.90 1.51 1.41 3.23 3.14 1.77
MRI25 CHOP_F25 4.5 2.87 3.40 4.70 1.40 2.77 2.36 1.00 1.83 1.64 2.28 2.45
MRI27 CHOP_F27 3.53 2.97 3.40 3.50 1.03 1.87 0.74 0.43 2.00 1.20 1.22 2.30
MRI28 CHOP_F28 4.9 3.71 3.50 4.90 1.40 1.60 1.73 1.74 1.68 1.80 2.54 2.40
MRI29 CHOP_F29 3.7 2.42 2.00 3.50 1.80 1.65 1.30 0.71 2.00 2.30 2.40
MRI31 CHOP_F31 4.6 3.41 3.20 4.10 1.30 2.20 1.80 1.20 1.10 1.60 2.10 2.00
MRI32 CHOP_F32 7.5 3.75 8.00 7.00 0.88 6.20 5.18 1.50 2.80 4.20 4.00 3.00
MRI33 CHOP_F33 4.4 2.29 3.60 4.80 1.33 2.50 2.30 1.20 1.50 2.60 2.46 2.20
MRI34 CHOP_F34 2.5 2.36 1.50 3.10 2.10 1.00 0.80 0.71 0.90 1.20 1.50 1.60
MRI35 CHOP_F35 5.1 3.07 3.90 4.90 1.26 3.20 2.90 1.00 1.10 1.90 3.00 1.90
MRI36 CHOP_F36 5.2 2.80 4.50 5.70 1.33 2.54 3.10 0.40 1.60 2.70 3.40 2.30
MRI39 CHOP_F39 4.77 3.33 2.50 2.50 1.00 2.32 2.56 1.54 1.79 1.91 DNE DNE
MRI41 CHOP_F41 4.91 3.53 3.90 2.90 0.74 2.30 2.00 1.28 1.00 1.26 DNE DNE
MRI42 CHOP_F42 5.69 4.16 3.70 3.70 1.00 2.29 2.89 2.49 1.34 1.48 DNE DNE
MRI44 CHOP_F44 5 2.66 5.10 5.10 1.00 3.23 0.74 0.90 1.70 2.67 3.30 1.80
MRI45 CHOP_F45 4.9 3.77 3.50 4.20 1.20 2.70 2.50 1.00 1.00 1.80 2.54 1.50
MRI46 CHOP_F46 6.4 3.22 4.20 6.60 1.57 2.90 2.70 1.50 1.70 2.30 3.50 3.10





























MRI1 CHOP_F1 n/a n/a n/a 143.0 131.0 62.0 57.0 81.0 74.3 57.0
MRI3 CHOP_F3 0.83 82.70 2.22 94.9 125.3 43.8 57.8 51.1 67.4 53.8
MRI4 CHOP_F4 0.36 35.80 2.81 110.5 73.0 45.3 30.0 65.2 43.0 59.0
MRI5 CHOP_F5 0.57 56.58 1.69 102.0 102.0 40.0 40.0 62.0 62.0 61.0
MRI6 CHOP_F6 0.23 22.68 3.02 103.8 65.8 42.0 26.6 61.9 39.2 59.6
MRI7 CHOP_F7 0.32 32.41 1.34 123.4 124.3 76.2 76.8 47.2 47.5 38.0
MRI11 CHOP_F11 0.36 35.89 3.36 138.0 76.0 44.0 24.0 94.0 51.6 68.0
MRI12 CHOP_F12 0.35 34.50 4.26 116.4 61.9 51.1 27.2 65.3 34.7 56.1
MRI14 CHOP_F14 0.29 28.76 2.89 72.4 45.0 10.9 7.0 61.5 38.7 85.0
MRI15 CHOP_F15 0.38 38.04 3.69 180.0 94.7 90.0 47.4 90.0 47.4 50.0
MRI16 CHOP_F16 0.25 24.83 3.70 195.0 121.9 90.0 56.3 105.0 65.6 54.0
MRI17 CHOP_F17 0.63 62.57 3.14 121.0 93.1 59.0 45.4 62.0 47.7 51.0
MRI18 CHOP_F18 0.29 29.37 3.69 118.5 71.5 30.6 18.4 87.9 53.0 74.2
MRI19 CHOP_F19 0.29 29.43 2.82 218.5 171.2 159.3 124.8 59.2 46.3 27.1
MRI20 CHOP_F20 1.62 162.00 4.53 217.4 107.9 107.7 53.5 109.7 54.9 50.5
MRI22 CHOP_F22 0.31 31.42 3.91 323.0 181.0 218.0 122.0 105.0 59.0 33.0
MRI25 CHOP_F25 0.63 62.79 4.00 163.7 104.1 71.6 45.5 92.1 58.7 56.0
MRI27 CHOP_F27 1.29 129.29 1.70 122.0 102.6 43.3 36.4 78.7 66.1 64.5
MRI28 CHOP_F28 0.34 34.06 2.66 178.0 135.9 72.3 54.8 105.9 80.2 59.0
MRI29 CHOP_F29 0.45 44.62 1.97 119.0 77.6 44.1 28.7 75.0 49.0 63.0
MRI31 CHOP_F31 0.33 32.86 2.77 143.5 106.1 65.8 48.7 77.7 57.6 54.1
MRI32 CHOP_F32 0.25 25.17 6.22 253.0 126.7 80.1 40.1 173.0 86.5 68.4
MRI33 CHOP_F33 0.80 79.82 4.01 229.2 120.0 85.0 44.3 144.2 75.1 62.9
MRI34 CHOP_F34 1.18 117.68 1.94 138.5 130.6 62.0 58.4 76.5 72.2 5.3
MRI35 CHOP_F35 1.06 105.84 5.61 136.9 82.7 64.5 38.7 72.4 43.6 52.9
MRI36 CHOP_F36 0.24 24.27 4.52 301.0 162.0 190.0 102.0 111.0 59.8 36.0
MRI39 CHOP_F39 0.42 42.03 3.16
MRI41 CHOP_F41 0.19 18.97 2.45
MRI42 CHOP_F42 0.50 50.12 4.43
MRI44 CHOP_F44 1.04 104.13 1.40 141.0 73.0 72.0 37.0 68.0 36.2 49.0
MRI45 CHOP_F45 0.36 36.43 2.94 159.1 123.7 65.9 51.3 93.1 71.6 58.5
MRI46 CHOP_F46 0.67 67.14 4.06 183.6 92.3 96.7 48.6 87.0 43.7 47.4















































MRI1 CHOP_F1 10.234 11.294 12.454 8.0679 9.3338 10.387 8.2107 10.433 11.005 7.0476 8.5579 11.195
MRI3 CHOP_F3 10.526 16.197 20.767 10.569 11.557 12.616 3.5359 6.1029 12.983 7.1311 8.8451 13.051
MRI4 CHOP_F4 16.75 22.323 28.198 10.804 16.086 21.228 6.16 9.6431 20.15 6.4634 11.159 24.659
MRI5 CHOP_F5 13.957 15.388 20.336 13.515 14.226 14.801 2.7327 6.9594 14.757 9.8677 11.237 16.059
MRI6 CHOP_F6 12.093 17.639 28.101 12.67 14.382 15.921 9.7491 11.507 15.874 10.379 11.2 12.71
MRI7 CHOP_F7 14.626 15.811 17.329 14.012 16.938 18.378 7.4159 9.0659 14.359 7.6309 10.357 17.176
MRI11 CHOP_F11 13.636 16.293 25.111 11.434 12.072 13.222 9.3518 11.93 16.336 6.1145 8.6935 10.728
MRI12 CHOP_F12 18.085 23.056 29.664 9.7089 12.874 17.992 8.4707 12.45 19.819 10.978 12.142 17.353
MRI14 CHOP_F14 12.484 19.016 24.123 9.5095 12.872 16.311 10.262 12.347 19.531 6.9181 10.275 17.167
MRI15 CHOP_F15 17.816 21.241 24.958 17.045 18.06 20.837 13.63 15.656 21.3 10.412 12.778 21.816
MRI16 CHOP_F16 17.119 21.564 25.719 11.062 15.827 21.714 6.832 10.765 21.007 10.634 13.547 22.034
MRI17 CHOP_F17 16.092 20.19 26.029 10.336 11.578 14.546 7.3168 9.9328 16.02 8.9745 8.9754 8.9764
MRI18 CHOP_F18 9.7259 12.299 17.612 7.8906 10.199 13.131 7.9052 10.257 17.986 9.708 10.865 13.672
MRI19 CHOP_F19 11.078 15.29 18.293 13.997 16.06 19.045 5.3736 9.3465 19.197 6.796 9.0922 16.531
MRI20 CHOP_F20 11.863 16.2 23.49 14.137 17.22 20.243 10.103 13.916 19.679 9.4821 10.654 15.712
MRI22 CHOP_F22 15.991 19.915 24.981 14.683 17.71 20.751 5.2454 11.304 19.567 9.108 12.86 21.353
MRI25 CHOP_F25 12.99 15.966 19.779 12.654 13.377 13.952 7.6445 10.216 14.711 7.8838 9.3486 13.388
MRI27 CHOP_F27 8.3227 9.2007 10.247 6.886 7.9817 10.38 7.1152 10.081 14.016 6.1329 6.9318 9.0883
MRI28 CHOP_F28 11.108 12.266 14.822 13.215 13.432 13.589 6.6371 9.2507 13.578 7.9534 9.1815 11.204
MRI29 CHOP_F29 16.464 21.339 25.972 11.17 14.76 21.103 6.2404 11.596 23.682 9.7603 12.298 21.528
MRI31 CHOP_F31 12.749 15.502 22.106 13.989 14.627 14.984 7.6389 9.0512 14.208 7.1974 8.6964 14.477
MRI32 CHOP_F32 18.073 21.138 28.438 12.933 15.518 19.602 9.482 13.393 21.423 9.062 12.725 20.82
MRI33 CHOP_F33 13.828 20.352 26.401 13.233 17.364 23.423 11.01 16.167 26.261 11.738 14.364 22.412
MRI34 CHOP_F34 9.5052 13.376 18.628 9.1758 12.147 14.961 8.5203 9.7862 13.649 14.409 14.999 16.455
MRI35 CHOP_F35 20.954 23.399 29.409 9.646 13.47 18.87 4.7253 11.425 19.011 7.4309 10.204 20.216
MRI36 CHOP_F36 12.308 14.105 16.456 9.02 10.862 15.095 6.4009 8.8266 12.653 10.224 11.91 15.081
MRI39 CHOP_F39 14.724 16.299 21.933 10.704 11.922 14.219 8.3787 11.638 14.668 11.042 12.63 14.116
MRI41 CHOP_F41 12.303 14.533 21.728 9.1237 10.575 12.45 3.9056 7.5102 13.835 6.4391 8.2256 13.072
MRI42 CHOP_F42 12.851 13.534 14.639 13.108 14.876 17.1 5.2656 10.517 15.683 10.036 12.807 18.23
MRI44 CHOP_F44 10.521 12.089 12.866 9.9523 13.177 16.056 9.2595 10.453 12.188 6.5432 7.3948 11.284
MRI45 CHOP_F45 11.373 14.04 16.82 9.1784 13.763 16.929 5.2331 9.5578 16.758 9.4899 11.396 16.127
MRI46 CHOP_F46 19.018 23.377 28.313 12.984 14.501 17.108 9.699 12.087 19.253 13.223 15.28 20.28





























flow (% of 
AO)
MRI1 CHOP_F1 17.8902 25.2856 38.0642 32.1815 35.6981 1.23 1.009951154 0.8 24.9
MRI3 CHOP_F3 57.7665 16.367 66.4318 35.0009 45.1381 2.54 0.00291 1.072732118 0.915 27
MRI4 CHOP_F4 43.6979 54.89 59.1936 66.4516 63.3487 6 0.01279 3.378125303 0.45 13.5
MRI5 CHOP_F5 17.7341 9.74599 84.5816 22.8864 39.9902 3.7 0.0081 3.043837938 2.45 47
MRI6 CHOP_F6 52.9976 22.3905 28.2198 14.1234 21.3621 6.98 0.01614 3.280768662 0.6305 16.5
MRI7 CHOP_F7 14.4278 31.5654 33.0877 45.7145 40.2368 3.04 0.0069 2.601393462 1.194 31.5
MRI11 CHOP_F11 29.9558 10.2906 38.5517 50.5311 42.7066 6.4 0.01218 4.482825607 2.995 41.5
MRI12 CHOP_F12 38.4725 43.1261 53.7086 18.2541 36.4253 10.36 0.02518 6.374246507 0.68 13
MRI14 CHOP_F14 56.9008 45.4213 30.9218 54.6675 40.6378 4.6 0.00733 1.98256308 1.03 26
MRI15 CHOP_F15 29.649 10.9244 24.2068 33.6039 27.9639 6.23 0.01051 4.382869471 1.05 17.5
MRI16 CHOP_F16 36.9771 51.1494 59.722 38.3821 46.6417 5.17 0.00722 3.258282086 2.2 30
MRI17 CHOP_F17 36.4746 20.3037 45.7376 0.02005 25.1878 5.04 0.00809 3.201680172 1.25 27.5
MRI18 CHOP_F18 37.4655 40.1444 40.6002 20.1638 29.7942 1.12 0.00034 0.700386908 0.841 16.3
MRI19 CHOP_F19 47.5062 24.0411 66.9453 44.1313 55.8529 2.61 0.00241 1.370087355 0.53 15.17
MRI20 CHOP_F20 46.376 32.6018 47.2926 20.7893 37.4987 5.56 0.00682 2.981493201 0.69 41.32
MRI22 CHOP_F22 35.5251 31.2627 78.4676 49.8392 62.3175 7.21 0.01329 4.648639732 0.46 8.27
MRI25 CHOP_F25 33.8049 10.5175 44.0067 28.8822 37.1137 3.92 0.00384 2.594849173 1.20 26.73
MRI27 CHOP_F27 18.1749 25.5708 50.1842 21.722 41.0471 1.27 0.00095 1.039179238 0.10 2.83
MRI28 CHOP_F28 17.9902 3.20499 48.5237 24.9625 36.8315 3.61 0.00489 2.960554248 1.45 29.49
MRI29 CHOP_F29 40.4718 42.7291 71.0393 37.0121 53.0269 5.46 0.01513 3.250238503 1.60 43.11
MRI31 CHOP_F31 32.3642 8.53334 28.7722 31.5029 30.083 5.61 0.01137 3.794369655 1.50 32.61
MRI32 CHOP_F32 26.8974 30.5412 49.8762 49.2855 49.5959 7.02 0.00792 5.131801179 0.00 0.00
MRI33 CHOP_F33 53.8359 41.9213 53.6216 33.2214 44.622 6.83 0.01162 3.153009342 0.80 12.50
MRI34 CHOP_F34 49.5025 42.9376 24.1978 7.71246 12.6348 3.17 0.00518 1.600771195 1.00 39.80
MRI35 CHOP_F35 19.8065 48.7187 82.8941 46.9675 66.9525 10.15 0.01835 8.139642422 1.20 23.53
MRI36 CHOP_F36 23.8572 31.0406 47.411 26.3084 33.7897 2.51 0.00139 1.911184065 1.05 20.19
MRI39 CHOP_F39 18.3926 19.3891 48.1682 23.5656 34.8629 5.87 0.01092 4.790356107 0.67 14.05
MRI41 CHOP_F41 28.3343 25.5643 72.9559 38.7205 54.285 4.79 0.00935 3.432788245 1.63 33.20
MRI42 CHOP_F42 9.83842 22.3573 74.9324 38.5918 53.2282 1.94 0.00085 1.749134608 0.31 5.45
MRI44 CHOP_F44 24.2586 42.9555 21.5319 21.7062 21.59 1.31 0.00122 0.992212243 0.00 0.00
MRI45 CHOP_F45 34.3831 55.5258 70.022 30.6545 46.9111 3.76 0.00481 2.467196315 1.32 26.94
MRI46 CHOP_F46 33.8161 19.8283 35.6102 25.1118 29.1526 7.96 0.0156 5.268235739 2.55 39.84
MRI47 CHOP_F47 37.2697 12.6199 60.0829 45.2698 50.7149 4.52 0.007 2.83541049 0.90 20.93
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APPENDIX G – SPECIFIC AIM 2A SERIAL STUDY 
PATIENT DATA 
 
This appendix contains data for all patients included in the longitudinal portion of Specific Aim 
2A. This includes 21 unique patients. Of these 21, six have multiple CMR data sets. The scans are 
numbered chronologically such as “LB06_1” and “LB06_2.” This indicates that patient “LB06” 
had two scans. The earliest CMR scan was used to investigate correlations between flow rates, 
ventricular function and other metrics with collagen deposition.   
In addition, 11 patients overlapped between the two studies in Specific Aim 1A. This allowed an 
investigation of how fluid mechanics and anatomic metrics changed from a time point ~ 7 years 





















































LB03_1 22.9 2 1 20 41177 38589 7.09 27.09 32735
LB04_1 19 2 1 11 41010 39338 4.58 15.58 35908
LB05_1 41.8 2 1 14 40722 38567 5.9 19.9 34087
LB06_1 36.6 1 2 10 41184 38433 7.54 17.54 35817
LB06_2 36.6 1 2 11 41184 38755 6.65 17.65 35818
LB06_3 36.6 1 2 12 41184 39415 4.85 16.85 35819
LB06_4 36.6 1 2 13 41184 40056 3.09 16.09 35820
LB06_5 36.6 1 2 14 41184 40435 2.05 16.05 35821
LB07_2 14 2 2 23 41225 40305 2.52 25.52 35916
LB07_3 14 2 2 24 41225 40655 1.56 25.56 36281
LB08_1 18.2 1 2 16 41229 40672 1.53 17.53 34984
LB09_2 20.1 2 1 15 41246 39464 4.88 19.88 35172
LB10_1 49 2 2 9 41262 37873 9.28 18.28 34950
LB12_1 34.6 2 1 17 41415 40779 1.74 18.74 34821
LB13_2 12.1 2 2 3 41477 38282 8.75 11.75 38279
LB15_1 8.7 2 1 11 41604 37845 10.3 21.3 34339
LB15_2 8.7 2 1 15 41604 39259 6.42 21.42 34340
LB16_1 22.6 1 2 9 41649 37802 10.54 19.54 35241
LB17_2 46 2 1 22 42093 39469 7.19 29.19 31856
LB17_4 46 2 1 26 42093 41106 2.7 28.7 31857
LB18_2 37.8 2 1 3 42144 38666 9.53 12.53 38470
LB19_1 32.9 2 1 6 42184 39660 6.92 12.92 38072
LB20_2 20 1 1 7 42181 40868 3.6 10.6 38966
LB21_1 14.4 1 2 15 42429 40602 5.01 20.01 35816
LB21_2 14.4 1 2 17 42429 41502 2.54 19.54 35817
LB22_1 30 1 1 12 42514 39476 8.32 20.32 35922
LB23_1 22 2 1 5 42545 38470 11.16 16.16 37686
LB24_1 7 1 1 9 42548 40764 4.89 13.89 38630
LB25_1 22 1 1 6 42681 39119 9.76 15.76 37711



























LB03_1 16.04 23.13 1.53 1.62748 0.01985 0.06356 0.21575 3.90 2.55
LB04_1 9.4 13.98 0.98 3.18452 0.1068 0.44212 0.79597 1.90 1.94
LB05_1 12.27 18.18 1.29 5.2286 0.03858 0.18339 0.65688 4.50 3.49
LB06_1 7.17 14.7 1.21 3.57222 0.03142 0.15342 0.49662 - -
LB06_2 8.05 14.7 1.1 13.2176 0.09531 0.56461 1.83255 6.00 5.45
LB06_3 9.85 14.7 0.88 8.53003 0.03582 0.34214 1.14599 5.80 6.59
LB06_4 11.61 14.7 1.41 21.7465 0.10603 0.51393 2.24261 7.10 5.04
LB06_5 12.64 14.69 1.6 5.2695 0.05476 0.17426 0.64283 7.60 4.75
LB07_2 12.02 14.55 1.48 1.32243 0.02409 0.07055 0.20489 4.10 2.77
LB07_3 11.98 13.55 1.57 6.91411 0.05709 0.20115 0.7911 4.74 3.02
LB08_1 15.58 17.11 1.96 7.03389 0.02384 0.08408 0.51588 6.75 3.44
LB09_2 11.76 16.64 1.02 2.08092 0.03167 0.16174 0.38917 3.90 3.82
LB10_1 8.01 17.29 1.1 2.30405 0.03206 0.15256 0.39771 3.05 2.77
LB12_1 16.32 18.07 1.48 2.58194 0.11048 0.24337 0.53176 4.94 3.34
LB13_2 0.01 8.76 0.62 3.40141 0.03104 0.36514 0.74759 2.10 3.39
LB15_1 9.61 19.9 1.23 5.39196 0.06904 0.291 0.84028 5.30 4.31
LB15_2 13.48 19.9 1.63 7.87366 0.06475 0.21732 0.8775 4.90 3.01
LB16_1 7.02 17.56 1.04 0.9874 0.02209 0.0967 0.20728 3.70 3.56
LB17_2 20.86 28.05 1.4 8.46206 0.06214 0.26526 1.00503 4.60 3.29
LB17_4 25.34 28.04 1.44 10.3019 0.07131 0.29902 1.17738 4.60 3.19
LB18_2 0.54 10.07 0.58 1.04476 0.01552 0.16959 0.28237 2.40 4.14
LB19_1 4.35 11.27 0.8 1.40089 0.04032 0.23022 0.38096 3.63 4.53
LB20_2 5.21 8.81 1 4.45902 0.03738 0.23913 0.69269 5.39 5.39
LB21_1 13.11 18.12 1.68 9.05774 0.03567 0.14698 0.77401 6.02 3.58
LB21_2 15.58 18.12 1.9 7.19642 0.0455 0.13588 0.66334 5.80 3.05
LB22_1 9.74 18.06 1.1 1.24286 0.02064 0.09257 0.22754 3.60 3.27
LB23_1 2.15 13.31 0.66 1.11194 0.0278 0.21498 0.32798 2.00 3.03
LB24_1 5.85 10.73 1 1.53286 0.0264 0.13286 0.30273 3.60 3.60
LB25_1 3.86 13.62 0.63 1.06267 0.00973 0.11194 0.23136 1.76 2.79
























LB03_1 2.52 65 74 0.878 1.43 1.785 0.44479 0.505 19
LB04_1 1.20 63 60 0.8 0.9 1.1 0.45 0 146
LB05_1 1.68 37 64 0.939 1.4 2.2 0.38889 1.88 89
LB06_1 1.83 - 57 1.403 1.217 2.019 0.37608 11
LB06_2 2.00 33 61 1.3 1.5 1 0.6 2.7 28
LB06_3 1.90 33 58 1.4 1.5 0.8 0.65217 2.5 15
LB06_4 2.70 38 68 1.3 1.7 1.4 0.54839 3.1 14
LB06_5 2.50 33 64 1.4 1.7 1.3 0.56667 3.7 27
LB07_2 2.00 49 71 0.83 1.5 1.1 0.57692 1.27 17
LB07_3 3.04 64 74 1.05 1.83 1.78 0.50693 0.65 21
LB08_1 4.30 64 67 2.1 3.09 3.29 0.48433 0.35 31
LB09_2 1.43 37 59 0.981 1.088 0.745 0.59356 1.493 64
LB10_1 1.48 48 72 0.57 1.39 0.6 0.69849 0.442 10
LB12_1 1.84 37 84 0.34 0.6976 1.4824 0.32 2.757 15
LB13_2 0.53 25 41 0.75 1.701 0.399 0.81 0 93
LB15_1 2.01 38 70 0.878 0.856 1.497 0.36379 2.412 8
LB15_2 2.77 57 62 1.7 1.4 3.4 0.29167 0.4 13
LB16_1 1.29 35 60 0.858 1.058 0.809 0.56668 1.557 43
LB17_2 3.10 67 82 0.7 1.2 1.5 0.44444 0.8 130
LB17_4 3.10 67 82 0.7 1.3 1.5 0.46429 0.8 134
LB18_2 0.94 39 57 0.724 0.755 0.644 0.53967 0.735 51
LB19_1 1.05 29 60 0.689 0.531 0.906 0.36952 1.456 110
LB20_2 1.16 21 40 1.7 0.63 2.4 0.20792 2.536 44
LB21_1 3.46 57 79 0.933 2.79 2.47 0.53042 1.017 8
LB21_2 4.00 69 80 1 2.9 2.1 0.58 0.65 15
LB22_1 1.76 49 71 0.71 0.897 1.019 0.46816 1.135 31
LB23_1 0.74 37 48 0.791 0.583 0.918 0.38841 0.474 62
LB24_1 1.10 31 50 1.1 1 1.1 0.47619 1.4 89
LB25_1 1.17 66 57 0.894 0.612 0.666 0.47887 0 19
































LB03_1 22.4 15.4 15.3 14.1 13.8 9.9
LB04_1 62 97 37 60 16.4 15.3 21.4 21.2 9.2 7.9
LB05_1 60 139 56 84 16.6 15.1 16.4 16.4 11.7 10
LB06_1 16.9 16.2 13.1 13.1 13.9 10.9
LB06_2 53 104 50 55 16.3 15.6 13.6 13.4 12.8 7.3
LB06_3 66.2 86.8 29.3 57.4 17.5 15.5 12.9 12.8 12.3 8.4
LB06_4 59 114 47 67 16.6 15.6 12.4 12.3 11.8 6.6
LB06_5 64 123 44 79 16.2 16 13.8 13.1 15.1 13.6
LB07_2 72 89 25 64 18.1 14.2 12.8 12.8 15.6 15.4
LB07_3 71.7 110.4 31.2 79.2 18.3 14.5 12.7 12.7 13 11.2
LB08_1 62.5 127.3 47.7 79.5 20.2 19.6 17.9 17.7 18.6 17.7
LB09_2 46 22.3 17.5 15.3 13.1 12.2 9.7
LB10_1 14.6 12.8 10.7 9.5 8.8 8.8
LB12_1 15.2 13.5 11 10.5 9.1 6.8
LB13_2 56 42.7 18.7 24 12.8 12.2 7.5 6.9 8.3 8.3
LB15_1 17.5 15.1 13.6 13.3 12.5 4.5
LB15_2 61 128 50 78 19.6 15.8 17.7 16.5 13.1 7.6
LB16_1 19.8 16.7 12.5 12.5 11.7 9.4
LB17_2 59
LB17_4 74 77.2 20 57.3
LB18_2 24 18.7 18.1 10.7 9.7 10.2 9.8
LB19_1 56 46 20 26 17.2 15.4 9.9 9.2 8.7 5.1
LB20_2 17 15.5 23.5 21.9 6.5 5.1
LB21_1 70 71.6 21.4 50.2 15.7 14.4 16.7 16.7 13.8 13.8
LB21_2 58 144.9 60.8 84.1 18 16.1 22.7 22.3 13.1 12.4
LB22_1 64 26 22.2 19.6 13.3 9.9 7.4
LB23_1 24 18.5 17.2 10.7 10.7 12.9 5.5
LB24_1 57 80.3 35 45.3 20.6 18.3 13.3 13 10.7 8.7
LB25_1 17.9 16.5 14.7 14.5 9.4 8.6































LB03_1 14 13.9 53 14.3 49.1 0.9 24.78 1.86
LB04_1 13.7 5.5 13.5 1.3 25.6 83.7 65.7 1.83
LB05_1 11.6 11.6 17.1 0 27.2 0 13.71 1.79
LB06_1 7 7 7.5 0.9 38.2 0 30.43 2.07
LB06_2 5.8 5.2 7.5 2 67.5 17.3 59.02 1.92
LB06_3 5.1 4.7 21.6 1.9 52.7 17.6 47.45 1.89
LB06_4 7 6.5 11.3 2.3 69.2 14.3 55.07 1.91
LB06_5 9.3 8.5 2.5 9.4 19.9 16.2 18.87 2.01
LB07_2 10.7 10.7 38.9 0 2.4 0 1.64 1.58
LB07_3 9.9 9.4 37.2 0 25.2 9.9 19.58 1.64
LB08_1 13.8 12.5 5.8 2.1 9.5 17.5 12.31 3.01
LB09_2 11.5 7.8 38.7 27.4 37.3 54 45.15 2.4
LB10_1 12.9 10.1 22.3 20.6 0 38.7 26.45 1.29
LB12_1 11.6 10.1 20.7 7.5 43.4 24.4 31.62 1.44
LB13_2 5.3 5.1 8.8 17.4 0 8.1 2.36 1.18
LB15_1 10 10 25.2 3.4 87.3 0 53.18 1.79
LB15_2 10.8 8.9 34.9 13.6 66.7 31.9 52.56 1.96
LB16_1 23.3 13.5 28.7 0 35.5 66.4 60.2 2.19
LB17_2
LB17_4
LB18_2 7.5 7.5 5.5 16.9 9 0 5.86 2.58
LB19_1 7.2 7.2 20.3 14.1 64.9 0 38.46 1.86
LB20_2 16.6 10.7 17 12.9 37.6 58 37.02 1.87
LB21_1 12.9 11.6 16.2 0 0 19.5 9.11 1.63
LB21_2 13.9 12.7 19.8 3.5 10.1 16.5 16.47 2.04
LB22_1 11.3 11.3 27.2 54.1 43.8 0 18.97 3.86
LB23_1 11.3 9.4 13 0 81.9 31.1 34.64 2.34
LB24_1 17 9.6 21.1 4.3 33.3 67.7 39.03 2.63
LB25_1 13.1 10.2 15.5 3 16.4 39.5 22.69 2.13
LB25_2 10.8 10.8 9.3 3.5 10.5 0 5.14 2.11
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LB03_1 22.9 20 7.09 2.517 1.65
LB03_overlap 22.9 26 2.34 1.481012658
LB03_change 22.9 6 -0.177 -0.168987342
LB06_1 36.6 10 7.54 1.833 1.51
LB06_overlap 36.6 16 2.83 1.554945055
LB06_change 36.6 6 0.997 0.044945055
LB07_2 14 14 2.52 2 1.35
LB07_overlap 14 26 2.27 1.427672956
LB07_change 12 0.27 0.077672956
LB08_1 18.2 16 1.53 3.5 1.785714286
LB08_overlap 18.2 18 2.64 1.478947368
LB08_change 2 -0.86 -0.306766917
LB09_2 20.1 15 4.88 1.426 1.4
LB09_overlap 20.1 19 1.5 1.153846154
LB09_change 4 0.074 -0.246153846
LB10_1 49 9 9.28 1.478 1.34
LB10_overlap 49 19 2.72 1.638554217
LB10_change 10 1.242 0.298554217
LB13_2 12.1 3 8.75 0.53 0.85
LB13_overlap 12 12 0.74 0.621848739
LB13_change 9 0.21 -0.228151261
LB16_1 9 10.54 1.285 1.24
LB16_overlap 22.6 19 2.59
LB16_change 10 -1.285 1.35
LB18_2 37.8 3 9.53 0.941 1.62
LB18_overlap 37.8 12 2.56 1.785216179
LB18_change 9 1.619 0.165216179
LB19_1 32.9 6 6.92 1.05 1.31
LB19_overlap 32.9 12 2 1.438848921
LB19_change 6 0.95 0.128848921
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